10/18/18

CURRICULUM VITAE

JOEL W. HAY, PhD

PERSONAL INFORMATION Business/Mail Address Professor of Pharmaceutical Economics and Policy & Professor of Health Policy and Economics University of Southern California

Schaeffer Center for Health Policy and Economics University Park Campus, Verna & Peter Dauterive Hall (VPD 214-L) 635 Downey Way Los Angeles, CA 90089-3333 USA

Business Telephone Office: (818) 338-5433 Assistant: (213) 821-7940 Fax: (213) 740-3460 (ATTN: Joel Hay) E-Mail jhay@usc.edu USC Websites : http://healthpolicy.usc.edu/ListItem.aspx?ID=4

http://pharmacyschool.usc.edu/faculty/profile/?id=374 Graduate Program Website : http://pharmacyschool.usc.edu/programs/pep/ Schaeffer Center Street Address 635 Downey Way

Los Angeles, CA 90089-3333 USA (Deliveries, e.g. Fedex, UPS) Main Phone/Front Desk: (213) 821-7940

J Hay Office: (213) 821-8160 Fax: (213) 740-3460 (ATTN: Samantha) http://healthpolicy.usc.edu

Contact Information for Non-USC Activities Joel W. Hay, PhD 22101 Dardenne St. Calabasas, CA 91302 818-338-5433 joel.hay@gmail.com

Joel W. Hay, Ph.D. -- C.V. -2- 10/18/18 EDUCATION

1974 B.A., (Summa cum laude), Economics, Amherst College 1975 M.A., Economics, Yale University 1976 M.Phil., Economics, Yale University 1980 Ph.D., Economics, Yale University PROFESSIONAL EXPERIENCE

March 2009 – Present Full Professor (with tenure), Pharmaceutical Economics and Policy;

School of Pharmacy Professor (by courtesy), Department of Economics;

University of Southern California, Los Angeles, California. September 2009-Present Full Professor, Health Economics and Policy

Leonard D. Schaeffer Center for Health Policy and Economics University of Southern California, Los Angeles, California 1992 – 2009 Associate Professor (with tenure),

Pharmaceutical Economics and Policy; School of Pharmacy.

Associate Professor (by courtesy), Department of Economics;

University of Southern California, Los Angeles, California. September 1985 - May 1992 Senior Research Fellow, Hoover Institution, Stanford University, Stanford, California. July 1983 - September 1985 Senior Policy Analyst, Project HOPE, Center for Health Affairs, Millwood, Virginia. January 1981 - June 1983 Visiting Lecturer, M.P.H. Program, Yale University, Department of Epidemiology

and Public Health, and Institution for Social and Policy Studies. June 1980 - September 1984 Assistant Professor, Department of Behavioral Sciences and Community Health, School of Dental Medicine

University Connecticut Health Center, Farmington, Connecticut. (from 9/81) Assistant Professor, Department of Economics, UConn Storrs. University of Connecticut Graduate School, Storrs, Connecticut. June 1978 - June 1980 Assistant Research Professor, Human Resources Research Center, University of Southern California, Los Angeles, California. ADDITIONAL EXPERIENCE: 2018-present Distinguished Member, European Union Academy of Sciences. 2017-present External Consultant, Office of the Attorney General, State of California. 2016-2017 Conference Co-Chair and Planning Committee, International Academy of Health Preference

Research, North American Conference, Boston MA, June 2017. 2016 Invited Forum Participant, AMCP Partnership Forum: FDAMA Section 114—Improving the

Exchange of Health Care Economic Data, Academy of Managed Care Pharmacy. 2016-present Voting Member, Cochrane Collaboration, www.cochrane.org. 2015 External Reviewer, Italian Ministry of Health, General Direction for Scientific Research and

Health Innovation. 2015 Invited Advisor, U.S. Food and Drug Administration Policy on Review of Health Economics

Modeling Claims (FDAMA Section 114). 2014-present Founding Member, International Academy of Health Preference Research (iahpr.org). 2013-2015 Extramural Reviewer, Healthcare Systems & Value Research Study Section Review Panel,

Agency for Healthcare Research & Quality (AHRQ), U.S. Dept. of Health & Human Services.

Joel W. Hay, Ph.D. -- C.V. -3- 10/18/18 2012 External Reviewer, Cochrane Tobacco Addiction Research Group, Cochrane Collaboration,

www.cochrane.org. 2012 Health Economics Expert Consultant, State Attorneys General Working Group on

Pharmaceutical Benefits Management (PBM) Market Competition Issues. 2011-2013 Extramural Reviewer, Healthcare Systems & Value Research Study Section Review Panel,

Agency for Healthcare Research & Quality (AHRQ), U.S. Dept. of Health & Human Services. 2011 Extramural Grant Reviewer, Health Services Research Study Section, Agency for Healthcare

Research & Quality (AHRQ), U.S. Dept. of Health & Human Services. 2010 Extramural Grant Reviewer, Health Services Research Study Section, Agency for Healthcare

Research & Quality (AHRQ), U.S. Dept. of Health & Human Services. 2010 External Grant Reviewer, Netherlands Organisation for Health Research and Development

(ZonMw) Health Technology Assessment Methodology Programme. 2010 External Program Contract Reviewer, Agency for Healthcare Research & Quality (AHRQ), U.S.

Dept. of Health & Human Services; Developing Evidence to Inform Decisions about Effectiveness-2: The DEcIDE-2 Network.

2007-2013 Leadership Group, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Disease Management and Prevention Task Force.

2007-2009 Leadership Group, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Patient Preferences Research Task Force.

2006-2010 Co-Chair, ISPOR Drug Cost Task Force. 2006 Chair, Awards Committee; “The 2006 ISPOR Avedis Donabedian Outcomes Research Lifetime

Achievement Award.” Presented to Prof. George Torrance at the 11’th Annual International Meeting, Philadelphia, PA.

2005 External Project Reviewer; “The Uninsured and Access to Prescription Drugs in California. The Petris Center on Health Care Markets & Consumer Welfare, University of California, Berkeley.

2005 External Program Reviewer, Agency for Healthcare Research & Quality, Dept. of Health & Human Services; Developing Evidence to Inform Decisions about Effectiveness: The DEcIDE Network.

2004-2010 Health Policy Scientific Council, Intl. Soc. for Pharmacoeconomics & Outcomes Research. 2004-2014 Elected Executive Board Member, American Society of Health Economists (Ashecon.org). 2004-2010 Scientific Advisory Board Member, Disease Management Association of America 2002-2003 Institute of Medicine, National Academy of Sciences. Commissioned Author “Vaccine

Reimbursement Policy in the US.” 2001-Present Health Economist, UCLA Center for Vaccine Research, UCLA Harbor Medical Center,

Torrance, CA. 2001 Health Plan Reform Consultant, Hong Kong Hospital Authority, Hong Kong. 2000 External Reviewer, National Institute on Aging, NIH Small Grants Program. 1999 External Reviewer, National Institutes of Health, National Institute on Aging, 1999-2011 Co-Investigator, USC Alzheimer Research Centers of California Research Program, California

Dept. of Health Services. 1999 Consultant, Univ. Michigan Survey Research Center ADAMS/HRS Dementia Project 1999 External Reviewer, National Insts. of Health, National Institute of Digestive Diseases and

Nutrition, Division of Digestive Diseases and Nutrition Hepatitis C Antiviral Long-term Therapy to Prevent Cirrhosis (HALT-C) Ancillary Studies Committee.

1999-2000 Economics Research Consultant, U.S. AHRQ, Southern California Evidence-Based Medicine Practice Project: Deep Vein Thrombosis Treatment in Trauma Surgery Literature Synthesis and Guideline Development.

1999 Member, Long Range Steering Committee Task Force, Harbor-UCLA Medical Center Research and Education Institution, Torrance, CA.

1998-2011 Rand USC Project Coordinator, U.S. Agency for Health Research and Quality, Southern California Evidence-Based Medicine Practice Project.

1998-2002 Founding Editor-In-Chief, Value in Health, Journal of the International Society for Pharmacoeconomics and Outcomes Research.

1998 External Reviewer, Cal Dept of Health Services Alzheimer’s Program Research Fund. 1998-2008 Member, Pharmacy Practice Research Roundtable. 1998-2007 Member, Intl. Working Group on Alzheimer Disease Pharmacoeconomics Research.

Joel W. Hay, Ph.D. -- C.V. -4- 10/18/18 1998-2006 Member, Coronary Heart Disease: The Interdisciplinary Council on Reducing the Risk, co-

sponsored by the American Heart Association & Bristol-Myers Squibb. Dallas, TX. 1997-98 Co-Chair: ISPOR Working Group on Guidelines for Pharmacoeconomic Research. 1997-98 External Reviewer. Asset and Health Dynamics among the Oldest Old- Dementia Survey

Supplement. University of Michigan Inst. for Social Research, Ann Arbor, MI. 1997 – Present Economic Consultant, Rand Corporation, Health Outcome Research Group, Santa Monica, CA 1996-1998 Co-Chair and Primary Organizer: ISPOR Lipid Pharmacoeconomics Conference. Orlando, FL. 1996-1998 Elected Member, Board of Directors, and Founding Member, International Society for

Pharmacoeconomics and Outcomes Research (ISPOR), Philadelphia, PA. 1995-2000 Member, Expert Advisory Panel on Drug Utilization Review, United States Pharmacopoeial

Convention, Rockville, MD. 1995-96 Research & Graduate Affairs Cmte., American Assoc. Colleges of Pharmacy, Alexandria, VA. 1994-95 Technical Review Study Section, "HIV Costs and Services Utilization Study (HCSUS),”

Agency for Health Care Policy & Research, US Dept. Health & Human Serv., Rockville, MD. 1993-94 Member, Research Advisory Panel for Outcome Studies, Wellpoint Pharmacy Management,

Blue Cross of Southern California. 1993-1998 Member, Advis. Cmte., American Soc. Consultant Pharmacists Research Foundation 1993 Member, Planning Committee, American Society of Consultant Pharmacists for ASCP

Foundation Pharmacoeconomics Fellowship in Geriatric Long-Term Care 1992-1993 Technical Review Panelist, Drug Utilization Review Demonstration Project Contracts, Health

Care Financing Administration, Baltimore, MD. 1992 Member, Council of Advisors, Geriatric Drug Therapy Research Inst., Arlington, VA. 1992 Access to Health Care Task Force Member, American Heart Assoc., Washington, D.C. 1992 Judge, Masters of Innovation Software Competition, Zenith Data Systems, Chicago, IL 1991 Advisor, Hungarian Parliament Health Care Reform Committee, Budapest, Hungary. 1991 Chief U.S. consultant, Hungarian health care reform project, Px Ltd., Budapest, Hungary. 1990-91 Visiting Scholar, Hong Kong Centre for Economic Research, Chinese University of Hong

Kong, Shatin, New Territories. 1990 Invited outside reviewer, U.S. Congressional Budget Office Long Term Care Policy Statement. 1990 Invited outside expert, California AIDS Leadership Commission Hearings, Los Angeles, CA. 1989 Proposal Review Consultant, The Smith Richardson Foundation. 1989 Invited outside expert, Select panel on HIV/AIDS estimates and projections. U.S. Public Health

Service, Centers for Disease Control. 1989 Consultant, The Henry J. Kaiser Family Foundation, Menlo Park, California. 1988 Consultant, General Assistance Program for the Homeless, Office of the County Counsel,

County of Sacramento, CA. 1988 Proposal Reviewer, Special Study Section, National Institutes of Health, U.S. Dept. of Health &

Human Services. 1988 Issue Development Participant, "Medication Use in the Elderly: A Critical Analysis," Geriatric

Pharmacy Institute, Philadelphia College of Pharmacy and Science. 1988 Consultant, Patient Care/Health Service Delivery Subgroup, Executive Task Force on AIDS,

U.S. Public Health Service. 1987 Consultant, Cost-benefit analysis of HIB vaccine, U.S. Food and Drug Administration. 1987 Proposal Reviewer, National Center for Health Services Research, U.S. Dept. of Health &

Human Services. 1986, 1989 Proposal Review Consultant, The Henry J. Kaiser Family Foundation, Menlo Park, California. 1984 – 1986 Principal Investigator, Robert Wood Johnson Foundation; An Incentive Reimbursement Plan for

Medicaid Home Health Care Services. 1985 Technical Consultant, Research Projects Approval Committee-Economics, The World Bank. 1985 Technical Advisory Panelist, HCFA Contract No. 500-84-0033; Market Study for Home Health

Care Services, Center for Health Policy Studies. 1984 Technical Review Consultant, National Center for Health Services Research, Hospital Care and

Utilization Project. 1984 Consultant, County of San Diego; Member of Proposal Review Committee for County Regional

Contracts to Provide Care to Medically Indigent Adults. 1983 Visiting Asst. Prof., Inst. for Social Sciences, University of Basel, Basel, Switzerland.

Joel W. Hay, Ph.D. -- C.V. -5- 10/18/18 1983 Principal Investigator, U.S. Environmental Protection Agency; Mortality and Air Pollution: A

Microanalytic Analysis. 1981 – 1982 Principal Investigator, Connecticut Research Found.; Child Health Status & Cognitive

Development. University of Connecticut, Storrs, CT. 1981 Visiting Fellow, Institution for Social & Policy Studies, Yale University, New Haven, CT. 1980 Consultant, National Preventive Dentistry Demonstration Project Evaluation Model, American

Fund for Dental Health. 1980 Consultant, National Health Services Corps Personnel Selection Project, Policy Research Inc. 1979 – 1980 Principal Investigator, Doctoral Research Grant, National Center for Health Services Research. 1979 – 1980 Consultant, Cost Benefit Analysis of Outpatient Treatment for Patients from the Psychiatric

Ward of L.A. County/USC Medical Center. 1977 – 1978 Instructor, Department of Economics, Yale University, New Haven, Connecticut. 1976 – 1977 Teaching Assistant, Dept. of Economics, Yale University, New Haven, Connecticut. 1974 – 1976 Research Consultant, National Bureau of Economic Research. 1975 Bibliographical Research Project (Russian Language) on Works of Academic Leo Kantorovich

for Professor Tjalling Koopmans prior to their joint Nobel Prize Award in Economics.

Joel W. Hay, Ph.D. -- C.V. -6- 10/18/18 HONORS AND DISTINCTIONS: Distinguished Member (by invitation), European Union Academy of Sciences. January 2018 – present. “Top Performing Reviewer,” Journal of Managed Care and Specialty Pharmacy. 2017. Western Pharmacoeconomics & Outcomes Research Conference: Best Student Poster Award 2017; Lam J, Hay JW, Kenyon N. Cost-effectiveness Analysis of Reslizumab in Patients with Poorly Controlled Eosinophilic Asthma. Invited Poster Presentation, University of New Mexico, October 4, 2017, Albuquerque, NM. (Joel Hay, faculty mentor). Western Pharmacoeconomics & Outcomes Research Conference: Best Student Poster Award 2017; Salcedo J, Hay JW. Cost-Effectiveness of Rivaroxaban Versus Warfarin for Treatment of Nonvalvular Atrial Fibrillation in Patients with On-Treatment Worsening Renal Function. Invited Poster Presentation, Western Pharmacoeconomics & Outcomes Research Conference, University of New Mexico, October 4, 2017, Albuquerque, NM. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research Mentor: Best Student Poster Award 2016; Nikhil Bhagvandas. Bhagvandas Nikhil, Hay Joel W. Cost Effectiveness of Lurasidone, Quetiapine, and Olanzapine Monotherapy in the Treatment of Bipolar I Disorder Depression. Poster PMH39. ISPOR 21’st Annual International Meeting, May 21-25, 2016; Washington, DC. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research Mentor: Best Student Podium Presentation Award 2016; Yifan Xu. Xu, Yifan; Barzi, Afsaneh; Hay Joel W. Comparative Effectiveness of Panitumumab Versus Cetuximab in Patients with Chemo-Refractory Wild-Type Kras Metastatic Colorectal Cancer. Oral Presentation PCN108. ISPOR 21’st Annual International Meeting, May 21-25, 2016; Washington, DC. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research Mentor: Best Student Poster Award Finalist; Shraddha Chaugule, 2015: “Exploring heterogeneity in attribute processing strategies: Use of hybrid random utility maximization-random regret minimization models in a Discrete Choice Experiment." S. Chaugule and J. Hay. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research Mentor: Best Student Poster Award Finalist; Emmanuel Drabo, 2014: “A Cost-effectiveness analysis of pre-exposure prophylaxis (PrEP) for the prevention of HIV among the MSM population of Los Angeles County.” (Joel Hay, faculty mentor). Academy of Managed Care Pharmacy Research Mentor, Best Student Poster Award; Kai Yeung, 2011. Yeung K, Hay JW. Cost-Utility Analysis of Romiplostim Versus Splenectomy in the Treatment of Chronic Refractory Immune Thrombocytopenic Purpura. Poster presentation at the Academy of Managed Care Pharmacy 23’rd Annual Meeting, March 29, 2011 Minneapolis, MN. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research: Best New Investigator Podium Presentation Award 2010 to Dr. Haesun Suh. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research: Distinguished Service Award, 2009. International Society for Pharmacoeconomics and Outcomes Research: Outstanding Student Chapter of the Year, Joel Hay Student Chapter Faculty Advisor, 2009. Joel Hay was Founding Editor-in-Chief of Value in Health the peer-reviewed scientific journal of the International Society for Pharmacoeconomics and Outcomes Research until 2003. This journal, started in 1998, became Medline-listed in 2002. In its first impact factor, Value in Health was ranked #1 in two categories for the year 2004, by the ISI Journal Citation Reports® (JCR) with an impact factor of 3.657. Value in Health led all other journals listed both in the Health Care Sciences and Services category in the JCR Science Edition and in the Health Policy & Services category in the JCR Social Sciences Edition.

Joel W. Hay, Ph.D. -- C.V. -7- 10/18/18 International Society for Pharmacoeconomics and Outcomes Research Mentor: Best Student Poster Award; Danielle Zammit, 2004: “Preliminary Economic Analysis of The American Cancer Society Guidelines For Mammography Screening In Average-Risk Women Under 70 Years of Age.” D. Zammit and J. Hay. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research Mentor: Best Student Poster Award; Danielle Zammit, 2003: “Economic Analysis of The Use of Angiotensin Converting Enzyme Inhibitors in Patients With Diabetes Mellitus.” D. Zammit and J. Hay. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research: Distinguished Service Award, 2002. Founding Member, American Society for Health Economics, San Diego, CA, 2002. International Society for Pharmacoeconomics and Outcomes Research Mentor: Best Student Poster Award; Eric Wu, 2001: “Survival & Nursing Home Free Survival (NHFS) of Alzheimer's Disease Patients." E. Wu and J. Hay. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research Mentor: Best Student Poster Award; Jinmei Li, 2000: “Cost Effectiveness of Retinopathy Screening in Pediatric Patients with Type 1 Diabetes Mellitus.” J. Li and J. Hay. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research Mentor: Best Student Poster Award; Nishan Sengupta, 2000: “Cost Effectiveness Analysis of Tamoxifen in Breast Cancer Risk Reduction.” N. Sengupta and J. Hay. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research Mentor: Best Student Poster Award; Michelle Luo, 1999: “Cost Effectiveness Analysis of Genetic Testing For Breast Cancer.” M. Luo and J. Hay. (Joel Hay, faculty mentor). International Society for Pharmacoeconomics and Outcomes Research: Research Excellence Award; 1999 Wallace Lectureship. Idaho State University College of Pharmacy, 1999 International Society for Pharmacoeconomics & Outcomes Research Exec. Board Recognition Award; 1998 International Society for Pharmacoeconomics and Outcomes Distinguished Service Award; 1998 Outstanding Speaker Award, American Association for Clinical Chemistry 1996 Founding Member, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Philadelphia, PA, 1995. USC School of Pharmacy QSAD Centurion Professorship: 1993-1999 USC School of Pharmacy Founding Chair, Dept. of Pharmaceutical Economics & Policy, 1992 Reviewer, National Science Foundation, 1982: Economics Section, 1987: Economics Section, 1989: Economics Section Yale University Fellowship, 1974 - 1978 W.T. Akery Prize for Undergraduate Thesis in Economics, 1974 Elected Phi Beta Kappa, 1974

Joel W. Hay, Ph.D. -- C.V. -8- 10/18/18 LANGUAGES: French (reading), Russian (reading), APL, PL/1, FORTRAN, IBM 370 JCL, TSP, SAS, SPSS/X, STATA, LIMDEP, NLOGIT, QUAIL, BMDP, MS DOS, LOTUS 123, SPSS/PC, RATS, SST, VAX/VM. FIELDS OF GRADUATE TRAINING: Econometrics, Money, Labor RESEARCH INTERESTS: Pharmacoeconomics, Outcomes Research, Pharmaceutical Care, Health Economics, Econometrics PROFESSIONAL SOCIETIES: Academy of Managed Care Pharmacy American Association of Colleges of Pharmacy American Economic Association American Public Health Association American Society of Health Economists Disease Management Association of America Eastern Economic Association Econometrics Society International Academy of Health Preferences Research International Health Economics Association International Society for Pharmacoeconomics and Outcomes Research International Society for Quality of Life Research International Society of Technology Assessment in Health Care Southern Economic Association Western Economic Association

Joel W. Hay, Ph.D. -- C.V. -9- 10/18/18 TEACHING: 1976 – 1977 Teaching Assistant, Department of Economics, Yale University, New Haven,

Connecticut. 1977 – 1978 Instructor, Department of Economics, Yale University, New Haven, Connecticut. September - November 1980 Health Economics at the Waterbury Hospital Pediatric Residency Program. September - November 1980 Social and Behavioral Sciences Seminar "Cost of Illness and Related Topics,"

Medical/Dental student; Required curriculum, University of Connecticut Health Center.

September 1980 - December 1982 Social and Behavioral Sciences Lecturer "Issues in Health Care Financing and

Delivery," Medical/Dental student required curriculum, University of Connecticut Health Center.

September - November 1981 Social and Behavioral Sciences Seminar "Competition in the Health Care Delivery

System," Medical/Dental student required curriculum, University of Connecticut Health Center.

September - November 1982 Social and Behavioral Sciences Seminar "HMOs and the Market for Health Care,"

Medical/Dental Student required curriculum, Univ. of Connecticut Health Center. December 1980 - January 1983 Introductory Biostatistics Instructor, Medical/Dental student required curriculum,

University of Connecticut Health Center. January 1981 - June 1983 Health Economics, M.P.H. Program, Yale University, Department of

Epidemiology and Public Health, and Institution for Social and Policy Studies. Fall Semester 1982 Graduate Independent Studies Course, Department of Economics, University of

Connecticut. Spring Semester 1982 Undergraduate Health Economics, University of Connecticut, Department of

Economics. Spring Semester 1983 Undergraduate Independent Studies Course, Department of Economics, University

of Connecticut. Fall Semester 1992 The Costs of Drug Abuse, Health Behavior (PSC 439); Economic Assessment of

Pharmaceuticals, Contemporary Issues (PSC 551); Health Care Organization in the U.S., Public Health and Social Pharmacy (PSC 437); Department of Pharmaceutical Economics and Policy, USC

Spring Semester 1993 Biostatistics and Literature Evaluation (PSC 331): Co-taught with Prof. McCombs;

Department of Pharmaceutical Economics and Policy, USC Fall Semester 1993 The Costs of Drug Abuse, Health Behavior (PSC 439); Health-related Quality of

Life Assessment, Contemporary Issues (PSC 551); U.S. Health Care Finance and Reform, Public Health and Social Pharmacy (PSC 437); Department of Pharmaceutical Economics and Policy, USC

Spring Semester 1994 Biostatistics and Literature Evaluation (PSC 331): Cotaught with Prof. McCombs;

Department of Pharmaceutical Economics and Policy, USC Summer, 1994 Introductory Undergraduate Health Economics (Econ 194BB), University of

California, Santa Barbara, Summer Session

Joel W. Hay, Ph.D. -- C.V. -10- 10/18/18 Fall Semester 1994 Health Status/Quality of Life Assessment Health Behavior (PSC 439);

Contemporary Issues (PSC 551); U.S. Health Care Finance and Reform, Public Health and Social Pharmacy (PSC 437); Department of Pharmaceutical Economics and Policy, USC

Spring Semester 1995 Biostatistics and Literature Evaluation (PSC 331) Spring Semester 1996 Biostatistics and Literature Evaluation (PSC 331) Spring Semester 1996 Pharmacoeconomics: Introductory Graduate Course (PMEP 538) Summer Semester 1996 Pharmacoeconomics: Introductory Graduate Course (PMEP 538) Spring Semester 1997 Statistics Computer Laboratory (Phar 366) Summer Semester 1997 Pharmacoeconomics: Introductory Graduate Course (PMEP 538) Spring Semester 1998 Statistics Computer Laboratory (Phar 366) Summer Semester 1998 Pharmacoeconomics: Introductory Graduate Course (PMEP 538) Spring Semester 1999 Statistics Computer Laboratory (Phar 366) Summer Semester 1999 Pharmacoeconomics: Introductory Graduate Course (PMEP 538) Spring Semester 2000 Statistics Computer Laboratory (Phar 366) Spring Semester 2000 Pharmacy Level III Elective: Disease State Management. Pharmacoeconomics (1

Lecture) (Phar 571) Fall Semester 2000 Pharmacoeconomics Unit on Decision Analysis (Phar 553) Summer Semester 2000 Pharmacoeconomics: Introductory Graduate Course (PMEP 538) Fall Semester 2001 Pharmacoeconomics Unit on Decision Analysis (Phar 553) Spring Semester 2001 Pharmaceutical Econometrics: Graduate Course (PMEP 549) Summer Semester 2001 Pharmacoeconomics: Graduate Course (PMEP 538) Fall Semester 2002 Pharmacoeconomics Unit on Decision Analysis (Phar 553) Spring Semester 2002 Pharmaceutical Econometrics: Graduate Course (PMEP 549) Summer Semester 2002 Pharmacoeconomics: Graduate Course (PMEP 538) Spring Semester 2002 Pharmaceutical Econometrics: Graduate Course (PMEP 549) Spring Semester 2003 Pharmaceutical Econometrics: Graduate Course (PMEP 549) Summer Semester 2003 Pharmacoeconomics: Graduate Course (PMEP 538) Fall Semester 2003 Pharmacoeconomics Unit on Decision Analysis (PHRD 553) Fall Semester 2003 Health Care Policy (PHRD 507) Spring Semester 2004 Pharmaceutical Econometrics: Graduate Course (PMEP 549)

Joel W. Hay, Ph.D. -- C.V. -11- 10/18/18 Fall Semester 2004 Health Care Policy (PHRD 507) Fall Semester 2004 Pharmacoeconomics Unit on Decision Analysis (PHRD 614) Summer Semester 2005 Pharmacoeconomics: Graduate Course (PMEP 538) Fall Semester 2005 Health Care Policy (PHRD 507) Spring Semester 2006 Pharmaceutical Econometrics: Graduate Course (PMEP 549) Fall Semester 2006 Health Care Policy (PHRD 507) Fall Semester 2006 Research Design – Applied Cost Effectiveness Analysis (PMEP 509)

Summer Semester 2007 Pharmacoeconomics: Graduate Course (PMEP 538) Fall Semester 2007 Health Care Policy (PHRD 507) Fall Semester 2007 Research Design – Applied Cost Effectiveness Analysis (PMEP 509) Spring Semester 2008 Pharmaceutical Econometrics: Graduate Course (PMEP 549) Fall Semester 2008 Health Care Policy (PHRD 507) Fall Semester 2008 Research Design – Applied Cost Effectiveness Analysis (PMEP 509) Fall Semester 2008 Pharmaceutical Economics and Policy Graduate Seminar (PMEP 698) Spring Semester 2009 Pharmaceutical Economics and Policy Graduate Seminar (PMEP 698) Summer Semester 2009 Pharmacoeconomics: Graduate Course (PMEP 538) Fall Semester 2009 Health Care Policy (PHRD 507) Fall Semester 2009 Industrial Systems Engineering Lecturer (ISE 599) Spring Semester 2010 Pharmaceutical Econometrics: Graduate Course (PMEP 549) Summer Semester 2011 Pharmacoeconomics: Graduate Course (PMEP 538) Spring Semester 2012 Pharmaceutical Econometrics: Graduate Course (PMEP 549) Spring Semester 2012 Health Economics Lecture: Social Work Graduate Course (SOWK 590) Summer Semester 2013 Pharmacoeconomics: Graduate Course (PMEP 538) Spring Semester 2014 Pharmaceutical Econometrics: Graduate Course (PMEP 549) Summer Semester 2015 Pharmacoeconomics: Graduate Course (PMEP 538) Spring Semester 2016 Pharmaceutical Econometrics: Graduate Course (PMEP 549) Spring Semester 2017 Economic Analysis of Health Care I: Graduate Course (PMEP 525) Summer Semester 2017 Economic Analysis of Health Care II: Graduate Course (PMEP 526) Fall Semester 2017 Economic Analysis of Health Care III: Graduate Course (PMEP 527)

Joel W. Hay, Ph.D. -- C.V. -12- 10/18/18 USC UNIVERSITY SERVICE 2018 - Present Curriculum Committee, School of Pharmacy 2018 American Association of Pharmaceutical Scientists - USC Chapter, Moving

Targets Faculty Reviewer 2016 Admissions Committee Procedures and Evaluation Retreat, School of Pharmacy 2015- 2016 Faculty Position Search Committee, Dept. of Pharmaceutical and Health

Economics, School of Pharmacy 2013 – Present Member, Task Force on Appointments and Promotions, School of Pharmacy 2011 External Reviewer, Sol Price School of Public Policy 2009 Chair, Faculty Position Search Committee, Dept. of Clinical Pharmacy,

Pharmaceutical Economics and Policy, School of Pharmacy 2006 - Present Faculty Merit Review Coordinating Committee, School of Pharmacy 2004-2005 Chair, Faculty Position Search Committee, Dept. of Pharmaceutical Economics

and Policy, School of Pharmacy 2003 - 2014 Admissions Committee, School of Pharmacy 2003-2006 Chair, Advanced Technology Committee, School of Pharmacy 2002-2004 New Curriculum Development: Course Coordinator, Phar 507: Health Policy for

Pharmacists, School of Pharmacy 2002 - 2011 Advanced Technology Committee, School of Pharmacy 2002 Presentation on Human Subjects Review Policy, USC Faculty Senate Retreat 2000-2001 Computer Committee, School of Pharmacy 2001 Graduate Teaching Assistantship Program Evaluation Committee 2000 – Present Faculty Advisor, USC ISPOR Student Chapter 1994 - Present Pharmacy Student Applicant Interview Committee 1992 - 1997 Founding Chair, Dept. of Pharmaceutical Economics & Policy, Schl of Pharmacy 1993 - 1995 Member, Pharmacy Dean's Search Committee, Office of the Provost. 1992 - 1997 Member, Dean's Executive Committee, School of Pharmacy 1992 - 1997 Member, Appointments and Promotions Committee, School of Pharmacy 1993 - 1995 Economic Advisor, East Los Angeles/USC Project on Managed Care for the

Medically Indigent; Pacific Center for Health Policy and Ethics 1995 - 1997 Member, Quality/Outcomes Group USC Physicians Office of Clinical Services 1994 - 1997 Member, Ph.D. Pharmaceutical Economics and Policy Admissions Committee 1994 - 1997 Member, M.S. Pharmaceutical Economics and Policy Admissions Committee 1993 - 1997 Member, University Graduate Studies Advisory Committee, USC Graduate School 1993 Developed Ph.D. Program in Pharmaceutical Economics (Graduate School

Approved for Fall 1994) 1993 Proposal Reviewer, Zumberge Research and Innovation Fund Awards 1993 Candidate Interviewer, Pharm.D. Admissions Program, School of Pharmacy 1993 Chair, Graduate Ph.D. Program in Pharmaceutical Economics Curriculum

Development, School of Pharmacy 1992/1993 Chair, Junior Faculty Position Search Committee, Dept. of Pharmaceutical

Economics and Policy, School of Pharmacy 1994/1995 Chair, Junior Faculty Position Search Committee, Dept. of Pharmaceutical

Economics and Policy, School of Pharmacy OTHER UNIVERSITY SERVICE 2018 External Referee, Promotion and Tenure Committee, Arnold School of Public

Health, University of South Carolina, Columbia, SC. 2018 External Referee, Promotion and Tenure Committee, Department of Medicine,

University of Illinois College of Medicine, Peoria, IL. 2016 External Referee, Tenure and Promotions Committee, Department of Pharmacy

Practices and Administration, Western University of the Health Sciences, Pomona, CA.

Joel W. Hay, Ph.D. -- C.V. -13- 10/18/18 2016 External Examiner, Doctoral Thesis Committee, Department of Economics,

University of Calgary, Calgary, Alberta, Canada. 2016 External Referee, Tenure and Promotions Committee, Health Services Research

Division, College of Pharmacy, University of Iowa, Iowa City, IA. 2016 External Reviewer, School of Pharmacy, Chinese University of Hong Kong, Hong

Kong SAR, China. 2015 External Reviewer, School of Medicine, Pennsylvania State University, Hershey,

PA. 2015 External Reviewer, Faculty of Pharmacy, University of Toronto, Toronto, Canada. 2014-15 External Reviewer, Pharmacy School, Tianjin University, Tianjin, China. 2014-15 External Reviewer, National University of Singapore, Singapore. 2014 External Reviewer, Faculty of Pharmacy, University of Maryland School of

Pharmacy, Baltimore, MD. 2014 External Reviewer, Faculty of Pharmacy, University of Toronto, Toronto, Canada. 2013 External Reviewer, Department of Pediatrics, Harbor-UCLA Medical Center, Los

Angeles, CA. 2013 External Reviewer, Dept. of Health Policy and Management, Texas A&M Health

Sciences Center, College Station, TX. 2013 External Reviewer, Department of Pediatrics, Division of Neonatology, David

Geffen School of Medicine at UCLA, Los Angeles, CA. 2013 External Reviewer, Dept. of Social Pharmacy, College of Pharmacy, Ewha

Womans University, Seoul, Korea. 2013 External Reviewer, Department of Pediatrics, Division of Neonatology, David

Geffen School of Medicine at UCLA, Los Angeles, CA. 2012 External Referee, School of Nursing, University of Michigan, Ann Arbor, MI. 2011 External Referee, School of Pharmacy, University of Colorado Anschutz Medical

Campus, Aurora, CO. 2011 External Referee, University of Wisconsin School of Medicine and Public Health,

Department of Population Health Sciences, Madison, WI. 2010 External Referee, Virginia Commonwealth University, School of Pharmacy,

Department of Pharmacotherapy and Outcomes Sciences, Richmond, VA. 2010 External Referee, Nelson Mandela Metropolitan University, Faculty of Health

Sciences, Port Elizabeth, South Africa. 2010 Outside Examiner, Doctoral Dissertation Committee, College of Pharmaceutical

Sciences, Andhra University, Andhra Pradesh, India. 2009 External Referee, Tenure and Promotions Committee, Department of Pharmacy

Practice and Science, University of Iowa, Iowa City, IA.

Joel W. Hay, Ph.D. -- C.V. -14- 10/18/18 2009 External Referee, Tenure and Promotions Committee, Department of

Pharmaceutical Sciences, Oregon State University, Corvallis, OR. 2008 External Referee, Appointments and Promotions Committee, Division of

Pharmacy Practice and Administration, College of Pharmacy, Ohio State University, Columbus, OH.

2006 External Referee, Appointments and Promotions Committee, Department of

Medicine, Brigham and Women’s Hospital; Harvard Medical School, Boston, MA. 2004 External Referee, Appointments and Promotions Committee, Dept. Pediatrics,

Harbor-UCLA Medical Center, UCLA School of Medicine, Los Angeles, CA. 2002 External Examiner, Chinese University of Hong Kong Graduate School. Shatin,

Hong Kong 2001 External Referee, Appointments and Promotions Committee, College of

Pharmacy, University of Iowa, Iowa City, IA. 2000 External Referee, Appointments and Promotions Committee, Depart. of Pediatrics,

Harbor-UCLA Med Center, UCLA Schl of Medicine, Los Angeles, CA. 2000 External Referee, Appointments and Promotions Committee, Department of

Economics, Rice University, Houston, TX. 1997 External Referee, Appointments and Promotions Committee, School of Dentistry,

University of Connecticut, Farmington, CT. 1993 External Referee, Promotions Committee, Department of Medicine, Baylor

College of Medicine, Houston, TX. 1993 External Referee, Promotions Committee, Department of Medicine,

University of California, San Diego, CA. 1993 External Referee, Promotions Committee, School of Nursing, University of

California, San Francisco, CA. 1993 External Referee, Promotions Committee, Department of Economics, University

of Hong Kong, Hong Kong. 1992 External Referee, Promotions Committee, School of Nursing, University of

California, San Francisco, CA. 1988 External Referee, Tenure and Promotions Committee, Dept. of Economics, Univ.

of North Carolina at Chapel Hill, NC.

Joel W. Hay, Ph.D. -- C.V. -15- 10/18/18 ONGOING GRANT RESEARCH Sponsor: National Institute of Dental and Craniofacial Research PI: Sharon Cermak, PhD J Hay Role: Health Economist Title: Sensory Adapted Dental Environments to Enhance Oral Care for Children (1 U01 DE024978-01) Amount: $381,201 (First Year Directs) Dates: 4/01/15-3/31/20 Sponsor: National Institute of Dental and Craniofacial Research PI: Steve Yen, DMD J Hay Role: Health Economist Title: Clinical Effectiveness of Late Maxillary Protraction for Cleft Lip and Palate (U01 DE22937-01A1) Amount: $3,250,000 Dates: 9/1/13 – 8/31/18 Sponsor: National Institute of Child Health and Human Development T32 HD064578 PI: Florence Clark, PhD J Hay Role: Co-Investigator Title: TREET: Training in Rehabilitation Efficacy and Effectiveness Amount: $102,692 Dates: 04/01/11 - 03/31/22 COMPLETED GRANT RESEARCH (WHILE AT USC) Sponsor: Agency for Healthcare Research and Quality, US DHHS PI: Ken Zangwill, MD J Hay Role: Health Economist Title: Evaluation and Management of the Young Febrile Infant and Related Healthcare Costs and Morbidities (1 R03 HS024146-01) Amount: $100,000 Dates: 7/01/15-6/30/16 Sponsor: Baxter International PI: Joel W. Hay, PhD Title: Economic Evaluation of Hemophilia Inhibitor Bypass Agent Treatment: On Demand Versus Prophylaxis Amount: $99,000 Dates: 1/1/14 – 12/31/15 Sponsor: Children’s Hospital, Los Angeles PI: Guy Young, MD J Hay Role: Co-Investigator Title: Economic Evaluation of Hemophilia Inhibitor Treatments Amount: $95,000 Dates: 8/1/13 – 7/31/15 Sponsor: Agency for Healthcare Research and Quality, U.S. DHHS PI: Joel W. Hay, PhD Title: American Society of Health Economists Conference Grant Amount: $35,000 Dates: 1/1/14 – 2/31/15 Sponsor: US Dept. of Health and Human Services/Asst. Secretary for Policy and Evaluation (DHHS/ASPE) PI: Shinyi Wu, PhD J Hay Role: Co-Investigator Title: Care Management Technology to Facilitate Depression Care in Safety Net Diabetes Clinics Amount: $1,977,461 Dates: 9/1/10 – 8/31/14

Joel W. Hay, Ph.D. -- C.V. -16- 10/18/18 Sponsor: National Institutes of Health (trans agency) PI: Jason Doctor, PhD J Hay Role: Co-Investigator Title: Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections Amount: $8,353,371 Dates: 9/1/2010 – 8/31/2014 Sponsor: NIH, National Institute of Aging PI: Florence Clark, PhD J Hay Role: Co-Investigator Title: Lifestyle Redesign for Pressure Ulcer Prevention in Spinal Cord Injury Amount: $2,111,000 Dates: 9/08 – 8/14 Sponsor: EconoMedRx PI: Joel W. Hay, PhD Title: Economic Evaluation of the Market for Pediatric Antidepressants Amount: $99,000 Dates: 8/1/12 – 7/31/14 Sponsor: Baxter International PI: Joel W. Hay, PhD Title: Economic Evaluation of Hemophilia Inhibitor Bypass Agent Testing Assay Amount: $99,000 Dates: 8/1/12 – 6/31/13 Sponsor: Auxillium Pharmaceuticals PI: Joel W. Hay, PhD Title: Economic Evaluation of Dupuytren’s Contracture Therapy Amount: $165,000 Dates: 1/1/11 – 12/31/12 Sponsor: Sunovion Pharmaceuticals PI: Joel W. Hay, PhD Title: Costs of COPD Treatments Amount: $85,000 Dates: 3/10 – 8/11 Sponsor: Baxter Pharmaceuticals PI: Joel W. Hay, PhD Title: Meta-analysis of Hemophilia Patient Inhibitor Therapy Efficacy Amount: $85,000 Dates: 3/10 – 8/11 Sponsor: Baxter Pharmaceuticals PI: Joel W. Hay, PhD Title: Economic Evaluation of Hemophilia Patient Inhibitor Therapy Amount: $80,000 Dates: 9/08 – 8/10 Sponsor: Prolacta Biosciences PI: Joel W. Hay, PhD Title: Economic Evaluation of Human Milk Fortifier in Necrotizing Enterocolitis Amount: $80,000 Dates: 9/08 – 8/10

Joel W. Hay, Ph.D. -- C.V. -17- 10/18/18 Sponsor: NIH, National Institute of Mental Health PI: Kathy Ell, PhD J Hay Role: Co-Investigator Title: Major Depression in Diabetes Patients Amount: $678,000 Dates: 9/04 –8/10 Sponsor: NIH, National Institute of Mental Health PI: Megan Dwight-Johnson, MD J Hay Role: Co-Investigator Title: Patient Centered Care in the Public Sector Amount: $2,642,000 Dates: 7/04 – 6/08 Sponsor: California Dept. of Health Services PI: Lon Schneider, MD J Hay Role: Economist Title: Alzheimer Disease Costs, Quality of Life and Disease Burden Amount: $600,000 Dates: 1/01 – 12/04 Sponsor: US Centers for Disease Control and Prevention, NIH PI: Ken Zangwill, MD J Hay Role: Sub-grant PI Title: Economic Assessment of Rotavirus Burden of Illness in the Kaiser Southern California Health Plan Amount: $260,000 Dates: 11/97 – 12/03 Sponsor: US Alzheimer Association, Merck Foundation, Janssen Pharmaceutica PI: Joel W. Hay, PhD J Hay Role: Economist Title: Alzheimer Disease Global Burden of Illness Amount: $200,000 Dates: 6/99 – 12/01 Sponsor: US National Institute on Aging PI: Florence Clark, PhD J Hay Role: Project Economist Title: Well Elderly Occupational Therapy Demonstration Project Amount: $1.3 million Dates: 1/96 – 6/98 Sponsor: US PHS Agency for Health Care Policy Research PI: Paul Schekelle, MD J Hay Role: USC Project Coordinator Title: Southern California Evidenced-Based Practice Center Amount: $420,000 Dates: 3/98 – 9/99 Sponsor: Parke-Davis PI: Joel W. Hay, PhD J Hay Role: Economist Title: Economic Assessment of Epilepsy Disease Management Intervention Amount: $60,000 Dates: 6/95 9/98

Joel W. Hay, Ph.D. -- C.V. -18- 10/18/18 Sponsor: US NIH, National Institute on Aging PI: Mary Mittelman, PhD J Hay Role: Sub-Grant Co-PI Title: Economic Evaluation of Alzheimer Disease Caregiver Support Intervention Amount: $190,000 Dates: 1/96 – 7/98 Sponsor: Bristol Myers Squibb PI: Joel W. Hay, PhD J Hay Role: USC Project Coordinator Title: Pharmacoeconomics Fellowship Amount: $30,000 Dates: 6/96 Sponsor: Bristol Myers Squibb PI: Joel W. Hay, PhD J Hay Role: USC Project Coordinator Title: Pharmacoeconomics Training Amount: $60,000 Dates: 6/96 Sponsor: Parke-Davis PI: Joel W. Hay, PhD J Hay Role: Economist Title: Cognitive Function and the Costs of Alzheimer’s Disease Amount: $90,000 Dates: 6/94 8/96 Sponsor: Astra-Merck PI: Phil Rappa J Hay Role: USC Project Coordinator Title: Pharmacoeconomics Training Amount: $90,000 Dates: 8/94 Sponsor: Allergan PI: Phil Rappa J Hay Role: USC Project Coordinator Title: Pharmacoeconomics Training Amount: $20,000 Dates: 8/95 Sponsor: Amgen PI: Phil Rappa J Hay Role: USC Project Coordinator Title: Pharmacoeconomics Training Amount: $30,000 Dates: 7/94 Sponsor: Glaxo-Welcome Pharmaceuticals PI: Phil Rappa J Hay Role: USC Project Coordinator Title: Pharmacoeconomics Training Amount: $140,000 Dates: 3/93, 3/94

Joel W. Hay, Ph.D. -- C.V. -19- 10/18/18 Sponsor: Miles Pharmaceuticals PI: Joel W. Hay PhD J Hay Role: Economist Title: Economic Assessment of Anti-TNF in Treatment of Septic Shock Amount: $130,000 Dates: 4/94 – 3/95 Sponsor: Kaiser Permanente Southern California Health Care Plan PI: Jeff McCombs, PhD J Hay Role: Project Economist Title: The Kaiser/USC Pharmaceutical Care Demonstration Project Amount: $860,000 Dates: 3/93 – 9/97 Sponsor: Syntex Roche Pharmaceuticals PI: Joel W. Hay, PhD J Hay Role: Project Coordinator Title: Pharmacoeconomics Graduate program development Amount: $120,000 Dates: 6/92 – 5/93

Joel W. Hay, Ph.D. -- C.V. -20- 10/18/18 PEER-REVIEWED PUBLICATIONS: Joel W Hay H-Index: 49 9,100+ citations of JW Hay peer-reviewed articles in the scientific literature. 1. Hay JW. "Public Service Delivery in Chicopee, Massachusetts," in Student Originated Studies Conference

Proceedings, National Science Foundation, 1973, NSF No. 74-33. 2. Hay JW. Occupational Choice and Occupational Earnings: Selectivity Bias in a Simultaneous Logit-OLS

Model, Ph.D. dissertation, Yale University, New Haven, 1980, published by the National Technical Information Service, Rockville, Maryland.

3. Formicola A, Gottsegan R, Hay JW. "Commentary on 'Periodontal Disease: Assessing the Effectiveness and

Costs of the Keyes Technique'," in Implications of Cost-Effectiveness Analysis of Medical Technology, Office of Technology Assessment, U.S. Congress, Washington, D.C., 1981.

4. Yett D, Der W, Ernst R, Hay JW. "Blue Shield Plan Physician Participation." Health Care Financing

Review, June 1981 pp. 9-24. 5. Alvesalo I, Reisine S, Hay JW, Bailit H. "Effects of Fluoride and Regular Dental Care on Personal Dental

Expenditures of Young Adults in Finland," Community Dentistry and Oral Epidemiology, 1982; 10:15-22. 6. Yett D, Der W, Ernst R, Hay JW. "A Model of Physician Pricing, Output, and Health Insurance

Reimbursement: Findings from Study of Two Blue Shield Plans' Claims Data." In Essays in Health Economics, edited by Jacques Van der Gaag, William Neenan and Theodore Tsukahara, Praeger Press, New York, 1982, pp. 197-230.

7. Hay JW, Bailit H, Chiriboga D. "The Demand for Dental Health," Social Science and Medicine, Volume 16

(1982), pp. 1285-1289. 8. Hay JW, Leahy M. "Physician-Induced Demand: An Empirical Analysis of the Consumer Information Gap,"

Journal of Health Economics, Volume 1, (December 1982), pp. 231-244. 9. Hay JW. "A Simultaneous Econometric Model for Physicians' Specialty Choice and Specialty Income," in

Actes du Dixieme Colloque International D'Econometrie Appliquee: Econometrie de la Sante, Hospices Civil de Lyon, Lyon, France. February 1983, pp. 260-270.

10. Hay JW. "The Impact of Public Health Care Financing Policies on Private Sector Hospital Costs." Journal of

Health Politics, Policy and Law, Volume 7, No. 4 (1983), pp. 945-952. 11. Yett D, Der W, Ernst R, Hay JW. "Physician Pricing and Health Insurance Reimbursement," Health Care

Financing Review, (December 1983), pp. 69-80. 12. Hay JW, Leahy M. "Competition Among Health Plans: Some Preliminary Evidence," Southern Economic

Journal 50 (January 1984), pp. 831-847. 13. Hay JW, Mandes G. "Home Health Care Cost-Function Analysis," Health Care Financing Review 5(3),

(Spring 1984), pp. 111-116. 14. Hay JW, Olsen R. "Let Them Eat Cake: A Note on Comparing Alternative Models of the Demand for

Medical Care," J Business and Economic Statistics 2(3), (July 1984), pp. 279-282. 15. Hay JW. "Occupational Choice and Occupational Earnings: A Method for Dealing with Selection Bias

Among Economic Activities," in Research in Population Economics, Volume 5, edited by T. Paul Schultz and Kenneth Wolpin, JAI Press, Greenwich, Connecticut (1984) pp. 309-329.

16. Hay JW. "Variation in Per Capita Pharmaceutical Expenditures: Are Drugs Complements or Substitutes?" In

Pharmaceutical Economics, Bjorn Lindgren, ed., Liber Forlag Press, Malmo, Sweden, 1985, pp. 21-36.

Joel W. Hay, Ph.D. -- C.V. -21- 10/18/18 17. Yett D, Der W, Ernst R, Hay JW. "Fee Screen Reimbursement and Physician Fee Inflation," Journal of

Human Resources 20(2), (Spring, 1985), pp. 278-291. 18. Hay JW, Hill WL. "Cost-Effectiveness of Two Transdermal Nitroglycerin Controlled-Release Systems,"

Clinical Therapeutics, 8(1), 1985, pp. 35-40. 19. Sloan F, Hay JW. "Medicare Pricing Mechanisms for Physician Services: An Overview of Alternative

Approaches," Medical Care Review, 43(1), (Spring, 1986), pp. 59-100. 20. Hay JW, Ernst R. "The Cost Effectiveness of Home Intravenous Antibiotics," in Proceedings: Outpatient

Parenteral Antibiotic Therapy Symposium, J.E. Putnam, Ed., IntraMed, New York, NY, 1987 pp. 7-14. 21. Welch B, Hay JW, Miller D, Olsen R, Rippey R, Welch A. "The Rand Health Insurance Study: A Summary

Critique," Medical Care, 25(2), (February 1987) pp. 148-156. 22. Hay JW, Daum R. "Cost Benefit Analysis of Two Strategies for Prevention of Haemophilus Influenzae Type

B Infection," Pediatrics, 80(3) (September 1987) pp. 319-329. 23. Hay JW, Leu R, Rohrer P. "Ordinary Least Squares and Sample Selection Models of Health Care Demand:

Monte Carlo Comparison," Journal of Business and Economic Statistics, 1987; 5(4):499-506. 24. Hay JW, Ernst R. "The Economic Costs of Alzheimer's Disease," American Journal of Public Health, 77(9)

(September 1987) pp. 1-7. 25. Hay JW, Anderson G. "The Hospital Services Market: A Disequilibrium Analysis," Southern Economic

Journal, 54(3) (January 1988) pp. 656-665. 26. Hay JW, Osmond D, Jacobson M. "Projecting the Medical Costs of AIDS and ARC in the United States,"

Journal of Acquired Immune Deficiency Syndromes, 1(5) (October 1988) pp. 466-485. 27. Hay JW. "Cost-Effectiveness of Three Transdermal Nitroglycerin Controlled-Release Systems," Clinical

Therapeutics, 10(4), 1988, pp. 450-455. 28. Hay JW. "Econometric Issues in Modeling the Costs of AIDS," paper presented at the Johns Hopkins

University Conference on The Economic Impact of AIDS: Research Methodology. Health Policy, 11(2) (April 1989) pp. 125-145.

29. Hay JW. "Projecting the Medical Costs of HIV/AIDS: An Update with Focus on Epidemiology." In New

Perspectives on HIV-Related Illness: Progress in Health Services Research--Conference Proceedings. National Center for Health Services Research, Pub. No. DHHS (PHS) 89-3449. 1989:84-97. Rockville, MD.

30. Hay JW. "The Health Care Cost Crisis," in L. Holland, ed., Managed Health Care Strategies for the 1990s:

Proceedings of a Symposium for Managed Care Professionals, IntraMed, New York, 1990 pp. 30-39. 31. Hay JW. "AIDS Point and Counterpoint." Priorities; the American Council on Science and Health, Winter

1990, pp. 35-39. 32. Wittels E, Hay JW, Gotto A. "Medical Costs of Coronary Artery Disease." American Journal of Cardiology,

February 1990, Vol. 65, pp. 432-440. 33. Hay JW, Daum R."Cost-benefit Analysis of Haemophilus influenzae Type B Prevention: Conjugate

Vaccination at Eighteen Months of Age," Ped Inf Dis J, April 1990, Vol. 9, pp. 246-252.

Joel W. Hay, Ph.D. -- C.V. -22- 10/18/18 34. Gotto A, LaRosa J, Hunninghake D, Grundy S, Wilson J, Clarkson T, Hay JW. "The Cholesterol Facts: A

Summary of the Evidence Relating Dietary Fats, Blood Cholesterol and Coronary Artery Disease" A Joint Statement of The American Heart Association and the National Heart, Lung and Blood Institute. Circulation, May 1990, Vol. 81, No. 5, pp. 1721-1733.

35. Hay JW. "Physicians' Specialty Choice and Specialty Income," in G. Duru and J. H. P. Paelinck, eds.

Econometrics of Health Care, Kluwer Academic Publishers, Amsterdam, Holland, 1990. pp. 95-113. 36. Hay JW, Robin E. "Cost-Effectiveness of Alpha-1 Antitrypsin Replacement Therapy in Treatment of

Congenital Chronic Obstructive Pulmonary Disease." American Journal of Public Health, April 1991, Vol. 81, No. 4, pp. 427-433.

37. Hay JW, Wittels E, Gotto A. "An Economic Evaluation of Lovastatin for Cholesterol Lowering and

Coronary Artery Disease Reduction," American Journal of Cardiology, April 15, 1991, Vol. 67, No. 9, pp. 789-796.

38. Hay JW. "Is Hong Kong Ready for Free Market Health Care?" in Financing Health Care in the 1990s, Hong

Kong Medical Association and Hong Kong Society of Medical Executives, September 1991, pp. 16-21. 39. Hay JW. "The Harm They Do to Others: A Primer on the External Costs of Drug Abuse," in E. Lazear and

M. Krauss, eds. Searching for Alternatives: Drug Control Policy in the United States, Hoover Institution Press, Stanford, CA, November 1991, pp. 200-225.

40. Hay JW, Hay AR. "Inflammatory Bowel Disease Costs-of-Illness," Journal of Clinical Gastroenterology,

1992, Vol. 14, No. 4, pp. 309-317. 41. Hay AR, Hay JW. "Inflammatory Bowel Disease Medical Cost Algorithms," Journal of Clinical

Gastroenterology, 1992, Vol. 14, No. 4, pp. 318-327.

42. Hay JW. Health Care in Hong Kong: An Economic Policy Assessment, Chinese University Press, Hong Kong; 1992, 124pp. Chinese Language Edition, Chinese University Press, 1993, 114 pp.

43. Hay JW. "Pharmacoeconomics in the Hospital," California Journal of Hospital Pharmacy, Vol. 5, November

1993, pg. 7.

44. Hay JW, Ernst R. A Perspective on the Costs and Benefits of Combination Vaccination for Prevention of Haemophilus Influenzae type B, Diphtheria, Pertussis and Tetanus, Vaccine Bulletin. December 1993, 1 - 7.

45. Hay JW, Kizer K. "Medi-Cal Expenditures for Persons with AIDS," AIDS and Public Policy Journal, Vol.

8, No. 2, Summer, 1993, pp. 91-102.

46. Hay JW. "Incorporating Pharmacoeconomics into your Business Plan," Managed Health Care Pharmacy Vol. 1, No. 4., December 1993, pp. 11-13.

47. Hay JW, Wolak F. "A Procedure for Estimating the Unconditional HIV Infection Distribution and Its

Variability." Journal of the Royal Statistical Society, Series C: Applied Statistics, 1994; 43(4): 599-624.

48. Bozzette S, Parker R, Hay JW. "A Cost Analysis of Approved Antiretroviral Strategies in Advanced Human Immunodeficiency Virus Disease," Journal of AIDS, Vol. 7, 1994, pp. 355-362.

49. Ernst R, Hay JW. "The Economic and Social Costs of Alzheimer's Disease Revisited," American Journal of

Public Health, Vol. 84, No. 8, August 1994, pp. 1261-64. 50. DiMasi J, Mitchell J, Hay JW. "The Cost of Drug Development," Pharmacy and Therapeutics, Vol 19 No.

1, January 1994, pp. 68-80.

Joel W. Hay, Ph.D. -- C.V. -23- 10/18/18 51. Hay JW. "Evaluation of Pharmacoeconomics Studies," Annals of Pharmacotherapy, 1994;28:539-40. 52. McCombs J, Nichol M, Johnson K, Hay JW, Ebin V, Lawrence G, Schneider J. The Health Care

Reformation and Pharmaceutical Care: Is Pharmacy’s Vision Too Narrow? American Journal of Health-Systems Pharmacy, Vol. 52, June 1, 1995. pp. 1208-14.

53. McCombs J, Cody M, Besinque K, Borok G, Ershoff D, Groshen S, Hay JW, et al. “Measuring the Impact of

Patient Counseling in the Outpatient Setting: The Research Design of the Kaiser Permanente/USC Patient Consultation Study,” Clinical Therapeutics, Vol 17, No. 6, 1995. pp. 1188-1206.

54. Ashraf TA, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, Furberg C, Radican L. “Cost

Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery Disease,” American Journal of Cardiology Vol 78, 1996. pp. 409-414.

55. Hay JW. “Commentary: The Scope of the AIDS Epidemic in the United States,” JAMA HIV/AIDS Journal

Scan Website, January 1996. 56. Hay JW, Ernst R, Meissner C. “Respiratory Syncytial Virus Immune Globulin: A Cost Effectiveness

Analysis,” American Journal of Managed Care Vol 2, No. 7, 1996. pp. 851-861.

57. Gotto, A., Hay JW. “Costs of Lipid-Lowering Statin Drugs,” Readers’ Comments, American Journal of Cardiology, January 15, 1996, Vol. 77, pp. 225-226.

58. McCombs, J, Nichol M, Johnson, K, Hay JW, Ebin, V, Lawrence G, Schneider, J. La Visione del Futuro della Farmacia è troppo limitata? Pro Pharmacopæa Supplemento Redazionale a L’Informatore Farmacuetico-Aggiornamento. Vol. 3 # 1, 1996; pp. 17-24.

59. Ernst R, Hay JW, Fenn C, Tinklenberg J, Yesavage J. “Cognitive Function and the Costs of Alzheimer’s

Disease: An Exploratory Study,” Archives of Neurology, Vol. 54, 1997. pp. 687-693. 60. Ernst R, Hay JW. “Economic Research on Alzheimer Disease: A Review of The Literature,” Alzheimer

Disease and Associated Disorders, 1997. Vol. 11, Suppl 6, pp. 135-145. 61. Hay JW, Sano M, Whitehouse P. The Cost and Social Burdens of Alzheimer Disease. Editorial. Alzheimer

Disease and Associated Disorders. 1997, Vol. 11, No. 4, pp.1-3. 62. Clark, F. Azen, S, Zemke, R, Jackson J, Carlson, M, Mandel, D, Hay JW, et al. Occupational Therapy for

Independent-Living Older Adults: A Randomized Controlled Trial. JAMA, 1997; Vol. 278 pp. 1321-1326. 63. Hay JW, Yu W, Ashraf T. “Pharmacoeconomics of Lipid-lowering Agents for Primary and Secondary

Prevention of Coronary Heart Disease,” Pharmacoeconomics, 1998; Vol. 15, No. 1, pp.47-74. 64. Hay JW, Schwartz S. “The ISPOR Lipid Conference,” Value in Health 1998. Vol. 1, No. 2. pp. 95-99. 65. Langley PC, Hay JW, Schwartz JS, Smith SC, McKenney J. From Research into Practice: How Should

Healthcare Organizations/Governments Decide About Lipid Therapy and Who Will Pay? Value in Health 1998. Vol. 1, No. 4. pp. 243-250.

66. Hay JW. “Economic Modeling and Sensitivity Analysis.” Value in Health 1998; 1(3) pp.187-193. 67. Hay JW, Ernst R. “A Direction for Value in Health,” Value in Health 1998. Vol 1, No. 3, pp. 149-154. 68. The International Working Group on Alzheimer’s Disease (JW Hay, member). First International

Pharmacoeconomic Conference on Alzheimer's Disease: Report and Summary. Alzheimer Disease and Associated Disorders, 1998. Volume 12, No. 4, pp. 266-280.

Joel W. Hay, Ph.D. -- C.V. -24- 10/18/18 69. McCombs JS, Cody M, Parker JP, Johnson KA, Besinque K, Borok G, Ershoff D, Groshen S, Hay JW,

Nichol MB, Nye MT. The Kaiser Permanente/USC Patient Consultation Study: Change in Use and Cost of Health Services. Am J Health-Syst Pharm 1998. Vol. 55, No. 2, pp. 2485-99.

70. Hay JW, Yu W. “Drug Patents and Prices, Can We Achieve Better Outcomes?” in Triplett J, ed. Measuring

the Prices of Medical Treatments, Brookings Press, Washington, DC. 1999, pp.152-195. 71. Hay JW, Jackson J. Methodological Issues in Conducting Pharmacoeconomic Evaluations—Modeling

Studies. Value in Health, 1999. Vol. 2 (No. 3), pp.78-81.

72. Hay JW, Ernst R, Kessler CM. “Cost-effectiveness analysis of alternative factor VIII products in treatment of hemophilia A,” Haemophilia, 1999, Vol. 5, pp. 191-202.

73. Gotto A, Grundy S, …, Hay JW,… et al. Lowering LDL Cholesterol: Questions From Recent Meta-Analyses

and Subset Analyses of Clinical Trial Data Issues From the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council Meeting. Circulation. 1999;99:E1-E7.

74. Hay JW. “Health Care Costs and Outcomes: How Should We Evaluate Real World Data?” Value in Health,

1999. Vol. 2 (No. 6), 417-20. 75. Hay JW, Yu W. Prevalence, Patient Awareness, and Treatment of Dyslipidemia in the Diabetes Mellitus

Population. Drug Benefit Trends, 1999. Suppl pp. 6-11. 76. Liu G, Hay JW. “An Economic Cost Analysis of Oral Ganciclovir Prophylaxis for the Prevention of CMV

Disease,” Pharmaceutical Research. 2000, 17(8): pp. 909-917.

77. Hay JW, Yu W, Ashraf T. “Pharmacoeconomics of Lipid-lowering Agents for Primary and Secondary Prevention of Coronary Heart Disease,” In: Prakash A, editor. Preventing Coronary Heart Disease. Auckland: Adis International Ltd, 2000: pp. 49-77

78. Marcy M, Takata G, Chan LS, Shekelle P, Mason W, Wachsman L, Ernst R, Hay JW, Corley PM, Morphew

T, Ramicone E, Nicholson C. Management of acute otitis media. Evid Rep Technol Assess. 2000 Jun;(15):1-4. 79. Hay JW, Yu W. Pharmacoeconomics and Outcomes Research: Expanding the Health Care “Outcomes”

Market. Value in Health, 2000. 3(3). pp. 181-185. 80. Hay JW. Commentary: Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes: Who

Should Be Treated? Journal of Evidence-Based Healthcare. 2001. 5(1): pp. 27-29. 81. Hay JW. Pharmacoeconomic Guidelines: Where do we go from here?” Value in Health, 2001. 4(3):211. 82. Clark F, Azen S, Carlson M, Mandel D, LaBree L, Hay JW, Zemke R, Jackson J, Lipson L. Embedding

health-promoting changes into the daily lives of independent-living older adults: Long-term follow-up of occupational therapy intervention. Journal of Gerontology: Psychological Sciences, 2001. 56B:60-63.

83. Hay JW. “Conjoint Analysis in Pharmaceutical Research.” J Managed Care Pharmacy 2002; 8(3):206-209. 84. Hay JW, LaBree L, Luo R, Clark F, Carlson M, et al. “Cost Effectiveness of Preventive Occupational

Therapy for Independent Living Adults.” Journal of the American Geriatrics Society. 2002 50(8):1381-1388. 85. Hay JW. Pharmacoeconomics of Lipid Management. Managed Care Consultant. 2002; 2(2): 54-64. 86. Boone J, Hay JW, Aguanno J, Getzen T, Hortin G. Are the Correct Economic Factors Influencing Point-of-

Care Testing? Point of Care; 2002 Vol. 1, #3, pp.212-221. 87. Hay JW. Long-term pravastatin treatment has sustained benefits for people with coronary heart disease.

Evidence-Based Cardiovascular Medicine, December 2002; 6:146-47.

Joel W. Hay, Ph.D. -- C.V. -25- 10/18/18 88. Hay JW. Expensive Medical Conditions. Health Affairs, November/December 2002; 21(6):271-72.

89. Knapp KK, Ray MD. (for the Pharmacy Research Roundtable, JW Hay member). A pharmacy response to

the Institute of Medicine's 2001 initiative on quality in health care. Am J Health-Syst. Pharm. 2002; 59:2443-50.

90. Hay JW. Recent U.S. Trends in Lipid Medication Use: 1998-2001. Cardiology Review, April 2003. 20(4)

Suppl: 35-37. 91. Chiou C-F, Hay JW, Wallace J, Bloom B, Neumann P, Sullivan S, Yu H-T, Keeler E, Henning J, Ofman J.

Development and Validation of A Grading System for the Quality of Cost-Effectiveness Studies. Medical Care 2003; 41:32–44.

92. Ofman J, Sullivan S, Neumann P, Chiou C-F, Henning J, Hay JW. Examining the Value and Quality of

Health Economic Analyses: Implications of Utilizing The QHES. Journal of Managed Care Pharmacy, 2003; 9(1):53-62.

93. Yuan Y, Hay JW, McCombs J. Mortality and Hospitalization Impacts of Pharmacy Consultation in

Ambulatory Care. American Journal of Managed Care. 2003; 9(1):101-112. 94. Forrest S, Goetghebeur M, Hay JW. “Understanding the Underlying Drivers of Inpatient Cost Growth: A

Literature Review. American Journal of Managed Care. 2003, 9(S1):S3-S13. 95. Hay JW. Hospital Cost Drivers: An Evaluation of 1998-2001 State-Level Data. American Journal of

Managed Care. 2003, 9(S1):S14-S24. 96. Etemad L, Hay JW. Cost Effectiveness Analysis of Pharmaceutical Care in a Medicare Drug Benefit

Program. Value in Health. 2003, 6(4):425-435. 97. Hay JW. Evaluating the Cost-Effectiveness of Statins. Journal of Managed Care Pharmacy. 2004; 10(1):

79-81. 98. Chen L, Hay JW. Cost-Effectiveness of Implanted Cardioverter Defibrillator for Sudden Death Prevention in

Congestive Heart Failure. Journal of Cardiovascular Drugs and Therapy. 2004; 18(2): 161-170. 99. Dwight-Johnson M, Largomarsino I, Aisenberg E, Hay JW. “Understanding Depression Treatment

Preferences among Low-Income Latinos using Conjoint Analysis”. Psychiatric Services 2004;55(8):934-37. 100. Purdy K, Hay JW, Botteman M, Ward J. “Cost-Benefit Analysis of Selective Strategies for use of Acellular

Pertussis Vaccine in Adolescents and Adults.” Clinical Infectious Diseases 2004; 39:20–28. 101. Hay JW. “Evaluation and Review of Pharmacoeconomic Models.” Expert Opinion on Pharmacotherapy,

2004; 5(9):1867-80. 102. Pharmacy Practice Research Roundtable (JW Hay, member). Advancing Pharmacy Practice Through

Research: A 2004 Perspective. J Am Pharm Assoc. 2004;44:621–628. 103. Narayan S, Hay JW. Cost-effectiveness of generic Ritalin® (methylphenidate) versus generic Adderall®

(amphetamine/dextroamphetamine mixed salts) for first-line treatment of attention deficit/hyperactivity disorder (ADHD) in children. Expert Review of Pharmacoeconomics & Outcomes Research, 2004; 4(6):1-8.

104. Hay JW, Zammit DC. Vaccine Policy Perspectives: Market Strategies. Paper commissioned by the Institute

of Medicine to support: Financing Vaccines in the 21st Century. Assuring Access and Availability. Institute of Medicine of the National Academies. The National Academies Press, Washington, D.C. 2004.

105. Hay JW. Cost Effectiveness of Cardiovascular Medicines. Current Atherosclerosis Reports, 2005, 7:79-80.

Joel W. Hay, Ph.D. -- C.V. -26- 10/18/18 106. Hay JW, Sterling K. “Cost Effectiveness Analysis of Fibrates for Dyslipidemia.” Pharmacoeconomics.

2005; 23(2):133-141.

107. Letourneau-Wagner J, Hay JW. “The Cost Impacts of Vaccination in the United States: An Overview.” Managed Care Consultant 2005; 4[2]:11-25.

108. Hay JW. “Application of Cost Effectiveness and Cost Benefit Analysis to Pharmaceuticals.” Chapter 14 in

Santoro M, Gorrie T, eds. The Grand Bargain: Ethics and the Pharmaceutical Industry In the 21st Century. Cambridge University Press, New York NY, 2005:225-248.

109. Fitzner K, Fox K, Schmidt J, Roberts M, Rindress D, Hay JW. Implementation and Outcomes of

Commercial Disease Management Programs in the United States: The Disease Management Outcomes Consolidation Survey. Disease Management Journal 2005; 8(4):253-64.

110. Hay JW. “Appropriate Econometric Methods for Pharmacoeconometric Studies of Retrospective Claims

Data: An Introductory Guide.” J Managed Care Pharmacy. 2005; 11(4): 344-348. 111. Hay JW, Ward J. Economic Considerations for Pertussis Booster Vaccination in Adolescents. Pediatric

Infectious Disease Journal 2005; 24(6): S127-S133. 112. Hay JW, Leahy M. “Cost Effectiveness of Oral Antihistamines in the California Medi-Cal Program.” Value

in Health 2005; 8(4):506-16.

113. Zhang L, Hay JW. “Cost Effectiveness Analysis of Rizatriptan and Sumatriptan versus Cafergot in the Acute Treatment of Migraine.” CNS Drugs 2005; 19(7): 635-642.

114. Forrest S, Goetghebeur M, Hay JW. Medicare Part B coverage and reimbursement of outpatient prescription

drugs: impact of current policy on clinical practices and health care expenditures. Applied Health Economics and Health Policy 2005; 4(1):9-14.

115. Hay JW. “Pharmacist Medication Review Study Design Concerns,” Rapid Response Letter, BMJ, January 28, 2005. (http://bmj.bmjjournals.com/cgi/eletters/bmj.38338.674583.AEv2).

116. Hay JW. “Where’s the Value in Health Care?” Value in Health; 2006; 9(2):11-14. 117. Stephens JM, Botteman MF, Hay JW. “Impact of Antidiabetic Medications on Utilization, Costs, and

Glycemic Control within Managed Care Organizations: A Review of the Literature.” J Managed Care Pharmacy 2006; 12(2):130-142.

118. Botteman M, Barghout V, Stephens J, Hay JW, Brandman J, Aapro M. Cost effectiveness of

bisphosphonates in the management of breast cancer patients with bone metastases. Annals of Oncology, July 2006; 17: 1072-1082.

119. Spalding J, Hay JW. “The Cost-Effectiveness of Tumor Necrosis Factor Alpha Inhibitors as First-Line

Agents in Rheumatoid Arthritis.” Pharmacoeconomics 2006; Vol. 24 (12): pp. 1221-1232. 120. Hay JW. “Comment on Comparing Patient Access to Pharmaceuticals in UK and US. Applied Health

Economics and Health Policy 2006; Vol. 5 (4): pp. 269-270(2). 121. Botteman MF, Hay JW, van Hout BA, Curry A, Wong R, Luo MP. Cost effectiveness of Adalimumab

Therapy vs. Conventional Care in UK Patients with Active Ankylosing Spondylitis (AS). Rheumatology 2007 46(8):1320-1328.

122. Carpiuc KT, Stephens JM, Botteman MF, Feng W, Hay JW. A review of the clinical and economic outcomes

of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy. November 2007, Vol. 8(16), pp. 2775-2787.

Joel W. Hay, Ph.D. -- C.V. -27- 10/18/18

123. Hay JW, Rindress D, Editors. Disease Management Principles and Practices: The Current State of the Art.

Disease Management Association of America, Washington, DC. 2007.

124. Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW. Economic Burden of Haematological Adverse Effects in Cancer Patients: A Systematic Review. Clinical Drug Investigations 2007; 27(6): 381-96.

125. Costanzo MR, Johannes RS, Pine M, Gupta V, Saltzberg M, Hay JW, Yancy CW, Fonarow GC. “Effects of intravenous therapies on outcomes of inpatients with acutely decompensated heart failure: A propensity analysis using the ADHERE database.” American Heart Journal. July 2007; 154: 267-277.

126. Yuan Y, Iloeje U, Li H, Hay JW, Yao GB. Economic Implications of Entecavir Treatment in Suppressing

Viral Replication In Chronic Hepatitis B (Chb) Patients In China. Value in Health March 2008; 11:S11-S22. 127. Zeiger R, Hay JW, Contreras R, Chen W, Quinn V, Seal B, Schatz M. “Risk-Stratified Medical Costs for

Asthma Patients in a Managed Care Organization (MCO).” J Allergy and Clinical Immunology. 2008; 121:885-92.

128. Yuan Y, Iloeje U, Hay JW. Long-Term Cost Effectiveness of Entecavir in Suppressing Viral Replication in

Chronic Hepatitis B (CHB) Patients Compared with Lamivudine.” J Managed Care Pharmacy. 2008; 14(1):21-33.

129. Gabel J, Fahlman C, Kang R, Kletke P, Wozniak G, Hay JW. Where Do I Send Thee? Does Physician-

Ownership Affect Referral Patterns to Ambulatory Surgery Centers? Health Affairs, 2008; 27:w165-w174. 130. Hay JW. Using Pharmacoeconomics to Value Pharmacotherapy. Clinical Pharmacology and Therapeutics.

2008; 84(2):197-200. 131. Hay JW. “Prices and Innovation in Pharmaceuticals and Biotechnology.” Chapter 5, pp. 81-99; in Research

in Human Capital and Development, Volume 16, The Value of Innovation: Impact on Health, Life Quality, Safety, and Regulatory Research, edited by Irina Farquhar, Kent Summers and Alan Sorkin. Emerald Group Publishing Limited, Bingley, U.K. 2008.

132. Hay JW. “The Pharmacoeconomics of Elevated Triglycerides and Their Management.” Medscape Expert

Column. June 16, 2008; (http://www.medscape.com/viewarticle/575862_print).

133. Orlewska E, Zammit D, Yuan Y, Kutikova L, Berak H, Halota W, Hay JW. Cost-effectiveness analysis of entecavir in the treatment of chronic hepatitis B (CHB) patients in Poland. Exp Clin Hep 2008; 4(3-4):20-28.

134. Gu NY, Gai Y, Hay JW. “The Effect of Patient Satisfaction with Pharmacist Consultation on Medication

Adherence: An Instrumental Variable Approach.” Pharmacy Practice, 2008 Oct-Dec;6(4):201-210.

135. Scranton R, Dhingra R, Lawler E, Hay JW, Yucel K, Guo A, Balzer T, Gaziano J. “A Six-Year Study of Diagnostic Lower Extremity Imaging Practice Patterns and Outcomes in Veterans Affairs Healthcare System.” International Journal of Angiology. 2008; 17(2): 78-82.

136. Le Q, Hay JW. Cost-Effectiveness Analysis of Lapatinib in HER2-Positive Advanced Breast Cancer.

Cancer 2009;115:489–98.

137. Hay JW, Scranton R, Yucel K, Guo A, Balzer T, Gaziano J. “Cost Impact of Diagnostic Imaging for Lower Extremity Peripheral Vascular Disease (PVD).” Value in Health 2009; 12(2):262-266.

138. Hay JW, Kaliner M. Review of the Pharmacoeconomics of Second-Generation Antihistamines in the

Treatment of Allergic Rhinitis: A U.S. Perspective. Current Medical Research and Opinion. 2009; 25(6): 1421-1431.

Joel W. Hay, Ph.D. -- C.V. -28- 10/18/18 139. Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal

B, Shi L. Good Research Practices in Measuring Drug Costs for Cost Effectiveness Analysis: A Report of the ISPOR Drug Cost Task Force. Value in Health 2010; 13(1):3-7.

140. Hay JW, Jhaveri M, Tangirala MK, Kaliner M. Cost and Resource Utilization Comparisons of Second Generation Antihistamines vs. Montelukast in Treatment of Allergic Rhinitis: Retrospective Analysis of a Large National Insurance Claims Database. Allergy and Asthma Proceedings 2009 Nov-Dec;30(6):634-42.

141. Garrison LP, Mansley E, Abbott T, Bresnahan B, Hay JW, Smeeding J. Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Part II: A Societal Perspective. Value in Health 2010; 13(1):8-13.

142. Mansley E, Carroll N, Chen K, Shah N, Tak Piech C, Hay JW, Smeeding J. Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Managed Care Perspective - A Report of the ISPOR Drug Cost Task Force Part III. Value in Health 2010; 13(1):14-17.

143. Mullins CD, Seal B, Seoane-Vazquez E, Sankaranarayanan J, Asche C, Jayadevappa R, Lee W, Romanus D,

Wang J, Hay JW, Smeeding J. Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Report of the ISPOR Drug Cost Task Force – Part IV: Medicare, Medicaid and Other US Government Payers Perspectives. Value in Health 2010; 13(1):18-24.

144. Hay JW, Zhou Z. Commentary: A systematic review of the cost-effectiveness of rFVIIa and APCC in the

treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia 2010; 16(2):366-368.

145. Mycka J, Dellamano R, Kolassa EM, Wonder M, Ghosh S, Hay JW, Smeeding J. Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: A Report of the ISPOR Drug Cost Task Force – Part V. Value in Health 2010; 13(1):25-27.

146. Shi L, Hodges M, Drummond M, Ahn J, Li SC, Hu S, Augustovski F, Hay JW, Smeeding J. Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An International Perspective: A Report of the ISPOR Drug Cost Task Force – Part VI. Value in Health 2010; 13(1):28-33.

147. Dwight-Johnson M, Lagomarsino I, Hay JW, Zhang L, Tang L, Green JM, Duan N. “Effectiveness of Collaborative Care in Addressing Depression Treatment Preferences Among Low-Income Latinos.” Psychiatric Services. Nov 2010; 61: 1112 - 1118.

148. Skrepnek GH, Seal B, Tangirala M, Hay JW. “Adverse Events and Intravenous Versus Oral Bisphosphonate Use in Patients With Osteoporosis and Cancer in the U.S.” General Dentistry, November/December 2010; 58(6):484-92.

149. Mark TL, Joish VN, Hay JW, Sheehan D, Johnson S, Cao Z. “Antidepressant use in geriatric populations:

the burden of side-effects and interactions on adherence and costs.” American Journal of Geriatric Psychiatry. March 2011; 19(3):211–221. http://dx.doi.org/10.1097/JGP.0b013e3181f1803d

150. Clark F, Mandel D, Carlson M, Chou C-P, Cherry B, Jordan-Marsh M, Knight B, Mandel D, Blanchard J, Granger DA, Wilcox RR, Lai MY, White B, Hay JW, Lam C, Marterella A, Azen S. “Effectiveness of a Lifestyle Intervention in Promoting the Wellbeing of Independently Living Older People: Results of the Well Elderly 2 Randomised Controlled Trial.” Journal of Epidemiology and Community Health, 2012 Sep; 66(9):782-90. http://dx.doi.org/10.1136/jech.2009.099754

151. Hay JW, Zhou Z. Economic comparison of aPCC vs rFVIIa in the home treatment of mild-to-moderate bleeding episodes in hemophilia patients with inhibitors. Haemophilia. 2011 Sep;17(5):e969-74.; http://dx.doi.org/10.1111/j.1365-2516.2011.02589.x

152. Ganapathy V, Hay JW, Kim JH. Analysis of Costs of Necrotizing Enterocolitis Among Extremely Premature

Infants Fed Mother’s Own Milk Fortified with Human-milk Based Supplement versus Bovine-milk based Supplement. Breastfeeding Medicine. February 2012, 7(1): 29-37. http://dx.doi.org/10.1089/bfm.2011.0002

Joel W. Hay, Ph.D. -- C.V. -29- 10/18/18 153. Hay JW, Zhou Z. aPCC versus rFVIIa in treatment of hemophilia patients with inhibitors: A structured

review of the pharmacoeconomic literature. Journal of Medical Economics, 2011; 14(4):516-525.

154. Hay JW, Katon W, Ell K, Lee P-J, Guterman J. An Economic Evaluation of Collaborative Care Management of Major Depression among Low-Income, Predominantly Hispanics with Diabetes. Value in Health, 2012 Mar-Apr;15(2):249-54. http://dx.doi.org/10.1016/j.jval.2011.09.008

155. Zhou Z, Hay JW. A systematic review and classical meta-analysis comparing the efficacy of bypassing agents in hemophilia patients with inhibitors. Clinical Therapeutics, February 2012; 34(2): 434-445. http://dx.doi.org/10.1016/j.clinthera.2012.01.001

156. Ding Y, Zangwill KM, Hay JW, Allred N, Yeh S. Cost-benefit Analysis of In-hospital Influenza Vaccination of Postpartum Women. Obstetrics & Gynecology, February 2012; 119(2, Part 1): 306-314. http://dx.doi.org/10.1097/AOG.0b013e318242af27

157. Suh H, Hay JW, Johnson K, Doctor J. Comparison of Cardiovascular Events between a Statin plus Fibrate

Combination Therapy and a Statin Monotherapy in Patients with Diabetes. Pharmacoepidemiology and Drug Safety, 2012; 21: 470–484. http://dx.doi.org/10.1002/pds

158. Kawatkar AA, Hay JW, Stohl W, Nichol MB. Incremental Expenditure of Biologic Disease Modifying Anti-

Rheumatic Treatment Using Instrumental Variables in Panel Data. Health Economics, July 2013. 22(7):807–823. http://dx.doi.org/10.1002/hec.2855

159. Hay JW, Chaugule SC, Young G. Bypass therapy assay testing as a strategy to reduce costs for treatment of hemophilia patients with inhibitors. Haemophilia, 2013. 19(5): 711–719; http://dx.doi.org/10.1111/hae.12171

160. Dwight Johnson MD, Hay JW, Unutzer J, Apesoa-Varano C, Hinton L. Depression Treatment Preferences of Older White and Mexican American Men. General Hospital Psychiatry, 2013. 35(1): 59-65. http://dx.doi.org/10.1016/j.genhosppsych.2012.08.003.

161. Ding Y, Yeh SH, Mink C, Zangwill KM, Allred NJ, Hay JW. Cost-benefit Analysis of In-hospital TDaP

Vaccination of Postpartum Women. Vaccine. 2013; 31:2558–2564. http://dx.doi.org/10.1016/j.vaccine.2013.03.053.

162. Messali A, Hay JW, Villacorta R. The Cost-Effectiveness of Temozolomide in the Adjuvant Treatment of

Newly Diagnosed Glioblastoma in the United States: A Literature Review and Markov Model. Neuro-Oncology. 2013; 15(11):1532-1542. http://dx.doi.org/10.1093/neuonc/not096

163. Hay JW (Section Chair). “Statistical Approaches for Evaluating Disease and Health Management Data,” in Esposito D, Migliaccio-Walle K, Molsen E., Editors. “Reliability and Validity of Data for Outcomes Research & Disease and Health Management Programs ISPOR Outcomes Good Practices Series, ISPOR, Princeton, NJ, 2013. Chapter 29, pp. 343-346.

164. Jain R, Hay JW. “Statistical Methods for Randomized Controlled Trials: Discrete Outcomes,” in Esposito D, Migliaccio-Walle K, Molsen E., Editors. “Reliability and Validity of Data for Outcomes Research & Disease And Health Management Programs ISPOR Outcomes Good Practices Series, ISPOR, Princeton, NJ, 2013. Chapter 34, pp. 365-373.

165. Petersen H, Hay JW. “Statistical Methods for Randomized Controlled Trials: Propensity Scores,” in Esposito D, Migliaccio-Walle K, Molsen E., Editors. “Reliability and Validity of Data for Outcomes Research & Disease and Health Management Programs ISPOR Outcomes Good Practices Series, ISPOR, Princeton, NJ, 2013. Chapter 40, pp. 405-408.

166. Hay JW. “Statistical Methods for Randomized Controlled Trials: Nonparametric Statistical Methods,” in

Esposito D, Migliaccio-Walle K, Molsen E., Editors. “Reliability and Validity of Data for Outcomes Research & Disease and Health Management Programs ISPOR Outcomes Good Practices Series, ISPOR, Princeton, NJ, 2013. Chapter 45, pp. 427-432.

Joel W. Hay, Ph.D. -- C.V. -30- 10/18/18

167. Aponte-González J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW. Cost-Effectiveness

Analysis of the Bivalent and Quadrivalent Human Papillomavirus Vaccines from a Societal Perspective in Colombia. PLOS One, 2013; 8(11): e80639. http://dx.doi.org/10.1371/journal.pone.0080639

168. Hay JW. Competition, Market Power and Pricing in Brand Name Pharmaceutical Markets. Harvard Health

Policy Review. Spring 2013 Vol. 14, No. 1; pp. 8-9. 169. Ganapathy V, Hay JW, Kim JH, Lee ML, Rechtman DL. Healthcare costs among survivors of neonatal

necrotizing enterocolitis in a Medicaid cohort. BMC Pediatrics, 2013, Vol. 13:127 http://doi:10.1186/1471-2431-13-127

170. Bollu V, Ejzykowicz F, Rajagopalan K, Karafilidis J, Hay JW. Risk of all-cause hospitalization in COPD

patients initiating long-acting or short-acting beta agonist therapy. Journal of Medical Economics, 2013, 16(8):1082-1088. http://dx.doi.org/10.3111/13696998.2013.815625

171. Villacorta R, Hay JW, Messali A. Cost effectiveness of moderate to severe psoriasis therapy with etanercept

and ustekinumab in the United States. PharmacoEconomics 2013; 31:823–839. http://dx.doi.org/10.1007/s40273-013-0078-x

172. Mehta D, Hay JW. “Cost-Effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.” Gynecologic Oncology 2014; 132(3):677-683. http://dx.doi.org/10.1016/j.ygyno.2014.01.021.

173. Gong C, Hay JW. “Cost-effectiveness analysis of abiraterone and sipuleucel-T in metastatic castration-

resistant prostate cancer." Journal of the National Comprehensive Cancer Network 2014;12(10):1417–1425. http://www.jnccn.org/content/12/10/1417.full

174. Villacorta R, Hay JW, Messali A. Novel methods of measuring clinical outcomes from psoriasis and

psoriatic arthritis clinical trials. Expert Review of Pharmacoeconomics and Outcomes Research, 2014; 14(4):1-14. http://dx.doi.org/10.1586/14737167.2014.917970

175. Hay JW. Current Issues in Pharmacoeconomic Modeling. Journal of Health Technology Assessment,

2014;2(1):6-9. 176. Messali A, Villacorta R, Hay JW. “A Review of the Economic Burden of Glioblastoma and the Cost

Effectiveness of Pharmacologic Treatments.” Pharmacoeconomics, 2014; 32(12):1201-1212. http://dx.doi.org/10.1007/s40273-014-0198-y

177. Clark F, Pyatak EA, Carlson M, Blanche EI, Vigen C, Hay JW, Mallinson T, Blanchard J, Unger JB, Garber SL, Diaz J, Florindez LI, Atkins M, Rubayi S, Azen SP and the PUPS 2 Study Group. Implementing trials of complex interventions in community settings: The USC–Rancho Los Amigos Pressure Ulcer Prevention Study (PUPS) Clinical Trials 2014; 11: 218–229. http://dx.doi.org/10.1177/1740774514521904

178. Thompson CA, Hay JW. Marijuana Use in Models for Health Outcomes. American Journal of Medicine, 2014; http://dx.doi.org/10.1016/j.amjmed.2014.07.039

179. Zhang X, Hay JW, Niu X. Cost-effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and

Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. CNS Drugs, 2014; http://dx.doi.org/10.1007/s40263-014-0207-x

180. Thompson CA, Hay JW. Estimating the Association between Metabolic Risk Factors and Marijuana Use in US Adults Using Data from the Continuous National Health and Nutrition Examination Survey. Annals of Epidemiology, 2015; S1047-2797(15)00041-1. http://dx.doi.org/10.1016/j.annepidem.2015.01.013

Joel W. Hay, Ph.D. -- C.V. -31- 10/18/18 181. Grosse SD, Chaugule S, Hay JW. QALYs and Hemophilia: A Review. Expert Reviews of

Pharmacoeconomics and Outcomes Research, 2015; 15(2): 267-283. http://dx.doi.org/10.1586/14737167.2015.1001372

182. Chen CX, Hay JW. Cost-Effectiveness Analysis of Alternative Screening and Treatment Strategies for Heterozygous Familial Hypercholesterolemia in the United States. International Journal of Cardiology, 2015; 181:417–424. http://dx.doi.org/10.1016/j.ijcard.2014.12.070

183. Cheetham C, Yuan Y, Niu F, Kalsekar A, Hechter R, Chiang K, Hay JW, Nyberg L. Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. Journal of Managed Care and Specialty Pharmacy 2015; 21(8):641-47. DOI: http://dx.doi.org/10.18553/jmcp.2015.21.8.641

184. Hay JW. A Special Commemorative Honoring William S. Comanor and 50 Years of Pharmaceutical Economics. International Journal of the Economics of Business 2015; 22(2):165-168. http://dx.DOI.org/10.1080/13571516.2015.1045742

185. Chen CX, Hay JW. Studies Should Avoid “Cherry-Picking” of Favorable Cost-Effectiveness Estimates. JAMA 2015; 314(16):1752. http://jama.jamanetwork.com/article.aspx?articleid=2466123

186. Chaugule SC, Hay JW, Young G. Understanding patient preferences and willingness to pay for hemophilia therapy. Journal of Patient Preference and Adherence 2015; 9:1623–1630. http://dx.doi.org/10.2147/PPA.S92985

187. Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld E, Hay JW. Estimating the potential cost of bypassing agent prophylaxis relative to the cost of rFVIIa on-demand using rFVIIa doses from multiple US registries. Journal of Managed Care and Specialty Pharmacy 2016; 22(2):149-57. DOI: http://dx.doi.org/10.18553/jmcp.2016.22.2.149 www.amcp.org

188. Meeker D, Linder JA, Fox CR, Friedberg MW, Perselle SD, Goldstein NJ, Knight TK, Hay JW, Doctor JN. Behavioral Interventions to Decrease the Inappropriate Use of Antibiotics: A Multicenter Cluster Randomized Trial. JAMA 2016. 315(6):562-570. http://dx.doi.org/10.1001/jama.2016.0275

189. Ejzykowicz F, Bollu V, Rajagopalan K, Hay JW. Health Care Use and Costs Among Medicare Patients with

Chronic Obstructive Pulmonary Disease Treated with Short-Acting Beta Agonists or Long-Acting Beta Agonists. J Clinical Pathways 2016;2(3):31-38. http://www.journalofclinicalpathways.com/article/health-care-use-and-costs-among-medicare-patients-chronic-obstructive-pulmonary-disease

190. Drabo E, Hay JW, Sood N, Vardavas R, Wagner Z. A Cost-Effectiveness Analysis of Pre-Exposure Prophylaxis (PREP) for the Prevention of HIV in the Los Angeles County MSM Population. Clinical Infectious Diseases. December 2016; 63(11):1495-1504. DOI: https://doi.org/10.1093/cid/ciw578

191. Gong C, Hay JW, Meeker D, Doctor J. Prescriber Preferences for Behavioral Economics Interventions to

Improve Treatment of Acute Respiratory Infections: A Discrete Choice Experiment. BMJ Open. 2016; 6(9): e012739. Published online 2016 Sep 22. DOI: http://dx.doi.org/10.1136/bmjopen-2016-012739

192. Hay, JW (Partnership Forum Participant). AMCP Partnership Forum: FDAMA Section 114—Improving the

Exchange of Health Care Economic Data. Journal of Managed Care & Specialty Pharmacy; July 2016. 22(7); 22(7):826-31. DOI: http://dx.doi.org/10.18553/jmcp.2016.22.7.826

193. Carlson M, Vigen C, Rubaye S, Blanche EI, Blanchard J, Atkins M, Bates-Jensen B, Garber SL, Pyatak EA,

Diaz J, Florindez LI, Hay JW, Mallinson T, Unger JB, Azen SP, Scott M, Cogan A, Clark F. Lifestyle intervention for adults with spinal cord injury: Results of the USC–RLANRC Pressure Ulcer Prevention Study. Journal of Spinal Cord Medicine. 2017 Apr 17:1-18. DOI: http://dx.doi.org/10.1080/10790268.2017.1313931

Joel W. Hay, Ph.D. -- C.V. -32- 10/18/18 194. Hay, JW (Partnership Forum Participant). AMCP Partnership Forum: Improving the Exchange of Pre-

Approval Health Care and Economic Information. Journal of Managed Care & Specialty Pharmacy; 2017 Jan;23(1):105-112. DOI: http://dx.doi.org/10.18553/jmcp.2016.16366

195. Xu Y, Hay JW, Lenz H-J, Barzi A. Impact of Drug Substitution on Cost of Care: An Example of Economic Analysis of Cetuximab versus Panitumumab. Forthcoming, Cost Effectiveness and Resource Allocation.

196. Wu S, Ell K, Jin H, Vidyanti I, Chou C-P, …, Hay JW, …Guterman, J. Comparative Effectiveness of a Technology-Facilitated Depression Care Management Adoption Model in Safety-Net Primary Care Patients with Type 2 Diabetes: 6-Month Outcomes of a Clinical Trial. J Med Internet Res.2018; 20(4):1-18. https://doi.org/10.2196/jmir.7692

197. Kawatkar AA, Hay JW, Stohl W, Nichol MB. Consistent Estimation of Polychotomous Treatment Effects with Selection-bias and Unobserved Heterogeneity Using Panel Data Correlated Random Coefficients Model. Health Services and Outcomes Research Methodology. June 2018; 18(2):75–95. https://doi.org/10.1007/s10742-018-0177-4

198. Gong C, Zangwill K, Hay JW, Meeker D, Doctor JN. Behavioral Economics Interventions to Improve

Antibiotic Prescribing for Acute Respiratory Infections: A Cost-Effectiveness Analysis. Journal of General Internal Medicine. Epub. 2018 May 8. https://doi.org/10.1007/s11606-018-4467-x

199. Hay JW, Lee P-J, Jin H, Guterman JL, Gross-Schulman S, Ell K, Wu S. Cost Effectiveness of a Technology-

Facilitated Depression Care Management Adoption Model in Safety-Net Primary Care Patients with Type 2 Diabetes. Value in Health. 2018 (21):561–568. https://10.1016/j.jval.2017.11.005

200. Lam J, Hay JW, Salcedo J, Kenyon N. A Cost-Effectiveness Analysis of Reslizumab in the Treatment of Poorly Controlled Eosinophilic Asthma. Journal of Asthma, 2018. Aug 29:1-10. DOI: https://doi.org/10.1080/02770903.2018.1500584

201. Hu X, Hay JW. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: a cost-effectiveness analysis from a UK healthcare perspective. Lung Cancer, 2018 123:166–171. DOI: https://doi.org/10.1016/j.lungcan.2018.07.012

202. Le Q, Hay JW, Becker R, Wang Y. Economic Analysis of Abaloparatide in High-Risk Postmenopausal Women with Osteoporosis in the United States - A Discrete-Event Simulation Model. Annals of Pharmacotherapy, 2018. DOI: https://doi.org/10.1177/1060028018798034

203. Aliyev E, Hay JW, Hwang C. The cost-effectiveness of ustekinumab compared to infliximab and adalimumab in adult patients with moderate-severe Crohn’s disease (TNF naïve population). Forthcoming, Pharmacotherapy.

204. Salcedo J, Hay JW, Lam J. Cost-Effectiveness of Rivaroxaban Versus Warfarin for Treatment of

Nonvalvular Atrial Fibrillation in Patients with On-Treatment Worsening Renal Function. Forthcoming, International Journal of Cardiology.

205. Cho S, Hay JW, Barzi A. Cost-Effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 2018 Aug 24. pii: S1533-0028(18)30167-1. https://doi.org/10.1016/j.clcc.2018.08.003 [Epub ahead of print]

206. Gong CL, Dasgupta-Tsinikas S, Zangwill KM, Bolaris M, Hay JW. Management of Newborns Within the

Proposed “Triple I” Algorithm for Intrapartum Fever: A Cost Benefit Analysis. Forthcoming, Journal of Perinatology.

207. Hay JW. Now is the Time for Transparency in Value-Based Health Care Decision Modeling. Submitted,

Value in Health.

Joel W. Hay, Ph.D. -- C.V. -33- 10/18/18 208. Hay JW, Zammit D, Schneider L. “Stated Preferences and Willingness to Pay for Treatment Attributes

Among Alzheimer Disease Caregivers: Validation of the HUI-3 Utility Scale.” Submitted. 209. Ganapathy V, Hay JW, Smoot K, Hermos J, Weber C, Grotzinger K. Resource utilization in

thrombocytopenia of chronic liver diseases in the Veterans Affairs population. Submitted.

210. Thompson CA, Hay JW, Lu Y, Doctor JN. Financial Incentives and Adolescent Health Promotion and Prevention: A Structured Review of the Literature. Submitted.

211. Xuan S, Hay JW, Zangwill K, Ma J, Ni W. Cost-Effectiveness Analysis of Alternative Diagnostic Methods for Clostridium difficile Infection. Submitted.

212. Hay JW. Cost Effectiveness Analysis with and Without Stochastic Uncertainty. To be submitted.

213. Chaugule S, Hay JW. Comparing Regret Minimization Model and Random Utility Model Willingness-to-Pay (WTP) Estimation Methods for Policy Evaluation. To be submitted.

214. Cohen B, Hay JW, Barzi A. Cost-Effectiveness of Short-Course Radiotherapy Compared to Long-Course Chemoradiotherapy in the Treatment of Stage III Rectal Cancer Patients from the US Societal Perspective. Submitted.

215. Bae Y, Hay JW. The cost effectiveness analysis of pd-1 and pd-l1 agents compared with docetaxel for second-line treatment of advanced non-small cell lung cancer. To be submitted.

216. Innis B, Hay JW. Cost Effectiveness Analysis of Evolocumab, a PCSK9 Inhibitor, from the US Societal Perspective. To be submitted.

TECHNICAL REPORTS: T1. Hay, JW. and Wolff, E.: "Educational Screening and Occupational Earnings," National Bureau of Economic

Research Working Paper No. 174, New York, 1976. T2. Hay, JW. "Physician Specialty Choice and Specialty Earnings," Final Report on Doctoral Research Grant

#OASH 03150, National Center for Health Services Research, 1980. T3. Yett, D., Der, W., Ernst, R., and Hay, JW. "Physician Pricing and Health Insurance Reimbursement," Final

Report on Contract #600-76-0160, Health Care Financing Administration, 1982. T4. Hay, JW. and Gareis, J. "Pollution Dose-Response Curves at the Micro Level," final report on Contract #68-

01-0543, Work Assignment #20, U.S. Environmental Protection Agency, 1983. T5. Hay, JW. "An Introduction to Cost-Benefit and Cost-Effectiveness Analysis of Pharmaceuticals," Final

Report to Rescon, Inc., Tysons Corner, Virginia, 1984. T6. Hay, JW., Leu, R., Rohrer, P. and Doppman, R. "A Monte Carlo Investigation of Sample Selection Models

with Application to Health Care Demand Estimation." Hoover Institution Working Papers in Economics, E-85-29, Stanford, CA, December 1985.

T7. Welch, B., Hay, JW., Miller, D., Olsen, R. Rippey, R., and Welch, A. "The Rand Health Insurance Study: A

Critique." Hoover Institution Working Papers in Economics, E-86-36, Stanford CA, August 1986. T8. Wilensky, G., Garrison, L., Hay, JW., Anderson, G., Reynolds, R., Headen, A. Schoenman, J. Study of the

Impact of Increasing Physician Supply. Final Report, Contract No. HHS-100-84-0072, Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services, Washington, D.C., March 1987.

Joel W. Hay, Ph.D. -- C.V. -34- 10/18/18 T9. Hay, JW., and Ernst, R. "The Economic Costs of Alzheimer's Disease." Hoover Institution Working Papers

in Economics, E-87-18, Stanford CA, April 1987. T10. Hay, JW. "Econometric Issues in Modeling the Costs of AIDS." Hoover Institution Working Papers in

Economics, E-88-36, Stanford CA, October 1988. T11. Ernst, R. and Hay, JW. Estrogen Replacement Therapy: A Review of the Literature, Report to Ciba-Geigy,

Inc., Summit, NJ, October 1988. T12. Hay, JW. Therapeutic Substitution and the Cost-effectiveness of Medication in Treatment of Acute Muscle

Spasm Back Injury. Report to Merck, Sharpe and Dohme, Inc., West Point, PA, October 1988. T13. Hay, JW. "Projecting the Medical Costs of HIV/AIDS: An Update with Focus on Political Epidemiology."

Hoover Institution Working Papers in Economics E-89-17, Stanford CA, June 1989. T14. Hay, JW., Wolak, F. "Bootstrapping HIV/AIDS Projection Models: Back Calculation with Linear Inequality-

Constrained Regression." Hoover Inst. Economic Working Papers, E-90-5, Stanford CA, February 1990. T15. Hay, A. and Hay, JW. "Urinary Tract Infections: Diagnosis, Treatment and Cost-of-Illness Algorithms."

Report to Abbott Laboratories, Chicago IL, May 1990. T16. Hay, JW. Cost Effectiveness of Calcium Channel Blockers, Report to Lederle Labs, Wayne, NJ, Feb. 1991. T17. Hay, JW., Osmond, D. and Wolak, F. Projecting the Costs of AIDS and ARC in the United States, Final

Report, Grant No. HS 06092-01, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, published by the National Technical Information Service, Springfield, VA, 1991.

T18. Hay, JW., Ernst, R. Alzheimer's Disease Cost of Illness: An Update, Report to Parke-Davis Division of

Warner-Lambert Co., Morris Plains, NJ, May 1991. T19. Hay, JW., Ernst, R. Cancer Costs of Illness, Report to Bristol Meyers Squibb, Evansville, IN, September

1991. T20. Hay, JW., Max W. Cost-Effectiveness Evaluation of Alzheimer's Disease Medications, Report to Hoechst-

Roussel Pharmaceuticals, Sommerville, NJ, October 1991. T21. Bozzette, S., Hay, JW. Cost-Effectiveness of ddI under Current FDA Marketing Indications, Report to

Bristol Meyers Squibb Pharmaceuticals, Evansville, IN, December 1991. T22. Hay, JW., and Ernst, R. Cost-Effectiveness of Ticlopidine vs Aspirin in Stroke Prevention, Report to Syntex

Laboratories, Palo Alto, CA, January 1992. T23. Hay, JW., and Ernst, R. Cost-Effectiveness of Oral Keterolac vs Narcotics for Outpatient Analgesia. Report

to Syntex Laboratories, Palo Alto, CA, March 1992. T24. Khedheri, S, and Hay, JW. Price Controls: An Interindustry Policy Analysis, Report to Bristol-Meyers

Squibb, Princeton, NJ, March 1993. T 25. Hay, JW, Ernst, R. Cost Effectiveness Analysis of Oral vs. IV Etoposide in Combination Cancer

Chemotherapy. Report to Bristol-Meyers Squibb, Princeton, NJ, October 1993. T26. Hay, JW., Ernst, R, and Meissner, C. Cost Effectiveness of Respiratory Syncytial Virus Immune Globulin

Prophylaxis. Report to Medimmune, Gathersburg, MD, November 1993. T27. Hay, JW., Ashraf, T. Cost Effectiveness Analysis of Human Erythropoietin Treatment of Chemotherapy-

Induced Anemia. Report to Ortho-Biotech, New Brunswick, NJ, October 1994.

Joel W. Hay, Ph.D. -- C.V. -35- 10/18/18 T28. Hay, JW, Ernst, R. Cost Effectiveness of Alternative Factor VIII Products in Treatment of Hemopilia A.

Report to the American Red Cross, New York, NY, December 1994. T29. Schroeder, V., and Hay, JW. “The Pravachol Cost of Care Model: Technical Summary. Report to Bristol-

Myers Squibb, Plainsboro, NJ, February 1997. T30. Ernst, R, Hay, JW. Quality of Life in an Alzheimer Caregiver Intervention Demonstration Project. Final

Report. NIH Grant No. 3-RO1-MH42216-08S1. December 1998. T31. Hay, JW, Luo, R, Ernst, R. Cost of Treatment in an Alzheimer Caregiver Intervention Demonstration

Project. Final Report. NIH Grant No. 3-RO1-MH42216-08S1. December 1998. T32. Hay, JW, Ernst, R, Luo, R. Cost Effectiveness of an Alzheimer Caregiver Intervention Demonstration

Project. Final Report. NIH Grant No. 3-RO1-MH42216-08S1. December 1998. T33. Hay JW. Retail Pharmacy Pricing Variation in the U.S. and Canada. Report to Abbott Laboratories,

Evanston, IL. June 2000. T34. Hay JW. Chemotherapy-Induced Neuropathy: Costs and Quality of Life Impacts. Report to Aventis

Pharmaceuticals, Bridgewater, NJ, 2001. T35. Hay JW. “Hospital Cost Drivers: An Evaluation of State-Level Data.” Report to Blue Cross and Blue

Shield Association, Chicago, IL, 2002. T36. Forrest S, Goetghebeur M, Hay JW. “Hospital Expenditure Growth in the United States 1990-2002: Findings

from the Literature. Report to Blue Cross and Blue Shield Association, Chicago, IL, 2002. T37. Forrest S, Goetghebeur M, Hay JW. Medicare Part B coverage and reimbursement of outpatient prescription

drugs: impact of current policy on clinical practices and health care expenditures. Report to Abbott Laboratories, Abbott Park, IL. June 2003.

T38. Hay JW. Health Economics and Outcomes Research Development Plan for Alzheimer disease and ADHD

compound. Report to Abbott Laboratories, Abbott Park IL. September 2003. T39. Hay JW, Roberts M, Wentworth C. Drivers of U.S. health care cost components:2000-2002. Report to the

Blue Cross and Blue Shield Association, Chicago, IL, 2004. T40. Hay JW, Zammit D. “Stated Preferences and Willingness to Pay for Treatment Attributes Among Alzheimer

Disease Caregivers: Validation of the HUI-3 Utility Scale.” Report to the State of California Alzheimer Research Centers, Sacramento, CA. April 2005.

T41. Le QA, Hay JW. “Traditional Regression Models versus Causal Models (Instrumental Variable, Propensity-

Score, Structural Equation Modeling, and Bayesian Network): Results from Monte Carlo Simulations.” September 2011.

T42. Hay JW. Cost Effectiveness Analysis with and Without Stochastic Uncertainty. CESR-Schaeffer

Working Paper No. 2015-005. May 2015. http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2601147.

Joel W. Hay, Ph.D. -- C.V. -36- 10/18/18 OTHER PUBLICATIONS: O1. Hay, JW."Comment on: The Influence of Economic Instability on Health: Proceedings," edited by J. John,

D. Schwefel, and H. Zollner. Kyklos, Vol. 37, No. 2 (1984), pp. 322-323. O2. Hay, JW. and Ricardo-Campbell, R.: "The Rand Health Insurance Study," Letter to the Editor, The Lancet,

Vol. II:8498 (7/12/86), pg. 106. O3. Hay, JW. and Buckels, J.: "Cost-Effectiveness: Antimicrobial Prophylaxis in General Surgery," in Infection:

A Complication of Surgery...Preventive and Management Techniques; MedEd, Ltd., Wilton, CT, 1987. O4. Hay, JW.: "An Introduction to Cost Effectiveness/Cost Benefit Analysis in Hospital Pharmacy Cost

Containment," Occasional Papers on Topics of Special Interest to Hospitals, Lederle Laboratories, Wayne, NJ, 1987.

O5. Hay, JW.: "Pharmaceutical Cost Benefit/Cost Effectiveness Analysis in the Hospital Setting," Occasional

Papers on Topics of Special Interest to Hospitals, Report #2, Lederle Laboratories, Wayne, NJ, 1987. O6. Hay, JW.: "Commentary: Government Estimates on AIDS Too High," (adapted from J. Hay) Volume 2,

Oncology, Number 11, (November 1988), pg. 34. O7. Hay, JW.: "AIDS Epidemiology: A View From the Outside," in The Economics of Health Care: Challenges

for the Nineties, Health Care Section, Center of Domestic and Comparative Policy Studies, Woodrow Wilson School of Public and International Affairs, Princeton University, 1990, pp.80-84.

O8. Hay, JW, Wittels EH, Gotto AM. “Reply: Economic Evaluation of Cholesterol Lowering,” American

Journal of Cardiology, Volume 68 October 15, 1991, pp. 1120-21. O9. Hay, JW. "Incorrectly Framing Pharmacoeconomics." Letter; American Journal of Hospital Pharmacy,

June 1994, Vol 51, # 11, pp. 1473-74. O10. Ernst, R, Hay, JW, Fenn, C, Tinklenberg, J, Yesavage, J. “Reply: Cognitive Function and the Costs of

Alzheimer’s Disease: An Exploratory Study,” Archives of Neurology, Vol. 55, 1998. O11. Hay, JW. “Commentary on Langley and McKenney Papers” Value In Health, Vol 1, No. 4. 1998. O12. Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease (JW Hay member). Highlights

from the 10th Anniversary Meeting: A New Look at Primary Prevention. December 1999. O13. Hay, JW. “The Author’s Reply to Comment on “Where’s the Value in Health Care?” Value in Health 10.

2007. O14. Hay, JW. "What is more valuable: Fenofibrate patents or fenofibrate clinical outcomes?" Archives of

Internal Medicine, Oct 22, 2012;172(19):1521-2. doi: 10.1001/archinternmed.2012.4386.2012. O15. Hay, JW. “Letter to the Editor: Economic Model of the Benefits of Male Circumcision is Highly Flawed,”

JAMA Pediatrics, February 2013;167(2): 198. doi:10.1001/jamapediatrics.2013.829. O16. Hay, JW. “Letter to the Editor: Baicker et al. The Oregon Experiment — Effects of Medicaid on Clinical

Outcomes,” New England Journal of Medicine; 2013. 369(6) pp. 581-582. DOI: 10.1056/NEJMc1306867.

Joel W. Hay, Ph.D. -- C.V. -37- 10/18/18 PEER-REVIEWED SCIENTIFIC PODIUM PRESENTATIONS AND POSTERS

1. Ernst RL, Hay JW, Fenn C, Tinklenberg J. Yesavage JA. Cognitive Function and the Costs of Alzheimer's Disease: An Exploratory Pharmacoeconomic Study. 2nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, April 1997.

2. Sung JCY, Hay JW, Louie G, Popovian R. Cost-Effectiveness of Cyclophosphamide, Doxorubicin, and 5-

Fluorouracil in Pre-Menopausal Women With Lymph Node Positive, Early Stage Breast Cancer. 2nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, April 1997.

3. Yuan Y, Hay JW, Groshen S. An Application of the Time-Dependent Cox Regression Model in the

Kaiser/USC Pharmacists' Consultation Intervention Study. 2nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, April 1997.

4. Venturini F, Hay JW. Cost-Effectiveness Analysis of Fluoxetine Versus Amitriptyline as Initial Treatment of

a Major Depressive Disorder in Primary Care. 2nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, April 1997.

5. Hay JW. Economic Modeling and Sensitivity Analysis. 3rd Annual International Meeting of the

International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, May 1998.

6. Hay JW, Schwartz S. The ISPOR Lipid Conference: Pharamacoeconomics and Outcomes Modeling Issues. 3rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, May 1998.

7. Yuan Y, Hay JW, LaPuerta P, Leahy M. Non-Parametric Analysis of Cost-Effectiveness Ratios of

Pravastatin in Primary Prevention of Cardiovascular Disease. 3rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, May 1998.

8. Hui RL, Hay JW. Cost-Effectiveness Analysis of Screening of Type II Diabetes Mellitus in Non-Pregnant

Adults. 3rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, May 1998.

9. Yu WM, Hay JW. Lipid Therapy and Cardiovascular Disease: How Many Americans Should be Treated.

3rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, May 1998.

10. Yuan Y, Hay JW, McCombs JS, Groshen S, Parker J. Time Dependent Survival Analysis of a Pharmacist’s

Intervention Study. 4th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 1999.

11. Luo R, Hay JW, and Hsiao C. Controlling for Simultaneity Bias in Outcomes Studies using Panel Data. 4th

Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 1999. This research led to a conference award of "Research Excellence."

12. Luo R, Hay JW, Clark F, Azen S, and Liu G. Cost-Effectiveness of Preventive Occupation Therapy on

Healthy Elderly People. Podium presentation. Annual Meeting of the International Society of Pharmaceutical Outcomes Research, Virginia, May 1999.

13. Mathes A, Hay JW. The Value of Home Care in Metastatic Breast Cancer Management: Modeling Oral

Versus Intravenous Chemotherapy at Home and at an Outpatient Clinic. 4th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 1999.

14. Juzba M, Hay JW. Cost-Effectiveness Analysis of Recombinant Human Erythropoientin vs Transfusion in

HIV Patients Treated with Zidovudine. 4th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 1999.

Joel W. Hay, Ph.D. -- C.V. -38- 10/18/18

15. Langley PC. Hay JW, Schwartz JS; Smith SC; McKenney J. From Research into Practice: How Should Healthcare Organizations/Governments Decide About Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum. 4th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 1999.

16. Li J, Hay JW. Cost-Effectiveness of Rentinopathy Screening in Pediatric Patients with Type I Diabetes

Mellitus. 5th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, May 2000.

17. Sengupta N, Hay JW. Cost-Effectiveness of Tamoxifen in Breast Cancer Risk Reduction. 5th Annual

International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, May 2000.

18. Hay JW, Jackson J. Methodological Issues in Conducting Pharmacoeconomic Evaluations-Modeling

Studies. 5th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, May 2000.

19. Sullivan PW, Hay JW. Cost-Effectiveness of Rofecoxib Versus NSAIDS in the Treatment of Osteoarthritis.

6th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2001.

20. Charles R, Hay JW. The Cost-Effectiveness of Lifetime Factor VIII Prophylaxis in the Treatment of Severe

Hemophilia A. 6th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2001.

21. Yu E, Hay JW, Varma R, Globe D. Four Year Cost-Effectiveness of Initial Trabeculectomy Versus

Conventional Therapy in Primary Open-Angle Glaucoma (POGA). 6th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2001.

22. Mulani P, Hay JW. Cost-Effectiveness Model of Thrombolytic Therapy for Acute Myocardial Infraction.

6th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2001.

23. Sokolskiy L, Hay JW. Cost-Effectiveness Model of Prostate-Specific Antigen (PSA) Screening for Prostate

Cancer. 6th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2001.

24. Chen K, Hay JW. Cost-Effectiveness of “Test &Treat” in Helicobacter Pylori (HP) Infected Dyspeptic

Patients in Primary Care Setting. 6th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2001.

25. Wu EQ, Hay JW. Alternative Management Strategies for Dyspepsia. 6th Annual International Meeting of

the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2001.

26. Bron MS, Hay JW. Cost-Effectiveness of Artificial Skin Substitute vs Allograft for Burn Patients. 6th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2001.

27. Shi JH, McCombs JS, Hay JW, Nichol MB, Chou CP, Hsiao C. Controlling for Biases from Measurement

Errors in Health Outcomes Research Using Structural Equation Modeling. 6th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2001.

28. Sterling KL, Hay JW. Cost-Effectiveness of the Fibrates in the Reduction of Coronary Heart Disease

Events. 7th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2002.

Joel W. Hay, Ph.D. -- C.V. -39- 10/18/18

29. Patel PA, Hay JW. The Cost-Effectiveness Analysis of Aspirin for Primary Prevention of Cardiovascular Disease. 7th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2002.

30. Etemad LR, Hay JW. Cost-Effectiveness Analysis of Pharmaceutical Care in a Medicare Drug Benefit

Program. 7th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2002.

31. Patel BV, Hay JW. Colorectal Cancer Screening: A Cost-Effectiveness Model Comparing Virtual

Colonoscopy and Conventional Colonoscopy. 7th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2002.

32. Park J, Hay JW. Cost-Effectiveness Analysis of Graftskin (Apligraf) and Becaplermin (Regranex) in

Diabetic Neuropathic Foot Ulcers. 8th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2003.

33. Zammit DC, Hay JW. Meta-Analysis of the Effectiveness of Mammography Screening for Breast Cancer.

8th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2003.

34. Zammit DC, Hay JW. Economic Analysis Of The Use Of Angiotensin Converting Enzyme Inhibitors In

Patients With Diabetes Mellitus. 8th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2003.

35. Yu YF, Hay JW, Yu AP. Cost-Effectiveness Analysis of Long-Term Hormone Replacement Therapy

(Estrogen Plus Progestin) in Healthy Postmenopausal Women for Osteoporosis Prevention. 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2004.

36. Yu AP, Hay JW. Cost-Effectiveness Analysis of Dose-Dense Chemotherapy with Filgrastim as

Postoperative Adjuvant Treatment of Breast Cancer. 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2004.

37. Setyawan J, Hay JW, Nichol MB. Cost-Effectiveness of Interventions to Improve Patient Medication

Compliance in Major Depressive Disorder. 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2004.

38. Spalding JR, Hay JW. Cost-Effectiveness of Tumor Necrosis Factor Alpha (TNF-ALPHA) Inhibitors as

First-Line Agents in Rheumatoid Arthritis. 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2004.

39. Barlev A, Hay JW. Cost-Utility of Cochlear Implants a Societal Perspective Analysis. 9th Annual

International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2004.

40. Tonnu IQ, Hay JW. The Cost-Effectiveness Analysis Recombinant Human Erythropoietin Growth Factors

vs. Transfusion in Chemotherapy Cancer Patients. 9thAnnual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2004.

41. Patel V, Hay JW. Cost-Effectiveness of Treatment Strategies for Rheumatoid Arthritis Patients with

Inadequate Response to Methotrexate. 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2004.

42. Zhang L, Hay JW. Cost-Effectiveness Analysis of Rizatriptan and Sumatripan versus Cafegot in the Acute

Treatment of Migraine. 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2004.

Joel W. Hay, Ph.D. -- C.V. -40- 10/18/18

43. Narayan S, Hay JW. Cost-Effectiveness of Ratalin® versus Adderall® for First-Line Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children. 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2004.

44. Zammit DC, Hay JW. Preliminary Economic Analysis of The American Cancer Society Guidelines for Mammography Screening in Average-Risk Women under 70 Years of Age. 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2004.

45. Tencer T, Hay JW. The Cost-Effectiveness of Prostate-Specific Antigen Screening for Prostate Cancer

Detection. 10th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, May 2005.

46. Kawatkar AA, Hay JW. Cost-Effectiveness of Taxanes as Second Line Agents in Treatment of Metastatic

Breast Cancer. 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, May 2006.

47. Vo P, Hay JW. Cost-Effectiveness Analysis for Treatments in Ankylosing Spondylitis. 11th Annual

International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, May 2006.

48. Suh HS, Hay JW. Cost-Effectiveness Analysis of Immunization Strategies for the Control of Meningococcal

Infectious disease. 12th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2007.

49. Gu NY, Hay JW, Gai YW. The Effect of Pharmacist Consultation on Patient Medication Adherence: An

Instrumental Variable Approach. 12th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Virginia, May 2007.

50. Yuan Y, Iloeje U, Parry D, Hay JW, Zammit D. Using Decision Simulation Model to Evaluate the Cost

Effectiveness of Entecavir Compared to Adefovir Therapy in Lamivudine Refractory Chronic Hepatitis B (CHB) Patients: Analyses from a US Payer Perspective Abstract and poster presentation at the 12th ISPOR Annual International Meeting, Virginia, May 2007.

51. Zammit DC, Hay JW, Globe DR, Sugar CA, Gauderman WJ Adjusting for Trial Quality in a Meta-Analysis.

Poster presentation at the 10th ISPOR Annual European Congress, Dublin Ireland, October 2007.

52. Zammit DC, Hay JW, Globe DR, Sugar CA, Gauderman WJ Framework For The Cost-Effectiveness Analysis Of Mammography Screening For Breast Cancer. Abstract and poster presentation at the 10th ISPOR Annual European Congress, Dublin Ireland, October 2007.

53. Ejzykowicz F, Hay JW. Cost-Effectiveness Analysis of Lapatinib Plus Capecitabine Vs Capecitabine Alone

in the Second Line Treatment for Breast Cancer. Poster PCM 23, 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, 2008.

54. An JJ, Hay JW. Cost-Effectiveness of Erythropoiesis Stimulating Agent Therapy by Hemoglobin Targets in

Chronic Kidney Disease. Poster PSY 15, 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, 2008.

55. Ganapathy V, Hay JW. Cost-Effectiveness of Once-Daily Stimulant, Non-Stimulant & Combined

Stimulant/Behavioral Therapy Interventions in the Treatment of ADHD in Children. Poster PMH 28, 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, 2008.

56. Le QA and Hay JW. Cost-utility Analysis of Lapatinib (Tykerb®)in 2nd-Line Treatment of HER2-Positive

Metastatic Breast Cancer. Poster PCN18, American Society of Clinical Oncology, San Diego, CA 2008.

Joel W. Hay, Ph.D. -- C.V. -41- 10/18/18

57. Turpcu A and Hay JW. The Cost-Effectiveness of Ranibizumab (Lucentis®) in Treating Patients with Predominantly Classic, Minimally Classic, and Occult Neovascular Age-Related Macular Degeneration (AMD). Poster PSS 15, 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, 2008.

58. Lescrauwaet B, Nevens F, Zammit D, Yuan Y, Hay JW. Modeling Long-Term Mortality and Morbidity

Impact with Entecavir Treatment in Chronic Hepatitis B Patients in Belgium. Podium presentation, ISPOR European Conference, Athens, Greece, November 2008.

59. Zammit D, Yuan Y, Intorcia M, Hay JW. Using a Decision Simulation Model to Evaluate the Cost-

Effectiveness of the Treatment of Nucleoside-Naïve HBe-Antigen Negative CHB Patients in Italy with Entecavir and Tenofovir Abstract and poster presentation at the 11th ISPOR Annual European Congress, Athens, Greece, November 2008.

60. Hay JW, Jhaveri M, Tangirala M, Kaliner M. Costs and Resource Utilization Comparisons of Second-

Generation Antihistamines vs Montelukast in Treatment of Allergic Rhinitis: Retrospective Analysis of a Large National Insurance Claims Database. American Academy of Allergy, Asthma and Immunology Annual Meeting, March 2009, Washington, DC.

61. Le QA, Hay JW. Comparison Between Propensity-Score & Traditional Covariate Adjustment with Logistic

Regression Models in Estimating Average Treatment Effects (ATES): Monte Carlo Simulation Results. Poster Session I [PMC10], ISPOR 14th Annual International Conference, May 2009, Orlando, FL.

62. Mark TL, Joish VN, Hay JW, Sheehan D, Johnston S, Cao Z. Unintended Consequences Of Current

Antidepressant Use In A Geriatric Population: The Burden Of Side-Effects On Adherence And Costs. ISPOR 14th Annual American Association of Psychiatry Conference, May 2009, Orlando, FL.

63. Mark TL, Joish VN, Hay JW, Sheehan D, Choi JC, Johnston S, Cao Z. Unintended Consequences of

Current Antidepressant Use In A Geriatric Population: Drug-Drug Interactions and Their Implications for Adherence. ISPOR 14th Annual American Association of Geriatric Psychiatry Conference, May 2009, Orlando, FL. Am J Geriatr Psychiatry 2009;17(3), Supplement 1:A98.

64. Skrepnek G, Seal B, Tangirala M, Hay JW. Adverse Dental Outcomes Associated With Intravenous Versus

Oral Bisphosphonate Use In Patients With Osteoporosis. 7th International Symposium on Osteoporosis, April 2009, Washington, DC.

65. Skrepnek G, Seal B, Tangirala M, Hay JW. The Association Between Adverse Dental Outcomes And

Intravenous Versus Oral Bisphosophonates Within Cancer Patients. European Calcified Tissue Society ECTS 2009, Vienna, Austria, 23-27 May 2009

66. Hay JW, Zhou ZY. “APCC Versus RFVIIA In Treatment Of Hemophilia Patients With Inhibitors: A

Structured Review Of The Pharmacoeconomic Literature” abstract N° 846 - XXII Congress of the International Society on Thrombosis and Haemostasis, Boston, MA, July 11-16 2009.

67. Hay JW, Zhou ZY, Young G. “Economic Comparison Of APCC Vs RFVIIA For Mild-To-Moderate

Bleeding Episodes In Hemophilia Patients With Inhibitors” abstract N° 836 - XXII Congress of the International Society on Thrombosis and Haemostasis, Boston, MA, July 11-16 2009.

68. Tangirala M, Jhaveri M, Hay JW. “Resource Use in Patients with Allergic Rhinitis (AR) Comorbidities:

Oral Second Generation Antihistamines (SGAs) versus Montelukast (MTLK)” Annual Meeting of the American College of Allergy, Asthma & Immunology, Nov. 5-10 2009, Miami Beach, Florida.

69. Colayco D, Hay JW. Cost-Effectiveness of Serotonin-Type 3 Receptor Antagonists For Chemotherapy-

Induced Emesis In Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy. Poster PCN95. ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

Joel W. Hay, Ph.D. -- C.V. -42- 10/18/18

70. Suh H, Hay JW. Dealing with Selection Bias in Nonlinear Settings: A Case Of Comparative Effectiveness Of Statin Plus Fibrate Combination Therapy Versus Statin Monotherapy In Type II Diabetes. Podium SB4. ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

71. Shin J, Hay JW. The Cost-Effectiveness of Isotretinoin In Patients With Moderate-To-Severe Acne Vulgaris.

Poster PSS6, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

72. Ganapathy V, Hay JW. Analysis of Necrotizing Enterocolitis Costs Among Extremely Preterm Infants Fed Exclusively Human-Milk Based Diet Vs. Human-Milk Fortified With Bovine-Milk Based Supplements. Poster PIH18, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

73. Tran JN, Hay JW. Obesity and Health Care Costs And Utilization In The Veteran Affairs Population. Poster

PSY34, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

74. Soo In Bang, JW Hay. Cost-Effectiveness Analysis of Dutasteride, Tamsulosin and Combination Therapy In The Treatment Of Benign Prostatic Hyperplasia. Poster PUK 11, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

75. Chu K, Hay JW. Economic Analysis of Endovascular Stenting for Peripheral Arterial Disease In Long

Lesions Of The Superficial Femoral Artery. Poster PCV 83, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

76. Ding Y, Hay JW. Cost-effectiveness analysis of multimodal screening for ovarian cancer. Poster PCN 73,

ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

77. Schwartz E, Hay JW. Cost-Effectiveness Analysis in treating Overactive Bladder with Urge Incontinence in Women: A comparison between Oxybutynin and Tolterodine with exploratory analysis of Fesoterodine. Poster PUK 16, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

78. Rashid N, Hay JW. Cost Effectiveness Analysis of Managing Chronic Gout with Febuoxstat (Uloric) versus

Allopurinol (Zyloprim). Poster PMS 20, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

79. Suh JK, Hay JW. Evaluation of Cost-Effectiveness of Chronic Hepatitis B Treatments: Entecavir And

Telbivudine. Poster PGI 22, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

80. Poon JL, Hay JW. Cost Effectiveness Analysis of Breast Cancer Risk Reduction Therapy: Comparing Tamoxifen and Raloxifene. Poster PCN 71, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

81. Wiegand PW, Hay JW. Cost-Effectiveness of Statin Therapy for the Primary Prevention of

Cardiovascular Events Predicted by the Reynolds Risk Score in Healthy Men and Women Aged 40 to 80 Years of Age. Poster PCV 74, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

82. Chang J, Hay JW. Cost Effectiveness Analysis of Anti-Epidermal Growth Factor Receptor (Anti-

EGFR) Agents for Treatment Refractory Metastatic Colorectal Cancer (mCRC). Poster PCN 84, ISPOR 15th Annual International Conference, May 2010, Atlanta, GA.

83. Hay JW, Katon WJ, Ell K, Lee P-J, Guterman JJ. Cost Effectiveness Analysis of Collaborative Care

Management of Major Depression among Low-Income, Predominantly Hispanics with Diabetes. Poster presentation at the ICMPE 10’th Workshop on Costs and Assessment in Psychiatry "Mental Health Policy and Economics " March 2011, Venice, Italy.

84. Unützer J, Dwight-Johnson, M, Apesoa-Varano C, Hay JW, Hinton L: Older men’s preferences for

depression care: Preliminary comparison of conjoint survey and qualitative interviews. American Association of Geriatric Psychiatry, March 18-21, 2011, San Antonio TX.

Joel W. Hay, Ph.D. -- C.V. -43- 10/18/18

85. Yeung K, Hay JW. Cost-Utility Analysis of Romiplostim Versus Splenectomy In The Treatment Of Chronic Refractory Immune Thrombocytopenic Purpura. Poster presentation at the Academy of Managed Care Pharmacy 23’rd Annual Meeting, March 29, 2011 Minneapolis, MN.

86. Ejzykowicz F, Hay JW, Sarocco P, Karafilidis J, Walsh J. Hospitalizations, medical management and

switch therapy patterns in the COPD Medicare population. Poster PRS 36, ISPOR 16th Annual International Conference, May 2011, Baltimore, MD.

87. Ding Y, Hay JW, Zangwill KM, Allred N, Yeh SH. Cost-benefit analysis of postpartum vaccination of

birth mothers with influenza vaccine. Poster PIN 19, ISPOR 16th Annual International Conference, May 2011, Baltimore, MD.

88. Zhou Z-Y, Hay JW. A systematic review and meta-analysis comparing the efficacy of bypassing agents

in hemophilia patients with inhibitors. XXIII Congress of the International Society on Thrombosis and Hemostasis, July 2011, Kyoto, Japan.

89. Ejzykowicz F, Rajagopalan K, Karafilidis J, Hay JW. Health Care Costs in a Medicare Population of

COPD Patients Treated with Beta-Agonists. Presented at the American Society of Health System Pharmacists Midyear Meeting, December 2011, New Orleans, LA.

90. Niu, X, Hay JW. Cost-Effectiveness Analysis of Nilotinib Versus Dasatinib In Patients with Imatinib-

Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia (CML). Poster PCN13, ISPOR 17th Annual International Conference, June 2012, Washington, DC.

91. Villacorta, R, Hay JW, Messali A. Cost Effectiveness of Treatment with Etanercept or Ustekinumab For

Moderate To Severe Psoriasis. Poster PSY27, ISPOR 17th Annual International Conference, June 2012, Washington, DC.

92. Messali A, Hay JW, Villacorta, R. Cost-Effectiveness of Temozolomide in the Adjuvant Treatment of Newly

Diagnosed Glioblastoma In the United States. Poster PCN78, ISPOR 17th Annual International Conference, June 2012, Washington, DC.

93. Chagule S, Hay JW. Cost Effectiveness of Cetuximab Plus Best Supportive Care (BSC) Versus BSC Alone

in Last Line For Kras Wild Type Metastatic Colorectal Cancer Patient Population. Poster PCN64, ISPOR 17th Annual International Conference, June 2012, Washington, DC.

94. Jiang Y, Hay JW. Cost-Effectiveness of Denosumab v Alendronate for Prevention of Osteoporotic Fractures

in the U.S. Poster PMS27, ISPOR 17th Annual International Conference, June 2012, Washington, DC.

95. Blaylock B, Hay JW, Zarchy T. Cost-Effectiveness of Diagnostic Sigmoidoscopy Before Colonoscopy in 40-49 Year-Old Symptomatic Patients. Poster PMD29, ISPOR 17th Annual International Conference, June 2012, Washington, DC.

96. Chaugule S, Hay JW. Bypass Therapy Assay Testing as a Strategy to Reduce Treatment Costs for

Hemophilia Patients with Inhibitors. Poster PMD18, ISPOR 17th Annual International Conference, June 2012, Washington, DC.

97. Matsuda T, Hay JW. Cost-Effectiveness of Bariatric Surgery: Laparoscopic Gastric Bypass and Banding.

Poster PSU24, ISPOR 17th Annual International Conference, June 2012, Washington, DC.

98. Ganapathy V, Hay JW, Smoot, KJ, Lawler, E, Weber, HC, Grotzinger, KM. Resource Utilization in Thrombocytopenia of Chronic Liver Diseases in the Veterans Affairs Population. Poster PGI14, ISPOR 17th Annual International Conference, June 2012, Washington, DC.

99. Ding Y, Hay JW, Zangwill K, Yeh S. Cost-Benefit Analysis of Hospital Based Postpartum Vaccination with

Combined Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap). Poster PMD18, ISPOR 17th Annual International Conference, June 2012, Washington, DC.

Joel W. Hay, Ph.D. -- C.V. -44- 10/18/18

100. Chaugule S, Hay JW, Young G. Bypass Therapy Assay Testing as a Strategy to Reduce Treatment Costs For Hemophilia Patients With Inhibitors. World Federation of Hemophilia, 2012 World Congress, June 2012, Paris, France.

101. Ding, Y, Hay JW, Zangwill, K, Yeh, S. Cost-Benefit Analysis of Hospital Based Postpartum Vaccination

with Combined Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (TDAP). Western Pharmacoeconomics Conference, June 2012, Austin, TX.

102. Messali A, Hay JW, Villacorta, R. Probabilistic Sensitivity Analysis of the Cost-Effectiveness of

Temozolomide in the Adjuvant Treatment of Newly Diagnosed Glioblastoma. Western Pharmacoeconomics Conference, June 2012, Austin, TX.

103. Hay JW. Cost Effectiveness Analysis With and Without Stochastic Uncertainty,” American Society for

Health Economics 4’th Biennial Conference, June 2012, Minneapolis, MN 104. Ejzykowicz F, Rajagopalan K, Bollu V, Karafilidis J, Hay JW. Effect of Long Acting Beta Agonist Therapy

on Risk of Hospitalization in New Start COPD Patients. Abstract 265134. American Public Health Association 140’th Annual Meeting and Expo, October 29, 2012, San Francisco, CA.

105. Ni W, Hay JW, Zangwill K. Potential U.S. Medical Cost Savings Associated With Routine Hospital-Based

Use Of A Rapid Diagnostic Tool For Bloodstream Infection. ISPOR 18th Annual International Conference, May 2013, New Orleans, LA.

106. Schwartz E, Hay JW. Modeling Diabetes Costs: a comparison of econometric methods using simulated error

distributions. ISPOR 18th Annual International Conference, May 2013, New Orleans, LA. 107. Gu NY, Gai Y, Wu J, Raisch DW, Hay JW. Predicting healthcare costs in asthma using the EQ-5D health-

related quality-of-life (HRQoL) index score with and without adjusting non-random positive spending using a US national representative population. 2nd International Allergen Symposium on Asthma & Economics, July 2013, Sydney, Australia.

108. Hay JW, Strylewicz G, Rothfeld A, Chesler R, Doctor J. Provider Preferences for Interventions for Reducing

Inappropriate Antibiotic Prescribing. Accepted Podium Presentation, Health Care Applications: Sawtooth Software Conference, October 2013, Dana Point, CA.

109. Gu NY, Gai Y, Wu J, Raisch DW, Hay JW. Predicting Health Care Costs In Asthma Using The EQ-5D

Index Score. ISPOR 16th Annual European Congress, 2-6 November 2013, Dublin, Ireland.

110. Hay JW, Oladapo AO, Epstein JD, Novack AR. Estimating the Potential Cost of Bypassing Agent Prophylaxis Relative to the Cost Of rFVIIa On-Demand Using Actual rFVIIa Doses From the UK NHD Registry. 7th Annual Congress of the European Association for Haemophilia and Allied Disorders, February 2014, Brussels, Belgium.

111. Linder JA, Meeker D, Friedberg MW, Persell SD, Fox CR, Goldstein NJ, Alan Rothfeld, Hay JW, Doctor

JN. Improving Antibiotic Prescribing for Acute Respiratory Infections using Behavioral Economic Principles: A Cluster Randomized Trial. Society for General Internal Medicine 37’th Annual Meeting, April 2014, San Diego, CA.

112. Grosse SD, Chaugule S, Hay JW. Preference-based Measures of Health-related Quality of Life for Adults

with Severe Hemophilia: Implications for the Cost-effectiveness of Prophylaxis. World Federation of Hemophilia 2014 World Congress, May 2014, Melbourne, Australia.

113. Chaugule S, Young G, Hay JW. Understanding how patients, physicians and the general population value

different types of hemophilia therapies and their willingness-to-pay for such therapies: a discrete choice experiment from the US perspective. World Federation of Hemophilia 2014 World Congress, May 2014, Melbourne, Australia.

Joel W. Hay, Ph.D. -- C.V. -45- 10/18/18

114. Hay JW, Oladapo AO, Epstein JD, Novack AR. Understanding how patients, physicians and the general population value different types of hemophilia therapies and their willingness-to-pay for such therapies: a discrete choice experiment from the US perspective. World Federation of Hemophilia 2014 World Congress, May 2014, Melbourne, Australia.

115. Hay JW, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ. Estimating the potential cost of bypassing agent

prophylaxis relative to the cost of rFVIIa on-demand using actual rFVIIa doses from multiple US registries. World Federation of Hemophilia 2014 World Congress, May 2014, Melbourne, Australia.

116. McGinnis JJ, Hay JW. Cost-Effectiveness of Hepatitis C Treatments in Treatment Naïve Genotype 1

Patients. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

117. Patel N, Hay JW. Management of Spinal Cord Injury-Associated Neuropathic Pain With Pregabalin is Cost-Effective Over Gabapentin. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

118. Gong C, Hay JW. Cost-Effectiveness Analysis of Abiraterone And Sipuleucel-T In Metastatic Castration-

Resistant Prostate Cancer. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

119. Chaugule S, Hay JW. Understanding What Patients Value and Their Willingness-To-Pay (WTP) For

Hemophilia Therapies: A Discrete Choice Experiment. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

120. Ding Yao, Hay JW. Economic Burden Associated With Patients Diagnosed With Peyronie's Disease in the

United States. Poster Tuesday morning, PIH21. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

121. Ding Yuchen, Hay JW. Cost-Effectiveness Comparison of Denosumab and Zoledronic Acid in the Treatment

of Postmenopausal Osteoporosis. Poster Monday morning, PMS36. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

122. Drabo E, Hay JW, Vardavas R, Wagner ZR, Sood N. A Cost-Effectiveness Analysis of Pre-Exposure

Prophylaxis (Prep) for the Prevention of HIV in the Los Angeles MSM Population. Poster, Wednesday morning, PIN43. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

123. Chen C, Hay JW. Cost-Effectiveness Analysis of Alternative Screening and Treatment Strategies for

Familial Hypercholesterolemia in the United States. Poster Monday afternoon, PCV70. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

124. Chu LH, Hay JW, Cohen DJ. A Hybrid Comparison of Cost-Effectiveness of Transcatheter Aortic Valve

Replacement Between Randomized Clinical Trials and Real World Practice in Treating Patients With Severe Aortic Stenosis, Poster Monday morning, PCV69. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

125. Jiao X, Hay JW. Cost-Effectiveness of Breast MRI and Mammography for Screening High Risk

Populations. Poster Tuesday morning, PHS55. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

126. Lin CW, Hay JW. Cost Utility Analysis of Aflibercept, Ranibizumab, and Bevacizumab for the Treatment

of Neovascular Agerelated Macular Degeneration. Poster Wednesday morning, PSS23. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

127. Massachi S, Hay JW. Cost-Effectiveness of Various Clostridium Difficile Infection (CDI) Treatments in

Patients with Recurrent Infections. Poster Wednesday morning, PIN50. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

Joel W. Hay, Ph.D. -- C.V. -46- 10/18/18

128. Mehta D, Hay JW. Cost-Effectiveness of Adding Bevacizumab to First Line Therapy for Patients with Advanced Ovarian Cancer. ISPOR 19th Annual International Conf., May 2014, Montreal, Quebec, Canada.

129. Ni W, Hay JW, Zangwill K. Economics Analysis of Diagnostic Methods for Clostridium Difficile Infection.

Poster, Wednesday morning, PIN58. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

130. Ning N, Hay JW. The Cost-Effectiveness of Liraglutide Vs Exenatide for the Treatment of Type 2 Diabetes

In The United States. Poster, Wednesday morning, PDB78. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

131. Thompson CA, Hay JW. Evaluating the Impact of Cannabis Use on Metabolic Syndrome Using Data From

the Continuous National Health and Nutrition Examination Survey, Poster Tuesday afternoon, PMH13. ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

132. Zhang X, Hay JW. Cost-Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular

Interferon Beta-1a In Relapsing-Remitting Multiple Sclerosis. Poster, Monday Morning, PND20 . ISPOR 19th Annual International Conference, May 2014, Montreal, Quebec, Canada.

133. Jiao X, Hay JW. Cost-Effectiveness of Breast MRI and Mammography for Screening High Risk Populations.

American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

134. Ding Yuchen, Hay JW. Cost-effectiveness Comparison between Generic zoledronic acid and denosumab (Prolia®) in the treatment of Postmenopausal Osteoporosis. American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

135. Hay JW. Behavioral Economics Interventions to Reduce Antibiotic Overprescribing. Organized Session,

American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA. 136. Hay JW, Strylewicz G, Rothfeld A, Doctor J. Provider Preferences for Interventions for Reducing

Inappropriate Antibiotic Prescribing. American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

137. Doctor J, Meeker D, Hay JW. Nudging guideline uptake: A randomized trial of physician public

commitments. American Soc. for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA. 138. Meeker D, Doctor J, Hay JW. A Behavioral Economics Multi-site Randomized Trial to Reduce Provider

Antibiotic Overprescribing. American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

139. Gong C, Hay JW. Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Metastatic Castration-

Resistant Prostate Cancer. American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

140. Thompson C, Hay JW. Evaluating the Impact of Marijuana Use on Metabolic Syndrome Using Data from

the Continuous National Health and Nutrition Examination Survey. American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

141. Patel N, Hay JW. Pregabalin (Lyrica®) is cost-effective over Gabapentin (Neurontin®) as a First-Line

Treatment for Neuropathic Pain (NeP) Management after Spinal Cord Injury (SCI). American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

142. Zhang X, Hay JW, Nu X. Cost-Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and

Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

Joel W. Hay, Ph.D. -- C.V. -47- 10/18/18

143. Chen CX, Hay JW. The Cost-Effectiveness of Screening and Management Strategies for Familial Hypercholesterolemia in the United States: A Markov Model Analysis. American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

144. Mehta D, Hay JW. Cost-Effectiveness of Adding Bevacizumab to First Line Therapy for Patients with

Advanced Ovarian Cancer. American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

145. Drabo E, Hay JW, Sood N, Wagner Z. A Cost-Effectiveness Analysis of Pre-Exposure Prophylaxis (PREP)

for the Prevention of HIV in the Los Angeles County MSM Population. American Society for Health Economics 5’th Biennial Conference, June 2014, Los Angeles, CA.

146. Ding Yao, Hay JW. Impact of Maternal Education On Child Immunization Propensity In China. ISPOR Asia

Conference, September 2014, Beijing, China.

147. Cheetham C, Yong Y, Niu F, Kalsekar A, Hechter R, Chiang K, Hay JW, Nyberg L. Characterization of Hepatitis C Patients who fail to Achieve Sustained Virologic Response with Triple Therapy (Peg-Interferon alfa and Ribavirin with Boceprevir or Telaprevir). The Liver Meeting, November 2014, Boston, MA.

148. Chaugule S, Hay JW. Impact of differential framing of opt-out alternatives: Comparison of utility maximization vs. regret minimization models in a hemophilia therapy preferences study. Inaugural meeting of the International Academy of Health Preference Research, November 2014, Amsterdam, Netherlands, EU.

149. Thompson C, Hay JW. Role Of Behavioral Confounding in the Association Between Marijuana Use And BMI in US Adults. Poster PSY12 Wednesday, May 20, 2015. ISPOR 20th Annual International Meeting, May 16-20, 2015; Philadelphia, PA.

150. Drabo E, Hay JW. Rolling Out Oral Pre-Exposure Prophylaxis (Prep) is a Cost-Effective HIV Prevention Strategy Among Los Angeles County (LAC) Men Who Have Sex With Men (MSM). Poster PIN54 Tuesday, May 19, 2015. ISPOR 20th Annual International Meeting, May 16-20, 2015; Philadelphia, PA.

151. McGinnis JJ, Hay JW. The Cost Effectiveness of a Novel High Priced Combination Therapy For Hepatitis C in Treatment Naïve Genotype 1 Infected Patients. Poster PIN65 Tuesday, May 19, 2015. ISPOR 20th Annual International Meeting, May 16-20, 2015; Philadelphia, PA.

152. Han X, Hay JW. Cost-Effectiveness Analysis of Certolizumab, Etanercept, Golimumab and Tofacitinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis. Poster PMS52 Tuesday, May 19, 2015. ISPOR 20th Annual International Meeting, May 16-20, 2015; Philadelphia, PA.

153. Chaugule S, Hay JW. Does Differential Framing of Opt-Out Alternatives in Discrete Choice Experiments (DCES) Matter? Comparison of Random Utility Maximization (RUM) and Random Regret Minimization (RRM) Models. Poster PRM85 Monday, May 18, 2015. ISPOR 20th Annual International Meeting, May 16-20, 2015; Philadelphia, PA.

154. Chaugule S, Hay JW. Exploring Heterogeneity in Attribute Processing Strategies: Use of Hybrid Random Utility Maximization-Random Regret Minimization (RUM-RRM) Models in a Discrete Choice Experiment (DCE). Poster PRM140 Monday, May 18, 2015. ISPOR 20th Annual International Meeting, May 16-20, 2015; Philadelphia, PA.

155. Mehta DA, Hay JW. Systematic Literature Review of Economics Analyses Comparing aPCC and rFVIIa Across On-Demand, Prophylaxis and Surgery. Poster International Society of Thrombosis and Hemostasis 2015 Congress, June 23, 2015; Toronto, Canada.

156. Cheetham C, Yong Y, Niu F, Kalsekar A, Hechter R, Chiang K, Hay JW, Nyberg L. Characterization of Hepatitis C Patients who fail to Achieve Sustained Virologic Response with Triple Therapy (Peg-Interferon Alfa and Ribavirin with Boceprevir or Telaprevir). XXIII Congresso Brasileiro de Hepatologia, September 2015; Sao Paulo, Brazil.

Joel W. Hay, Ph.D. -- C.V. -48- 10/18/18

157. Chaugule S, Hay JW. Advances in Willingness-to-Pay Estimation Methods for More Informed Decision Making. 2nd Meeting of the International Academy of Health Preference Research, October 2015, Brisbane, Australia.

158. Xu Y, Barzi A, Hay JW. Comparative Effectiveness of Panitumumab (P) and Cetuximab (C) in Metastatic

Colorectal Cancer (mCRC) with Wild-Type KRAS (WTKRAS). American Society of Clinical Oncology 2016 Gastrointestinal Cancers Symposium, (January 21-23, 2016) San Francisco, CA.

159. Cheng W, Sadeghi S, Lenz H-J, Hay JW, Barzi A. Comparative-Effectiveness of FOLFIRINOX (FOL) versus Gemcitabine and nab-Paclitaxel (GNP) for the First-Line Treatment of Metastatic Pancreatic Cancer. American Society of Clinical Oncology 2016 Gastrointestinal Cancers Symposium, (January 21-23, 2016) San Francisco, CA.

160. Thompson C, Hay JW, Doctor J. “Does marijuana use lead to weight loss? Exploring the role of effect

moderation in the association between marijuana use and BMI and waist circumference in US adults.” Scientific Poster Session, Marijuana and Cannabinoids: A Neuroscience Research Summit sponsored by the National Institutes of Health (March 22-23) Bethesda, MD.

161. Gong C, Hay JW, Meeker D, Doctor J. “Use of behavioral economics and social psychology to improve

treatment of acute respiratory infections (BEARI): A Discrete Choice Experiment.” Scientific Podium Presentation, 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 21-22, San Francisco, CA.

162. Henkhaus L, Hay JW. Cost Effectiveness of Empagliflozin/Linagliptin as 2nd-Line Therapy for Adults with

Type 2 Diabetes. Poster PDB35. ISPOR 21’st Annual International Meeting, May 21-25 2016, Washington, DC.

163. Priyadarshini M, Hay JW. Cost-Effectiveness Analysis of Lurasidone and Olanzapine in the Treatment of

Schizophrenia. Poster PMH40. ISPOR 21’st Annual International Meeting, May 21-25 2016, Washington, DC.

164. Bhagvandas N, Hay JW. Cost Effectiveness of Lurasidone, Quetiapine, and Olanzapine Monotherapy in the Treatment of Bipolar I Disorder Depression. Poster PMH39. ISPOR 21’st Annual International Meeting, May 21-25 2016, Washington, DC.

165. Nguyen A, Hay JW. Cost-Effectiveness of Trastuzumab in Adult Metastatic Gastric Cancer Patients with an

Overexpression of HER2. Poster PCN109. ISPOR 21’st Annual International Meeting, May 21-25 2016, Washington, DC.

166. Lu T, Hay JW. Cost Effectiveness of Pembrolizumab and Ipilimumab in Advanced Melanoma. Poster

PCN86. ISPOR 21’st Annual International Meeting, May 21-25 2016, Washington, DC.

167. Cheng W-H, Hay JW. Cost-Effectiveness Analysis Comparing Folfirinox and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Cancer from the US Societal Perspective. Poster PCN108. ISPOR 21’st Annual International Meeting, May 21-25 2016, Washington, DC.

168. Xu Y, Barzi A, Hay JW. Comparative Effectiveness of Panitumumab Versus Cetuximab in Patients With

Chemo-Refractory Wild-Type Kras Metastatic Colorectal Cancer. Oral Presentation PCN108. ISPOR 21’st Annual International Meeting, May 21-25 2016, Washington, DC.

169. Drabo E, Hay JW. Nudging vaccination with a 'no-fault' insurance: A discrete choice experiment. Oral

presentation at the 5’th Meeting of the International Academy of Health Preference Research, September 2 2016, Singapore.

Joel W. Hay, Ph.D. -- C.V. -49- 10/18/18

170. Linder JA, Meeker D, Fox CR, Friedberg MW, Persell SD, Goldstein NJ, Knight TK, Hay JW, Doctor JN. Durability of benefits of behavioral interventions on inappropriate antibiotic prescribing in primary care: follow-up from a cluster RCT. Oral presentation, IDWeek, October 27, 2016.New Orleans, LA.

171. Drabo E, Sood N, Hay JW, Doctor JN. Nudging vaccination with a no-fault insurance, Oral presentation,

INFORMS Annual Meeting, November 6, 2016; Nashville. TN.

172. Gong C, Hay JW, Zangwill K, Meeker D, Doctor JN. The Use of Behavioral Economics and Social Psychology to Improve Treatment of Acute Respiratory Infections (BEARI): A Cost-Effectiveness Analysis. Poster PRS24. ISPOR 22’st Annual International Meeting, May 20-24, 2017, Boston, MA.

173. Cohen B, Hay JW, Barzi A, Cost-Effectiveness of Short-Course vs. Long-Course Treatment for Stage III

Rectal Cancer. Invited Podium Presentation, Western Pharmacoeconomics & Outcomes Research Conference, University of New Mexico, October 4, 2017, Albuquerque, NM.

174. Aliyev E, Hay JW. Cost-effectiveness of ustekinumab in adult patients with moderate-severe Crohn’s disease

(conventional therapy failure and tumor necrosis factor naïve population). Invited Poster Presentation, Western Pharmacoeconomics & Outcomes Research Conference, University of New Mexico, October 4, 2017, Albuquerque, NM.

175. Kim J, Hay JW. Cost-Effectiveness Analysis of Regorafenib In Patients with Advanced Hepatocellular

Carcinoma. Invited Poster Presentation, Western Pharmacoeconomics & Outcomes Research Conference, University of New Mexico, October 4, 2017, Albuquerque, NM.

176. Lam J, Hay JW, Kenyon N. Cost-effectiveness Analysis of Reslizumab in Patients with Poorly Controlled

Eosinophilic Asthma. Invited Poster Presentation, Western Pharmacoeconomics & Outcomes Research Conference, University of New Mexico, October 4, 2017, Albuquerque, NM.

177. Salcedo J, Hay JW. Cost-Effectiveness of Rivaroxaban Versus Warfarin for Treatment of Nonvalvular Atrial

Fibrillation in Patients with On-Treatment Worsening Renal Function. Invited Poster Presentation, Western Pharmacoeconomics & Outcomes Research Conference, University of New Mexico, October 4, 2017, Albuquerque, NM.

178. Cho S, Hay JW. Cost-Effectiveness of Stivarga (Regorafenib) vs. Lonsurf (Trifluridine/Tipiracil) in Refractory Metastatic Colorectal Cancer. Invited Poster Presentation, Western Pharmacoeconomics & Outcomes Research Conference, University of New Mexico, October 4, 2017, Albuquerque, NM.

179. Xuan S, Zangwill K, Hay JW. Cost-Effectiveness Analysis of Alternative Diagnostic Methods for

Clostridium difficile Infection. Invited Podium Presentation, Western Pharmacoeconomics & Outcomes Research Conference, University of New Mexico, October 4, 2017, Albuquerque, NM.

180. Bae Y, Hay JW. The cost effectiveness analysis of pd-1 and pd-l1 agents compared with docetaxel for

second-line treatment of advanced non-small cell lung cancer. Invited Poster Presentation, Western Pharmacoeconomics & Outcomes Research Conference, University of New Mexico, October 4, 2017, Albuquerque, NM.

181. Hay JW, Le Q, Wang Y. Cost-Effectiveness of Abaloparatide vs. Teriparatide for Prevention of

Osteoporosis-related Fracture: a US Payer Perspective. Invited Poster Presentation AMCP Nexus Conference, October 16-19, Dallas, TX.

182. Mahajerin A, Formica M, Hay JW. Cost Analyses of Pediatric Thrombophilia Testing: A report from the

Children’s Hospital-Acquired Thrombosis Registry. Thrombosis and Hemostasis Societies of North America 4th Biennial Summit, March 8-10, 2018, San Diego, CA.

Joel W. Hay, Ph.D. -- C.V. -50- 10/18/18

183. Aliyev E, Hay JW, Hwang C. The Cost-Effectiveness of Ustekinumab Compared to Infliximab and Adalimumab in Adult Patients with Moderate-Severe Crohn's Disease (TNF Naïve Population). Research Poster Presentations - Session IV, PGI17: Gastrointestinal Disorders Tuesday, May 22, 2018. ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD.

184. Bae Y, Hay JW. The Cost Effectiveness Analysis of PD-1 And PD-L1 Agents Compared with Docetaxel for Second-Line Treatment of Advanced Non-Small Cell Lung Cancer. Research Poster Presentations - Session IV, PCN114 Cancer, Tuesday, May 22, 2018 3:30 PM - 7:30 PM. ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD.

185. Kim J, Hay JW. Cost-Effectiveness Analysis of Regorafenib In Patients with Advanced Hepatocellular Carcinoma. Research Poster Presentations - Session IV, PCN107 Cancer, Tuesday, May 22, 2018 3:30 PM - 7:30 PM. ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD.

186. Lam J, Hay JW, Salcedo J, Kenyon NJ. An Evaluation of the Cost-Effectiveness of Reslizumab in Poorly Controlled Eosinophilic Asthma. Research Poster Presentations - Session II, PRS29: Respiratory-Related Disorders Monday, May 21, 2018 3:30 PM - 7:30 PM. ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD.

187. Salcedo J, Hay JW, Lam J. Cost-Effectiveness of Rivaroxaban Versus Warfarin for Treatment of Nonvalvular Atrial Fibrillation in Patients with Worsening Renal Function. Research Poster Presentations - Session I, PCV49: Cardiovascular Disorders Monday, May 21, 2018 8:30 AM - 2:00 PM. ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD.

188. Innis B, Hay JW. Cost Effectiveness Analysis of Evolocumab, a PCSK9 Inhibitor, From the US Societal Perspective. Research Poster Presentations - Session I, PCV46: Cardiovascular Disorders Monday, May 21, 2018 8:30 AM - 2:00 PM. ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD.

189. Cho S, Hay JW, Barzi A. Cost-Effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. Podium Presentation Breakout Session P1: Cost-Effectiveness Studies Monday, May 21, 2018 11:00 AM - 12:00 PM. ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD.

190. Cohen B, Hay JW, Barzi A. Cost-Effectiveness of Short-Course Radiotherapy Compared to Long-Course Chemoradiotherapy in the Treatment of Stage III Rectal Cancer Patients from the US Societal Perspective. Research Poster Presentations - SESSION IV PCN129: Cancer Tuesday, May 22, 2018 3:30 PM - 7:30 PM. ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD.

191. Le QA, Hay JW, Becker R, Wang Y. Economic Analysis of Abaloparatide in High-Risk Postmenopausal Women with Osteoporosis in the United States - A Discrete-Event Simulation Model. Research Poster Presentations - Session I PMS35: Muscular-Skeletal Disorders Monday, May 21, 2018 8:30 AM - 2:00 PM. ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD.

192. Gong C, Dasgupta-Tsinikas S, Zangwill K, Bolaris M, Hay JW. Risk-Based Management of Newborns Exposed to Maternal Intrapartum Fever: A Cost Benefit Analysis. ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD.

193. Barzi A, Jiao X, Hay JW, Sadeghi S. Outcomes and utilization of adjuvant chemotherapy (AT) for stage II colon cancer (CC-II) in elderly population. 2019 Gastrointestinal Cancers Symposium (January 17-19, 2019), San Francisco, CA.

Joel W. Hay, Ph.D. -- C.V. -51- 10/18/18 OP-EDS & MEDIA POSTS, LETTERS, ETC.: Hay, JW. "Vouchers Take the Catastrophe out of Catastrophic Care," Editorial Page, Camden Courier, May 1, 1987. Hay, JW. "Time to Try to Bridge Gaps in Health Care for the Elderly," Editorial Page, Hartford Courant, May 13,

1987. Bernstam, M., Hay, JW. and Swan, P. "Minimum Wage: Bulwark of the Privileged," Editorial Page, Wall Street

Journal, June 15, 1987. Hay, JW. and Bernstam, M. "Raising Minimum Wage Hurts Teens, Minorities," Point of View, San Francisco

Chronicle, August 17, 1987. Bernstam, M. and Hay, JW. "At the Minimum, Wage Law Will Reduce Jobs for Youth," Editorial Page, Orange

County Register, December 23, 1987. Bernstam, M. and Hay, JW. "California Panel Opens a Pandora's Box on Minimum Wage," Editorial Page, San Diego

Union, February 14, 1988. Hay, JW. "Trojan Horse: Dukakis’ Health Plan is a Disaster," Editorial Page, San Jose Mercury News, August 11,

1988. Hay, JW. "The 'Dream' That Will Break Massachusetts: Dukakis' Health-Care Plan No Way to Help the Poor,"

Editorial Page, Los Angeles Herald Examiner, August 28, 1988. Hay, JW. and Ricardo-Campbell, R. "A Health Plan to Make Business Sick," Editorial Page, Hartford Courant,

October 30, 1988. Hay, JW. "Let's Not Exaggerate the Costs of AIDS," Editorial Page, Newsday, February 9, 1989. Hay, JW. "AIDS Won't Break the Health-Care System," Editorial Page, Omaha World-Herald, February 12, 1989. Hay, JW. "AIDS Isn't Bankrupting our Health-care System," Editorial Page, Sacramento Bee, February 13, 1989. Hay, JW. "AIDS Costs Will Not Sink Health Budget," Editorial Page, San Jose Mercury News, March 8, 1989. Hay, JW. "The Battle Against AIDS: Some of the Earlier Assumptions are Overdue for Reexamination," Editorial

Page, San Diego Union, April 9, 1989. Hay, JW. "The Good News About AIDS," Viewpoints, New York Newsday, May 18, 1989. Hay, JW. "AIDS Infection Data Difficult to Refute," Letters to the Editor, Wall Street Journal, June 28, 1989. Hay, JW. "Is Too Much Being Spent on AIDS?" Editorial Page, Wall Street Journal, October 3, 1989. Hay, JW. "AIDS Epidemic: Falling Short of Projections?" Editorial, Texas Tribune, Austin, TX, November 9, 1989. Hay, JW. "Crossings Dangerous," Letters to the Editor, Peninsula TimesTribune, December 3, 1989. Hay, JW. "American Medicine: Should We Save Lives or Dollars?" The Commonwealth, The Weekly Newsletter of

the Commonwealth Club of California, April 2, 1990; pp. 186-189. Hay, JW. "Healthcare Policy Directions," The Executive Speaker, Vol. 11, No. 8 (August 1990); pg. 2. Hay, JW. "Is Hong Kong Ready for Free Market Health Care?" HKCER Letters, Hong Kong Center for Economic

Research, (November 1990), pp. 1-4.

Joel W. Hay, Ph.D. -- C.V. -52- 10/18/18 Hay, JW. "Cocaine Abuse is Not a Victimless Crime," Editorial, The Los Angeles Daily Journal, Los Angeles, CA,

and The San Francisco Daily Journal, San Francisco, CA, January 8, 1991. Hay, JW. "Commentary: Cost-Effectiveness of Strategies for Detecting Diabetic Retinopathy," Diabetes Spectrum,

Vol 5(2), March/April 1992, pp. 109-110. Hay, JW. "World Bank's Loan Won't Cure Hungary," The Wall Street Journal, Europe, July 15, 1992. Hay, JW. "Amid Lofty Goals Lie Plethora Of Health-Care Myths," Los Angeles Daily News, September 26, 1993. Hay, JW. “Bitter pill: One reason prescription drugs cost more in California,” Opinion, San Jose Mercury News,

February 6, 2002. Hay, JW. “Allergy Drug-Cost Fight Carries Potential Risks,” Letter to the Editor, Wall Street Journal, May 23, 2003. Hay, JW. “Buying in Canada Won't Cut Drug Costs,” Editorial, Los Angeles Times, August 31, 2004. Hay, JW. “Against Marijuana Legalization” Editorial, New York Times Freakonomics Blog, May 22, 2009;

http://freakonomics.blogs.nytimes.com/2009/05/22/pot-quorum/. Hay, JW. “Against Proposition 19 Marijuana Legalization” Debatethisonline.com, October 25, 2010;

http://www.debatethisonline.com/debate/marijuana_legalization_in_california_proposition_19_part_two. Hay, JW. “A simple way to rein in health costs,” Editorial, Orange County Register, December 10, 2012.

http://www.ocregister.com/opinion/health-380238-care-tax.html. Hay, JW. “Why health system is so broken,” Editorial, Orange County Register, December 15, 2012.

http://www.ocregister.com/opinion/health-380788-medicare-care.html.

Hay, JW. “The Medicare Fiscal Cliff,” Editorial, Orange County Register, December 28, 2012. http://www.ocregister.com/opinion/health-380788-medicare-care.html.

Hay, JW. “Obamacare a deficit fighter?,” Editorial, Orange County Register, January 16, 2013. http://www.ocregister.com/opinion/health-383520-billion-obamacare.html. Hay, JW. “If you've got Obamacare, higher pay doesn't pay,” Editorial, Orange County Register, February 11, 2013. http://www.ocregister.com/opinion/tax-495245-income-obamacare.html. Hay, JW. “Drug company invests more in senators than new drugs,” Editorial, Orange County Register, March 4,

2013. http://www.ocregister.com/opinion/amgen-497914-political-drug.html. Hay, JW. “Big Pharma facing price controls,” Editorial, Orange County Register, March 20, 2013. http://www.ocregister.com/opinion/drug-500414-big-pharma.html. Hay, JW. “We can't afford the Affordable Care Act,” Editorial, Orange County Register, April 1, 2013. http://www.ocregister.com/opinion/health-501944-obamacare-care.html. Hay, JW. “Singapore’s Affordable Health Model,” Editorial, Orange County Register, April 7, 2013. http://www.ocregister.com/opinion/health-503115-care-singapore.html. Hay, JW. “Pipe Dreams and Quack Pot Medicine,” Editorial, Orange County Register, May 14, 2013. http://www.ocregister.com/articles/marijuana-508205-drug-medical.html. Hay, JW. “Medicaid: A costly, ineffective intervention,” Editorial, Orange County Register, May 21, 2013. http://www.ocregister.com/articles/health-509333-care-medicaid.html

Joel W. Hay, Ph.D. -- C.V. -53- 10/18/18 Hay, JW. “Obamacare: A ‘scandal' that keeps on giving,” Editorial, Orange County Register, June 10, 2013. http://www.ocregister.com/articles/health-511818-obamacare-insurance.html Hay, JW. “Beaming Up Profits: Priciest treatments not always best,” Editorial, Orange County Register, July 3, 2013. http://www.ocregister.com/articles/proton-515317-beam-treatment.html Hay, JW. “Making headway against HIV/AIDS,” Editorial, Orange County Register, July 8, 2013. http://www.ocregister.com/articles/hiv-515516-aids-drug.html Hay, JW. “Obamacare poor fit for long-term care,” Editorial, Orange County Register, July 30, 2013. http://www.ocregister.com/articles/term-518990-care-long.html Hay, JW. “Thank You for Smoking,” Editorial, Orange County Register, August 23, 2013.

http://www.ocregister.com/articles/health-522519-hie-plan.html Hay, JW. “Anatomy of health care billing,” Editorial, Orange County Register, September 10, 2013.

http://www.ocregister.com/articles/health-525003-medicare-mcallen.html Hay, JW. “Unaffordable Care Acts Unpopularity Grows,” Editorial, Orange County Register, October 1, 2013. http://www.ocregister.com/articles/health-528698-obamacare-care.html Hay, JW. “Pharmacist Status Boosts Health Care,” Editorial, Orange County Register, October 23, 2013. http://www.ocregister.com/articles/health-532413-care-pharmacists.html Hay, JW. “Keep your Health Plan? Have They Got a Plan for You!” Editorial, Orange County Register, November

18, 2013. http://www.ocregister.com/articles/health-537272-coverage-obamacare.html Hay, JW. and Huesch, M. “Health Prices: The Truth is Out There” Editorial, Orange County Register, November 25,

2013. http://www.ocregister.com/articles/health-538408-care-prices.html

Hay, JW. “The Doctor Won’t See You Now,” Editorial, Orange County Register, December 16, 2013. http://www.ocregister.com/articles/health-593400-plan-california.html Hay, JW. “Obamacare Flight 001,” Editorial, Orange County Register, January 9, 2014. http://www.ocregister.com/articles/hay-596654-introduction-joel.html Hay, JW. “Making silk purses from sows' ears: Using regulatory loopholes to gouge patients,” Editorial, Orange

County Register, February 3, 2014. http://www.ocregister.com/articles/acthar-599759-drug-questcor.html Hay, JW. “What’s Wrong with American Hospitals,” Editorial, Orange County Register, February 8, 2014. http://www.ocregister.com/articles/hospital-600886-care-year.html Hay, JW. “Obamacare’s Broken Promises,” Editorial, Orange County Register, March 25, 2014.

http://www.ocregister.com/articles/health-606912-obamacare-care.html Hay, JW. “Health Care at the End of Life,” Editorial, Los Angeles Register, April 18, 2014.

http://www.losangelesregister.com/common/printer/view.php?db=laregister&id=597957

Hay, JW and McGinnis, J. “A Medical Breakthrough Actually Worth Paying For,” Editorial, Orange County Register and Los Angeles Register, May 29, 2014.

http://www.ocregister.com/articles/new-616291-drugs-hcv.html

Joel W. Hay, Ph.D. -- C.V. -54- 10/18/18 Hay, JW. “Another serious blow for Obamacare,” Editorial, Orange County Register July 31, 2014 and Los

Angeles Register, August 1, 2014. http://www.ocregister.com/articles/health-630224-insurance-state.html

Hay, JW. “Catalina Island’s Drastic Job- and Business-Killing Drought Response,” Letter to the Editor, Los

Angeles Times, May 12, 2015. http://www.latimes.com/opinion/readersreact/la-le-0512-tuesday-mormon-temple-lawn-20150512-story.html

Hay, JW and Huesch M. “Death spirals loom for health insurers,” Orange County Register March 5, 2016.

http://www.ocregister.com/common/printer/view.php?db=ocregister&id=706859 Hay, JW. “An Obamacare replacement that will actually work,” Orange County Register March 23, 2017.

http://www.ocregister.com/articles/complex-747319-popular-most.html Hay, JW. “Regenerating medical research payouts?” Orange County Register May 18, 2017.

http://www.ocregister.com/2017/05/18/regenerating-medical-research-payouts/

Joel W. Hay, Ph.D. -- C.V. -55- 10/18/18 SCIENTIFIC JOURNAL EDITOR and/or EDITORIAL BOARDS Annals of Pharmacotherapy 1992-1997 Pharmaceutical Research 1992-1997 PharmacoEconomics 1992-1999 JAMA HIV/AIDS Web Site Editorial Review Panel 1995-2001 Journal of Cardiovascular Pharmacology and Therapeutics 1995-2015 Value in Health Founding Editor-in-Chief 1998-2002 Journal of Managed Care Pharmacy 2004-2008 CORE Evidence 2005-2018 CORE Evidence, Guest Editor 2015 The Open Health Services & Policy Journal 2007-present Expert Review of Clinical Pharmacology 2007-present International Journal of the Economics of Business Guest Editor, Special Issue: Commemorating William S. Comanor and 50 Years of Pharmaceutical Economics 2014-2015 JOURNAL REFEREE: Advances in Therapy, AIDS, American Journal of Cardiology, American Economic Review, American Heart Journal, American Journal of Health Economics, American Journal of Managed Care, American Journal of Managed Care and Specialty Pharmacy, American Journal of Public Health, Annals of Pharmacotherapy, Annals of the Rheumatic Diseases, Applied Health Economics and Health Policy, Archives of Pediatrics and Adolescent Medicine, BioDrugs, Blood, BMC Medicine, BMJ, Breastfeeding Medicine, Canadian Journal of Diabetes, Cancer, Cardiovascular Drugs and Therapy, Chest, Clinical Drug Investigation, Clinical Pharmacokinetics, Clinical Therapeutics, ClinicoEconomics and Outcomes Research, CNS Drugs, Consultant, Critical Care, Current Medical Research and Opinion, Drugs and Aging, Eastern Economic Journal, Econometric Reviews, Epilepsia, European Journal of Health Economics, Evaluation and Expert Opinion on Pharmacotherapy, Expert Opinion on Therapeutic Patents, Expert Review of Pharmacoeconomics and Outcomes Research, Farmeconomia: Health Economics and Therapeutic Pathways, Gerontology, Health Affairs, Health Care Financing Review, Health Economics, Health Professions, Health and Quality of Life Outcomes, International Journal of the Economics of Business, JAMA, Journal of Adolescent Health, Journal of Affective Disorders, Journal of Alzheimer Disease, Journal of the American Statistical Association, Journal of Applied Econometrics, Journal of Cardiovascular Pharmacology and Therapeutics, Journal of Chemotherapy, Journal of Clinical and Experimental Oncology, Journal of Econometrics, Journal of Environmental Management, Journal of Epidemiology and Community Health, Journal of Gerontology: Social Sciences, Journal of Health Care for the Poor and Underserved, Journal of Health Politics, Policy and Law, Journal of Human Resources, Journal of Managed Care Pharmacy, Journal of Manged Care and Specialty Pharmacy, Journal of Medical Economics, Journal of Medical Education, Journal of Pain Research, Journal of Perinatology, Journal of Public Economics, Journal of Public Health Dentistry, Medical Care, Medical Decision Making, Milbank Memorial Fund Quarterly, Nature Reviews Drug Discovery, New England Journal of Medicine, Obstetrics & Gynecology, Pediatric Drugs, Pediatrics, PharmacoEconomics, Priorities, Research in Population Economics, Review of Economics and Statistics, Social Science and Medicine, SciTechnol, Social Science Journal, Southern Economic Journal, Statistica Sinica, Topics in Hospital Pharmacy Management, Vaccine, Value in Health. BOOK MANUSCRIPT REFEREE: 2006 Lisa Gordon

Editorial Assistant Jones and Bartlett Publishers

Joel W. Hay, Ph.D. -- C.V. -56- 10/18/18 SCIENTIFIC CONFERENCE ORGANIZATION AND DEVELOPMENT 1996-1998 Co-Chair and Primary Organizer: ISPOR Lipid Pharmacoeconomics Conference. Orlando, FL. 2001-2003 International Health Economics Association 4th World Congress, San Francisco; Local Organizing

Committee Member 2004-2005 Scientific Track Evaluation Panel; Disease Management Association of America Annual

Conference. Orlando, FL. 2005 Scientific Advisory Committee, Third NIMH Pharmacoeconomics Workshop: MMA03 and

Psychotropic Medications 2007 American Society of Health Economics Meeting Organizer, Duke University, Durham, NC. 2009 Western Pharmacoeconomics Conference: Decision Tools for the Health Care Puzzle, Co-Chair and

Meeting Organizer; Pasadena CA. 2014 American Society of Health Economists: 4’th Biannual Conference, USC, Los Angeles, CA. 2015 Conference on a Half-Century of Pharmaceutical Economics, University of British Columbia,

Vancouver, BC, Canada. 2016-17 Conference Co-Chair, International Academy of Health Preference Research (iahpr.org) North

American Conference, Boston, MA.

Joel W. Hay, Ph.D. -- C.V. -57- 10/18/18 MEDIA APPEARANCES October 1989 Time Magazine: "A Recount of AIDS Carriers." Article about J Hay's back calculation model

for estimating the number of people infected with HIV/AIDS. October 9, 1989; pg. 103. June 1992 "Should Marijuana Be Legalized for Medicinal Purposes?" The Dr. Dean Show, NBC, San

Francisco. November 1992 "Prescription Drug Price Inflation: What Should Be Done?" Seniors Speak Out, KPBS, San

Diego. September 1993 "Health Care Reform: Access and Cost" syndicated Public Television show. June 1994 "Heterosexual AIDS," Diane Crowe/Chuck Whitten Show, KAVL, Lancaster, CA. September 1994 “Heterosexual AIDS,” The Dennis Praeger TV Show, Los Angeles, CA. October 1994 “Bias in Official Government Projections of HIV/AIDS,” FOX Television News Service, New

York, NY. January-March 1995 “Clinicoeconomics” Annenberg Center at Eisenhower Three Part Television Series written by

and featuring Joel W. Hay, Ph.D., Producer, Chuck Cox. Part 1: Principles of Clinicoeconomics; Part 2: The Outcomes Revolution--Measuring Health Related Quality of Life; Part 3: Practice Variation and Medical Guidelines Development. Rancho Mirage, CA.

September 2000 “Cost Effectiveness of Statins.” International Task Force for Prevention of Coronary Heart

Disease. Consensus on Statins Conference Webcast: www.chd-taskforce.com May 2001 “Economic Considerations in Moving Second-generation Antihistamines from Prescription to

OTC Status,” CNN Headline News interview. May 2001 “Economics of RU-481.” Los Angeles Times interview. April 2002 “Pharmacy Workforce Effects of Converting from the California to the National Pharmacy

Licensure Examination.” San Jose Mercury News interview. December 2002 "National Issues Briefing To Examine Rising Hospital Costs," Washington Press Club

Seminar covered by CSPAN http://www.kaisernetwork.org/healthcast/usnews/bcbs/02dec2002 .

October 2005 “Drug Safety in the Aftermath of Vioxx.” Investors Business Daily interview. January 2007 “Democratic Medicare drug plan poised to pass House,” McClatchy Newspapers,

http://www.mercurynews.com/mld/mercurynews/news/politics/16393085.htm. January 2007 “House Passes Bill to Require Medicare Part D Price Negotiations”. Lou Dobbs Show, CNN. January 2007 “House Passes Bill to Require Medicare Part D Price Negotiations”. Business & Media Institute

(http://www.businessandmedia.org/articles/2007/20070112164308.aspx). January 2007 “Pharmaceutical Industry Profitability, ” Investors Business Daily interview. April 2008 “Merck, Schering Keep Taking Heat For Vytorin Flub.” Investors Business Daily interview. November 2008 “Impact of CVS Generic Drug Pricing Plan.” NBC Today Show. November 2008 “Generic Drug Price Competition.” KNBC Evening News.

Joel W. Hay, Ph.D. -- C.V. -58- 10/18/18 November 2008 “Gains By Democrats Put Pharma On Edge” Investor’s Business Daily interview. March 2009 J Hay quotations in “Can Marijuana Help Rescue California's Economy?” By Alison Stateman

Time Online, March 13, 2009; http://www.time.com/time/nation/article/0,8599,1884956,00.html

July 2009 J Hay interview with Marc Brown on legalizing marijuana KABC TV Channel 7 Evening News.

July 28 and July 29, 2009. July 2009 J Hay interview with Nicole Busch on value of health co-op plans in the health insurance reform

legislation. Fox News, July 31, 2009. August 2009 J Hay interview on KCBS radio newsmaker show: Why marijuana shouldn’t be legalized.

KCBS August 2. August 2009 J Hay interview on KNBC-TV Sunday LA, August 2. Why marijuana shouldn’t be legalized. August 2009 J Hay interview on Montel Williams Across America, August 5. Why marijuana shouldn’t be

legalized. August 2009 J Hay interview on KCBS Radio news: Should new federal laws be passed to protect pharmacy

prescription information from commercial data vendors? August 19. October 2009 J Hay interview on KCBS Radio news: Medical Marijuana Dispensaries. October 19. October 2009 Panel discussion on Medical Marijuana and Marijuana Legalization. The Michael Krazny

Show, KQED Radio, October 20. December 2009 J Hay interview on KCBS Radio news: Marijuana Legalization in California, December 18. December 2009 J Hay interview by Reuters News: Marijuana Legalization in California, December 18. January 2010 "Recent Advances in Otolaryngology," (www.audio-digest.org). February 2010 J Hay interview on University of California media release on medical marijuana studies.

February 18. http://www.webmd.com/pain-management/news/20100218/medical-marijuana-has-merit-research-shows?page=2

March 2010 J Hay interview on Federal Restrictions on Cost Effectiveness Analysis, NPR’s Marketplace;

http://marketplace.publicradio.org/display/web/2010/03/16/pm-health-care-costs/# March 2010 “Orphan Drug Market Catches Pharma's Eye.” Investors Business Daily quotes from J Hay. July 2010 “Bright Future Seen For Vaccine Research.” Investors Business Daily quotes from J Hay. August 2010 “Walgren’s Flu Vaccine Gift Cards Don’t Make Sense,” Interview on KCBS Radio, San

Francisco, CA 8/17/10. September 2010 “Will Drugmakers' Fight To Defer Generics Hit Supreme Court?” Investors Business Daily

quotes from J Hay. November 2010 “Genentech Catching Some Heat For Pushing Expensive Eye Drug,” Investors Business Daily

quotes from J Hay.

Joel W. Hay, Ph.D. -- C.V. -59- 10/18/18 March 2011 “Medical Marijuana Deters Legitimate Medical Cannabinoids” March 13, 2011 Felice J. Freyer,

Rhode Island News. http://www.projo.com/news/content/THC_03-13-11_RMMUHVQ_v16.15cf632.html#

April 2011 “Medicare on the table.” Marketplace show, NPR 4-13-11, Gregory Warner,

http://marketplace.publicradio.org/display/web/2011/04/13/pm-medicare-on-the-table/ June 2011 “World Have Your Say: What would the world look like if all drugs were legalised?” BBC

World Service, http://www.bbc.co.uk/programmes/p00gx5gq August 2011 “Expert Discussion: Prescription For Pot—A Debate on the Merits of Medical Marijuana,” MD

Magazine: Peers & Perspectives: The Physician's Authority for Debate & Exchange. Podcast. December 2011 “Lipitor's patent loss is consumers' gain,” quotes from J Hay. Los Angeles Times, December 1,

2011. January 2012 “Excedrin, Gas-X and other Novartis drugs recalled,” radio quotes from J Hay. Marketplace

Morning Report, American Public Media, January 9, 2012. http://www.marketplace.org/topics/business/health-care/excedrin-gas-x-and-other-novartis-drugs-recalled

January 2012 “FDA: Novartis Recall May Also Affect Painkillers,” video quotes from J Hay. AP Video,

January 9, 2012. http://youtu.be/dttrjWA_Sn0 March 2012 “Individual mandate under review in Supreme Court,” Marketplace show, NPR 3-27-12, Amy

Scott, http://www.marketplace.org/topics/economy/health-care/individual-mandate-under-review-supreme-court

June 2012 “Health care reform trajectory won't be stopped by Supreme Court ruling,” Southern California

Public Radio 6-7-12. http://www.scpr.org/news/2012/06/07/32713/health-care-reform-trajectory-wont-be-stopped/

August 2012 Comment on “As circumcision declines, health costs will go up, study projects,” Los Angeles

Times, August 21, 2012. http://www.latimes.com/news/science/la-sci-circumcision-health-costs-20120821,0,6266293,print.story

August 2012 Comment on “Study claims decline in circumcision will lead to increase in STDs.” Larry

Mantle Airtalk, Southern California Public Radio 8-21-12. http://www.scpr.org/programs/airtalk/2012/08/21/27999/study-circumcisions-numbers-drop-std-increase-sex/

August 2012 Comment on “Walmart arms itself with vaccines,” NPR Marketplace Morning Report. 8-23-12.

http://www.marketplace.org/topics/business/health-care/walmart-arms-itself-vaccines April 2013 Comment on “Students discuss usefulness of marijuana legalization,” USC Daily Trojan, April

9, 2013. http://dailytrojan.com/2013/04/09/students-discuss-usefulness-of-marijuana-legalization/ November 2013 Comment on “Widespread confusion over flu shot insurance benefits,” Los Angeles Times,

November 7, 2013. http://www.latimes.com/business/la-fi-lazarus-20131101,0,1800506,full.column#axzz2jPZ7iJpn July 2014 Comment on “Does neurology need a faster FDA?” Lancet Neurology, Vol 13 August 2014; pp.

760-61. www.thelancet.com/neurology October 2014 Comment on “Why there is no ebola vaccine,” NPR Marketplace, October 1, 2014.

http://www.marketplace.org/topics/health-care/why-there-no-ebola-vaccine

Joel W. Hay, Ph.D. -- C.V. -60- 10/18/18 October 2014 Comment on “Economics of Ebola Vaccine,” NPR Marketplace, October 22, 2014.

http://www.marketplace.org/topics/health-care/economics-behind-rush-ebola-vaccine October 2014 Comment on “Big pharma collaborates on Ebola vaccine,” Australian Broadcast Company radio

interview, October 24, 2014. http://www.abc.net.au/am/content/2014/s4113595.htm May 2015 Comment on “CVS seeks to buy Omnicare,” Marketplace, American Public Media and National

Public Radio May 21, 2015. http://www.marketplace.org/topics/business/cvs-seeks-buy-omnicare

September 2015 Comment on “Doctor's attempt to bring lower-price diabetes drug to market thwarted,” Los

Angeles Times, September 4, 2015. http://www.latimes.com/business/la-fi-lazarus-20150904-column.html

September 2015 “Daraprim Drug Price Hike,” Top of Mind with Julie Rose, BYU Radio, September 24, 2015.

http://www.byuradio.org/show/e9a84fc9-4bb1-476f-bd5d-0e907b754af8/top-of-mind-with-julie-rose; http://www.byuradio.org/episode/5f014c3f-9e8e-452d-8c30-ba3100d70490?playhead=65&autoplay=true

December 2015 “Drug Pricing and Pharmacies,” Top of Mind with Julie Rose, BYU Radio, December 16, 2015.

http://www.byuradio.org/episode/80489567-65f0-4c8e-a6b1-bff75c6f2e3f?playhead=63&autoplay=true

January 2016 Comment on “Afrezza patients worry they'll lose access to their insulin,” Los Angeles Times,

January 8, 2016. http://www.latimes.com/business/la-fi-afrezza-patients-20160108-story.html January 2016 Comment on “The obscurity of drug spending in Medi-Cal: What do you want to know about

State spending on high-cost drugs?” Pauline Bartalone, www.calmatters.org. https://medium.com/california-s-legal-drug-dilemma/the-obscurity-of-drug-spending-in-medi-cal-4ccf1df97392#.v1rgwujib

February 2016 Comment on “The other ‘high-cost’ drugs: What specialty drugs mean for California.” Pauline

Bartalone, www.calmatters.org. https://medium.com/california-s-legal-drug-dilemma/the-other-high-cost-drugs-what-specialty-drugs-mean-for-california-df18ddf1e632#.ydyg7zybx

February 2016 Comment on “High Costs For Drugs Used By A Few Are Starting To Add Up,” Shots: NPR

Health News, http://www.npr.org/sections/health-shots/2016/02/05/465699654/high-costs-for-drugs-used-by-a-few-are-starting-to-add-up

March 2016 Comment on “Voter anger over surging prescription drug costs has generated a campaign

issue,” Los Angeles Times, March 11, 2016. http://www.latimes.com/politics/la-na-florida-campaign-drug-prices-20160311-story.html

April 2016 Comment on “What's California's prescription for rising drug costs?” Pauline Bartalone,

www.calmatters.org. https://calmatters.org/articles/california-takes-measures-to-control-drug-spending-but-costs-soar/

May 2016 Comment on “How Big Pharma Uses Charity Programs to Cover for Drug Price Hikes,”

Benjamin Elgin, Robert Langreth, Bloomberg Business Week, May 21, 2016. http://www.bloomberg.com/news/articles/2016-05-19/the-real-reason-big-pharma-wants-to-help-pay-for-your-prescription

June 2016 Comment on “U.S. regulator says too many drugmakers chasing same cancer strategy,” Reuters,

June 14, 2016. http://finance.yahoo.com/news/u-regulator-says-too-many-204549726.html

Joel W. Hay, Ph.D. -- C.V. -61- 10/18/18 June 2016 Comment on “Pharma: an industry shaped by shareholder value,” Marketplace, American

Public Media, June 15, 2016. http://www.marketplace.org/2016/06/08/world/profit-pharma June 2016 Comment on “Medi-Cal To Spend Nearly $1 Billion On Hepatitis C Drugs Next Year,”

California Healthline, California Healthcare Foundation, June 21, 2016. http://californiahealthline.org/news/medi-cal-to-spend-nearly-1-billion-on-hepatitis-c-drugs-next-year/

September 2016 Comment on “MannKind developing inhalable epinephrine to challenge Mylan's EpiPen,” Los

Angeles Times, September 6, 2016. http://www.latimes.com/business/la-fi-mannkind-epipen-20160901-snap-story.html

November 2016 Comment on “Soon adults in California could get a joint delivered faster than a pizza,” CBC

World November 12, 2016. http://www.cbc.ca/news/world/soon-adults-in-california-could-get-a-joint-delivered-faster-than-a-pizza-1.3848121

November 2016. Comment on “Impacts of Marijuana Legalization for Recreational Purposes in California,” The

Larry Fedoruk Show, CKTB Radio, November 14, 2016. http://www.iheartradio.ca/610cktb/shows/the-larry-fedoruk-show-1.1816268

February 2017 Comment on “Drug Firm Payouts Under Scrutiny,” Boston Herald, February 12, 2017.

http://www.bostonherald.com/business/business_markets/2017/02/drug_firm_payouts_under_scrutiny

March 2017 Comment on “Pompe Drug Lauded by Trump Costs $300,000 a Year,” New York Times,

March 1, 2017. https://www.nytimes.com/reuters/2017/03/01/world/europe/01reuters-usa-trump-drugpricing.html?_r=2

March 2017 Comment on “Patient advocacy groups raking in pharmaceutical dollars, USA Today, March 1,

2017. http://www.usatoday.com/story/news/2017/03/01/patient-advocacy-groups-pharmaceutical-dollars/98593458/

April 2017 Discussion of Joel Hay’s Health Reform Proposal “Grasping For The Middle Ground On

Obamacare.” California Healthline, California Health Care Foundation, April 14, 2017. http://californiahealthline.org/news/grasping-for-the-middle-ground-on-obamacare/

May 2017 Comment on “Amazon would be a disruptor if it sold prescriptions,” NPR Marketplace,

American Public Media, May 17, 2017. https://www.marketplace.org/2017/05/17/business/amazon-would-be-disruptor-if-it-sold-prescriptions

August 2017 Comment on “If Trump wanted, he could take steps to lower soaring drug prices.” David

Lazarus, Los Angeles Times, August 1, 2017. http://www.latimes.com/business/lazarus/la-fi-lazarus-drug-price-caps-20170801-story.html

December 2017 Comment on “Less choice, higher prices feared in CVS' takeover of health insurer Aetna.”

David Lazarus, Los Angeles Times, December 4, 2017. http://www.latimes.com/business/lazarus/la-fi-lazarus-phone-fees-20171205-story.html

December 2017 Documentary contributor, “Do No Harm: The Opioid Epidemic Media Project. Narrated by Ed

Harris.” Broadcasting on U.S. Public Broadcasting System in late spring 2018. 4-minute promo. https://vimeo.com/245499897

February 2018 Comment on “Trump once again vows to lower drug prices, and once again you shouldn't

believe him.” David Lazarus, Los Angeles Times, February 1, 2018 http://www.latimes.com/business/lazarus/la-fi-lazarus-sotu-trump-drug-prices-20180201-story.html

Joel W. Hay, Ph.D. -- C.V. -62- 10/18/18 May 2018 Radio Interview on “California bill to provide MediCal to all adults, regardless of immigration

status,” Air Talk with Larry Mantle, KPCC NPR Radio, May 22, 2018. https://www.scpr.org/programs/airtalk/2018/05/22/63062/california-bill-to-provide-medicaid-to-all-adults/

May 2018 Comment on “Pfizer Settles Kickback Case Related To Copay Assistance For $24M,” Kaiser

Health News, May 24, 2018. https://khn.org/news/pfizer-settles-kickback-case-related-to-copay-assistance-for-24m/

June 2018 Comment on “The FDA Approves the First Drug Derived From Cannabis,” American Public

Media and National Public Radio June 28, 2018. https://www.marketplace.org/2018/06/25/health-care/fda-considers-approval-drug-cannabis

September 2018 Comment on “When your prescription drug is tainted with a chemical 'used to make rocket

fuel'.” David Lazarus, Los Angeles Times, September 7, 2018. http://www.latimes.com/business/lazarus/la-fi-lazarus-contaminated-prescription-drugs-20180907-story.html

Joel W. Hay, Ph.D. -- C.V. -63- 10/18/18 PUBLIC HEARING TESTIMONY AND PRESENTATIONS: December 1985 "The cost implications of adding Ranitidine to the Medi-Cal Drug Formulary," Medi-Cal Drug

and Therapeutics Advisory Commission Hearings, California Department of Health Services, Sacramento, CA.

April 1987 "Cost-Benefit evaluation of Haemophilus influenzae type b capsular polysaccharide vaccine,"

FDA Workshop on Haemophilus b Polysaccharide Vaccine, US Food and Drug Administration, Rockville, MD.

January 1990 "AIDS Case Projections for California," California AIDS Leadership Committee, California

Department of Health Services, Los Angeles County, CA. August 1990 "A Comparative Analysis of CDC and Other HIV/AIDS Projections and Recent (1990)

Regional Cost Projections for California," Northern California Integrated Planning Project: HIV Epidemiology Task Force, Sacramento AIDS Foundation, Sacramento, CA.

September 1991 "Cost-Effectiveness Issues in Cholesterol Treatment of Coronary Artery Disease," Panel on

Adult Treatment Guidelines for Established Coronary Artery Disease; the National Institutes of Health, National Heart, Lung and Blood Institute and the American Heart Association, Washington, D.C.

July 1992 "Research and Demonstration Waiver Request for Kaiser-Permanente Enhanced Pharmacy

Services Project," California State Board of Pharmacy, Burlingame, CA. January 1994 "The Impact of the Clinton Health Care Reforms on Small Business," Congressional Testimony

held at Diamond Bar, California at the invitation of Hon. Jay Kim, U.S. House of Representatives.

November 1996 "The cost effectiveness of Pravastatin and the Medi-Cal Drug Formulary," Medi-Cal Drug

Program, California Department of Health Services, Sacramento, CA. May 2001 “Economic Considerations in Moving Second-generation Antihistamines from Prescription to

OTC Status,” presentation to the US Food and Drug Administration Committee on Non-Prescription Drugs, Gaithersburg, MD.

March 2002 “Pharmacy Workforce Effects of Converting from the California to the National Pharmacy

Licensure Examination.” Presentation to the California Assembly on AB 2165, Sacramento, CA.

February 2010 “Cost-effectiveness of An Exclusively Human-Milk Based Diet Vs. Bovine-Milk Based Diet In

The Prevention of Necrotizing Enterocolitis Among Extremely Premature Medicaid Infants (Gestation Age < 28 weeks)” Presentation to the Texas Medicaid Drug Utilization Review Program, Austin, TX.

February 2012 “Competition Issues in the Pharmaceutical Benefits Manager (PBM) Market,” Presentation to

the Federal Trade Commission Bureau of Economics and the State Attorneys General Task Force on PBM Market Issues, Washington, DC.

Joel W. Hay, Ph.D. -- C.V. -64- 10/18/18 CONFERENCES AND PRESENTATIONS SINCE 1998: February 1998 “Methodological Issues in Conducting Pharmacoeconomic Evaluation—Modeling Studies,”

Panel Co-Chair. ISPOR Pharmacoeconomic Guidelines Consensus Development Conference. Crystal City, VA.

May 1998 “Lipid Therapy Cost Effectiveness: Are All Statins Equivalent?” Invited Plenary Session,

Association of Managed Care Pharmacy Annual Meeting, Philadelphia, PA. May 1998 “Alzheimer Disease Pharmacoeconomic Issues,” Invited Session, Association of Managed Care

Pharmacy Annual Meeting, Philadelphia, PA. May 1998 “Hong Kong Health Care Reform,” Harvard School of Public Health, Cambridge, MA. June 1998 “Mortality and Hospital Utilization Differences in the Kaiser/USC Pharmaceutical Care

Intervention Study,” University of Florida College of Pharmacy, Gainesville, FL. July 1998 “Alzheimer Disease Pharmacoeconomics,” Invited Session, First International Conference on

Alzheimer Disease Pharmacoeconomics, Amsterdam, Netherlands. October 1998 “The Future of Pharmacy,” Pharmacy Practice Research Roundtable Conference, San Diego,

CA. October 1998 “Lipid Therapy Cost Effectiveness,” Calif. Society Health Systems Pharmacy, Anaheim, CA. December 1998 “The US Pharmacoeconomic Methods Consensus Guidelines,” ISPOR First Annual European

Conference, Cologne, Germany. March 1999 “Lipid Therapy Costs and Outcomes,” New York University Department of Cardiology Grand

Rounds, New York, NY. April 1999 “Drug Patents and R&D Protection.” The Wallace Lectureship, Idaho State University School

of Pharmacy. Pocatello, ID. April 1999 “Survival and Hospitalization in the Kaiser/USC Pharmaceutical Care Demonstration Project.”

The Wallace Lectureship, Idaho State Univ. School of Pharmacy. Boise, ID. May 1999 “Cost Effectiveness Analysis of Occupational Therapy for Independent Living Elderly,” ISPOR

Annual Meeting, Podium Presentation. Washington, DC. September 1999 “Rotavirus Cost of Illness,” Rotavirus Vaccine Advisory Panel, Wyeth-Ayerst, Radnor, PA. October 1999 “The Cost of Lipid Therapy: A Systems Approach,” Interdisciplinary Council on

Cardiovascular Risk Reduction, Washington, DC. October 1999 “Survival and Hospital Utilization in the Kaiser/USC Pharmaceutical Care Study,” Kaiser

Permanente Research and Evaluation Dept Seminar., Pasadena, CA. November 1999 “The High Cost of Drugs and What to Do About It,” Univ. of California Riverside Life Society

Extension Program, Riverside, CA. November 1999 “Pharmacoeconomics of Epilepsy Medications,” American Epilepsy Society, Orlando, FL. February 2000 “Rotavirus Costs of Illness,” Vaccine Research Center, Harbor-UCLA Medical Center,

Torrance, CA.

Joel W. Hay, Ph.D. -- C.V. -65- 10/18/18 February 2000 “Pharmaceutical Expenditure Growth and Medicare Outpatient Drug Benefits,” Mid-Valley

Independent Practice Association, Portland, OR. April 2000 “Alzheimer Disease Cognition Measures and Economic Costs,” Invited presentation. 2nd

International Alzheimer Disease Pharmacoeconomic Conference, Stockholm, Sweden. April 2000 “Pharmacoeconomics of Antibiotic Treatment Strategies,” 10th Congress of the International

Society for Infectious Disease, Buenos Aires, Argentina. April 2000 “Economic Research Issues in Alzheimer Disease.” State of California Alzheimer Research

Centers Site Visit. Los Angeles, CA. September 2000 “Cost Effectiveness of Statin Therapy.” International Task Force for Prevention of Coronary

Heart Disease. Consensus on Statins Conference. Invited Presentation. Paris, France. September 2000 “Cost Effectiveness of Statin Therapy.” Interdisclipinary Council on Coronary Heart Disease.

Invited Presentation. New York, NY. November 2000 “Pharmacy Retail Price Variation,” Pharmaceutical Economics Seminar, UCLA School of

Public Health. Westwood, CA. March 2001 “Choicecare: A Health Insurance Market Plan for Hong Kong. Invited Seminar, Hong Kong

Hospital Authority; Hong Kong. May 2001 “Cost Effectiveness Considerations in Adult/Adolescent Pertussis Vaccination Strategies,”

Vaccine Health Advisory Group Conference, La Romana, Dominican Republic. July 2001 “China’s Health Care Reform,” International Health Economics Assoc. Meeting, York, UK. September 2001 “Cost Effectiveness of Statins: Implications for the National Cholesterol Education Panel

Recommendations.” Washington, DC. November 2001 “Chemotherapy-Induced Neuropathy In Ovarian Cancer Cost Effectiveness.” ISPOR European

Conference, Cannes, France. March 2002 “Conjoint Analysis of Alzheimer Disease Treatment Preferences: Preliminary Results.”

CCH/HSRC Methods Seminar, UCLA/NPI Center for Community Health and Health Services Research Center, Westwood, CA.

March 2002 “Ethics and Economics in Health Care Decision-making.” USC Health Sciences Campus

Seminar on Moral and Spiritual Issues in Health Care, Los Angeles, CA. April 2002 “Current Status of Health Economics Checklists and Guidelines.” Academy of Managed Care

Pharmacy Annual Convention, Podium Presentation, Salt Lake City, UT. May 2002 “Quality of life effects of chemotherapy-induced neuropathy in ovarian cancer (Abst 886).”

“Neuropathy in Chemotherapy: Results of an Oncology Nurse Survey (Abst 2618).” Poster Presentations, American Society of Clinical Oncology Annual Meeting. Orlando, FL.

May 2002 “Vaccine Reimbursement Policy in the United States: Issue Development.” Institute of

Medicine, National Academy of Sciences. Washington, DC. September 2002 “Recent Trends in U.S. Lipid Medication Use: 1998-2002. Interdisclipinary Council on

Coronary Heart Disease. Invited Presentation. New York, NY. September 2002 “Drugbusters: How to Manage your Medicine Cabinet.” Invited Roundtable Presentation.

Los Angeles Times Festival of Fitness and Health. Los Angeles, CA.

Joel W. Hay, Ph.D. -- C.V. -66- 10/18/18 October 2002 “Recent Drivers of Hospital Inpatient Expenditure Growth.” Media presentation sponsored

by the Blue Cross Blue Shield Association, Chicago, IL. November 2002 “Rising Hospital Costs in California.” Panel Discussion sponsored by Blue Shield of

California, Univ. of California, Berkeley, CA. December 2002 “National Issues Briefing To Examine Rising Hospital Costs," Panel Discussion sponsored

by U.S. News & World Report. Washington, DC. January 2003 "What's Behind the Rise in Health Care Costs” Invited Keynote Presentation, Washington

Business Group on Health Employer Summit. New York, NY. March 2003 “High Tide for Benefits Budgets: Rising Healthcare Costs.” Invited Keynote Presentation,

Illinois BlueCross BlueShield Natl Accounts Conf, San Diego, CA. April 2003 “Current trends and future directions of Health-Systems in the US,” Health Economics and

Outcomes Research Invited Presentation, Abbott Laboratories, Evanston, IL. May 2003 “U.S. Health Care Expenditure Growth: Issues and Solutions.” St. Louis Civic

Entrepreneurs Organization, St. Louis, MO. June 2003 “U.S. Pharmaceutical Expenditure Growth:1999-2002” Paper presented at the Intl Health

Economics Association 4’th World Congress, San Francisco, CA. June 2003 “Medical Market Failures and Intellectual Property” Paper presented at the Intl Health

Economics Association 4’th World Congress, San Francisco, CA. August 2003 “Determinants of Survival and Nursing Home Placement for AD Patients.” Paper

presented at the International Psychogeriatrics Association Annual Meetings, Chicago, IL. December 2003 "Claritan's Shift to OTC Status: A Lesson for the HMOs." Paper presented at

Pharmaceutical Economics And Policy Seminar, UCLA Schl of Public Health, Westwood, CA.

April 2004 “Pharmacoeconomics & Biotech.” Invited presentation at PDL Biopharma, Fremont, CA. July 2004 “Cost Effectiveness Of Pertussis Vaccine In Adults And Adolescents.” Invited

presentation, Pediatric Vaccine Workshop, New York, NY. November 2004 “Vaccine Costs and Benefits.” Invited presentation, GSK Pediatric Vaccine Advisory

Board., Scottsdale, AZ. February 2005 “Patents, Drug R&D and Protection of Intellectual Property,” Invited Panel Presentation:

International Trade in Pharmaceuticals, The International Law Society Meetings, Costa Mesa, CA.

May 2005 “Dually Eligible Mentally Ill Population” Session Chair; Third NIMH Pharmacoeconomics

Workshop: MMA03 and Psychotropic Medications, NIMH, Bethesda, MD. May 2005 “How Should Intellectual Property be Rewarded and Protected in the Global

Pharmaceutical Industry?” Panel Discussion, USC Law School Intellectual Property Institute, Second Annual Conference. Beverly Hills, CA.

May 2005 “Structure & Design of Pharmacoeconomic Models.” With Marc Botteman and Ben Van

Hout. ISPOR Short Course presented at the 10th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Washington, DC.

Joel W. Hay, Ph.D. -- C.V. -67- 10/18/18 June 2005 "Implementation and Outcomes of Commercial Disease Management Programs in the

United States: the Disease Management Outcomes Consolidation Survey." Nationwide Teleconference presentation with Mark Roberts.

October 2005 “Using Conjoint Analysis to Assess DM Intervention Attributes: Application to

Alzheimer’s Disease Caregivers.” Paper presented at the Disease Management Association of America Annual Meeting, San Diego, CA.

October 2005 “Conjoint Analysis Validation Of The Hui-3 Utility Scale In An Alzheimer Disease

Caregiver Population.” Abstract 1216 presented at the International Society of Quality of Life Research, San Francisco, CA.

November 2005 “Economic Implication Of Hepatitis B Viral (HbV) Load Reduction For Entecavir In

Hepatitis B E Antigen-Positive Chronic Hepatitis B (CHb) Patients” Presented at the 8’th ISPOR European Conference, Florence, Italy.

January 2006 “Methods for Selection Bias Adjustment: Propensity Scores, Instrumental Variables and the

Heckman Method. Invited Grand Rounds Presentation, Maveric, Dept. of Veterans Affairs and Harvard Medical School, Boston, MA.

March 2006 “Cost Effectiveness of Entecavir for Chronic Hepatitis B Disease in China.” Presented at

the ISPOR Asian Conference, Shanghai, China. March 2006 “Adjusting for Selection Bias in Administrative Health Care Databases.” Invited

Presentation, China Center for Pharmacoeconomics and Outcomes Research, Peking University, Beijing, China.

April 2006 “Stated Preference Theory (Conjoint Analysis) is the Best Way to Assess Health-Related

Quality of Life for Economic Assessment of Drugs and Medical Interventions: An Application in Alzheimer Disease” Invited International Teleconference Presentation, ISPOR Student Chapter Network.

October 2006 “The Value of Biomedical Innovation.” Invited Seminar, AstraZeneca Pharmaceuticals,

Alderly Park, Cheshire, UK. October 2006 “Cost Effectiveness of Magnetic Resonance Angiography versus Digital Subtraction

Angiography for Peripheral Vascular Disease.” Presentation at the 9’th European ISPOR Conference, Copenhagen, Denmark.

January 2007 “Stated Preference Theory in Assessing Health-Related Quality of Life for Economic

Assessment in Alzheimer Disease. Invited Seminar; Medical University of South Carolina. February 2007 “Stated Preference Theory in Assessing Health-Related Quality of Life for Economic

Assessment in Alzheimer Disease. Invited Seminar; Tulane University School of Public Health.

October 2007 “Risk-Stratified Medical Costs for Asthma Patients in a Managed Care Organization

(MCO).” Presentation at the 10’th European ISPOR Conference, Dublin, Ireland. October 2007 “Stated Preference Theory in Assessing Health-Related Quality of Life for Economic

Assessment in Alzheimer Disease. Invited Seminar; National University of Ireland, Galway, Ireland.

January 2008 “How Should Drug Prices Be Measured?” Invited Seminar, School of Public Health,

University of California Los Angeles, Los Angeles, CA.

Joel W. Hay, Ph.D. -- C.V. -68- 10/18/18 February 2008 “How Not to Use Health Economics Data: Lessons from the U.S. Health Care Sector”

invited presentation at the Hong Kong Hospital Authority Conference “Use of Health Economics Data in the Health Care Environment of Hong Kong The Way Forward.” Hong Kong SAR, China.

March 2008 “Cost Effectiveness of Statins and Other Lipid Therapies.” Invited presentation at the 3rd

International Symposium on Healthy Aging: Meeting the Challenges of an Aging Population, Hong Kong SAR, China.

April 2008 “Pharmacoeconomic Modeling,” Invited Lister Hill Seminar presentation, University of

Alabama at Birmingham School of Public Health. Birmingham, AL. August 2008 “Pharmacoeconomics Modeling and Empirical Analysis,” Invited Lecture Series, National

University of Colombia. Bogota, Colombia. September 2008 “Issues in Pharmacoeconomic Methods,” Invited Lecture, Amylin Pharmaceuticals, San

Diego, CA. November 2008 “Modeling Long-Term Mortality and Morbidity Impact with Entecavir Treatment in

Chronic Hepatitis B Patients in Belgium.” Benedicte Lescrauwaet, Frederik Nevens, Danielle Zammit, Yong Yuan, Joel Hay. Podium presentation, ISPOR European Conference, Athens, Greece.

December 2008 “Successful Pharmacoeconomic Models,” Invited presentation, Mexico ISPOR Chapter,

Mexico City, Mexico. March 2009 “Drugs and Outcomes Research: Where are the Comparative Effectiveness Guideposts Moving

To?” Opening Keynote Address, Western Pharmacoeconomics Conference, Pasadena, CA. April 2009 “Comparative Effectiveness: What Does It Mean and How Do We Do It?” Invited University-

Wide Seminar, USC School of Pharmacy, Los Angeles, CA. April 2009 “Stated Preference Theory (Conjoint Analysis) Assessment of Health-Related Quality of Life

for Economic Assessment of Medical Interventions,” Invited Seminar, University of Washington School of Pharmacy, Seattle, WA.

April 2009 “Health Economic Evaluation of Oral versus IV Therapy in Oncology.” Invited Presentation,

Current And Emerging Trends In The Treatment Of Cancer: Pharmacoeconomics And Market Assessment, Guaraja, Brazil.

May 2009 “Comparative Effectiveness Research: What it is and Why We Need it.” Invited Podium

Presentation, International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting, Orlando, FL.

August 2009 “Outcomes Research, Comparative Effectiveness, Cost Effectiveness: What is Needed Now and

Why?” Invited Seminar, Colombia Chapter: International Society for Pharmacoeconomics and Outcomes Research, Bogota, Colombia.

August 2009 “Pharmacoeconomics of Autoimmune Disease Therapy.” Invited presentation, XII Colombian

Rheumatology Congress, Bogota, Colombia. October 2009 Debate on the Pros and Cons of Marijuana Legalization. Invited speakers, The Arsalyn

Foundation, Duarte, CA. November 2009 Resource Use in Patients with Allergic Rhinitis (AR) Comorbidities: Oral Second Generation

Antihistamines (SGAs) versus Montelukast (MTLK)” Podium Presentation, Annual Meeting of the American College of Allergy, Asthma & Immunology, Miami Beach, Florida.

Joel W. Hay, Ph.D. -- C.V. -69- 10/18/18 November 2009 “Impact of Obama’s Health Care Reform on Payers” Speaker Panel Moderator; USC School of

Pharmacy Board of Councilors Retreat. Los Angeles, CA. November 2009 “Debate on Obama’s Health Care Reform with Prof. Tom Rice, Vice Chancellor, UCLA,”

at UC Davis Mondavi Center, Davis CA. http://webcast.ucdavis.edu/IGA/2009/Health_Care_Debate_11-17-09.qtl

December 2009 “Resource Use in Patients with Allergic Rhinitis (AR) Comorbidities: Oral Second

Generation Antihistamines (SGAs) versus Montelukast (MTLK)” Podium Presentation, Annual Meeting of the American College of Allergy, Asthma & Immunology, Nov. 5-10, Miami Beach, Florida.

January 2010 “Medical Marijuana: The Quack Pot Cure,” Research Study Club Invited Presentation,

Providence Saint Joseph Medical Center, Los Angeles, CA. February 2010 “Health Care Reform,” Arsalyn Foundation, UCLA, Los Angeles, CA. March 2010 “Obama’s Health Care Reform,” USC Executive Master’s Program in Health Administration,

Lost Angeles, CA. April 2010 “Obama Health Care Reform,” USC Schl. of Pharmacy, Lamda Chi Seminar, Los Angeles, CA. June 2010 “Economic Comparison of aPCC versus rFVIIa for mild-to-moderate bleeding episodes in

hemophilia patients with inhibitors.” Invited presentation, 8th Inhibitor Workshop for Opinion Leaders in Hemophilia.” Gdansk, Poland.

September 2010 “Pharmacoeconomics & Comparative Effectiveness: A U.S. Perspective.” Invited presentation

to NECA (National Evidence-based Healthcare Collaborating Agency) Seoul, Korea. September 2010 “Cost-effectiveness of An Exclusively Human-Milk Based Diet Vs. Bovine-Milk Based Diet In

The Prevention of Necrotizing Enterocolitis Among Extremely Premature Infants.” Invited presentation to the Cedars-Sinai Dept. of Pediatrics, Beverly Hills, CA.

September 2010 “Marijuana Legalization: No on Proposition 19.” Invited presentation, Loyola Marymount

University, Los Angeles, CA. October 2010 “Marijuana Legalization: The Quack Pot Cure to California’s Fiscal Woes.” Invited presentation

UCLA Extension Campus, Westwood, CA. October 2010 “Marijuana Legalization Debate: Proposition 19.” Invited presentation UCLA, Westwood, CA. October 2010 “Marijuana Legalization Debate: Proposition 19.” Invited presentation UCSC, Santa Cruz, CA. October 2010 “Insurance Innovation: How to Succeed after Reform" Invited presentation, First Annual

Schaeffer Center Conference, Leonard Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA. http://www.youtube.com/watch?v=SraGxvHlZWs

October 2010 “Marijuana: Potential Medical Consequences & Societal Issues Related to Legalization,” Invited

presentation, The Marijuana Conference: A Forum for Discussion of Business, Legal & Health Issues. New York, NY.

October 2010 “Marijuana Legalization: Proposition 19,” Invited presentation, The Fell Conversation, School

of Policy, Planning, and Development, University of Southern California, Los Angeles, CA.

Joel W. Hay, Ph.D. -- C.V. -70- 10/18/18 December 2010 “ Econometric Issues in Pharmacoeconomics,” Invited presentation, National University of

Colombia, School of Pharmacy, Bogota, Colombia. December 2010 “Comparative Effectiveness Research in the Changing US Policy Environment,” Invited

presentation, ISPOR Chapter of Colombia, Bogota, Colombia. December 2010 “Introduction to Pharmacoeconomics,” Invited presentation, Universidad del Atlántico, School

of Pharmacy, Barranquilla, Colombia. December 2010 “Comparative Effectiveness and Outcomes Research,” Invited presentation, Universidad del

Atlántico, School of Pharmacy, Barranquilla, Colombia. February 2011 “Pharmacy’s Changing Roles Under Health Care Reform,” Invited presentation, USC Pharmacy

Student Industry Association. Los Angeles, CA. March 2011 “Pitfalls in Comparative Effectiveness Research: From Poison IVs to Uninformed Posteriors.”

Invited Plenary Presentation, Western Pharmacoeconomics Conference, University of Washington, Seattle, WA.

April 2011 “Medical Marijuana: Therapeutic, Economic and Policy Issues.” Invited presentation,

Providence Tarzana Medical Center, Tarzana, CA. April 2011 “Budget Impact Models in MCO Decision Making: Current Practice, Challenges and Insights,”

Invited Workshop presentation, Academy of Managed Care Pharmacy, 23’rd Annual Meeting, Minneapolis, MN.

May 2011 “Branded Pharmaceutical Markets and Anticompetitive Harm.” Invited presentation, UCLA

Dept. of Health Services, Graduate Seminar on Pharmaceutical Economics and Policy. Los Angeles, CA.

July 2011 “Health Economics Research Objectives.” Invited presentation, UCLA Dept. of Health

Services, Health Economics Workshop with Monash Univ., UCLA & USC, Los Angeles, CA. September 2011 “Optimal Health Care Treatment Allocation With and Without Stochastic Uncertainty.” Invited

presentation, University of Tennessee College of Pharmacy. Memphis, TN. October 2011 “Medical Marijuana: Therapeutic, Economic and Policy Issues.” Invited presentation, Ventura

Community Memorial Hospital, Ventura, CA. October 2011 “Medicare: Financial, Economic and Policy Issues.” Invited presentation, Association of Health

Care Journalists, Business of Health Care Workshop, San Francisco, CA. November 2011 “Meeting the Challenges of US Health Care Reform: Payer and Provider Perspectives for the

Biopharmaceutical Market.” Invited Panel Discussion, 2011 IMS Life Sciences Strategy Conference, San Francisco, CA.

November 2011 “Health Care Reform: Where Does Pharmacy Fit?” Invited presentation, USC Pharmacy

Student Industry Association. Los Angeles, CA. December 2011 “Health Care Costs in a Medicare Population of COPD Patients Treated with Beta-Agonists.”

American Society of Health System Pharmacists Midyear Meeting, New Orleans, LA. December 2011 “Optimal Health Care Treatment Allocation With and Without Stochastic Uncertainty—Part I,”

Schaffer Center for Health Policy and Economics, USC. Los Angeles, CA. February 2012 “Optimal Health Care Treatment Allocation With and Without Stochastic Uncertainty—Part II,”

Schaffer Center for Health Policy and Economics, USC. Los Angeles, CA.

Joel W. Hay, Ph.D. -- C.V. -71- 10/18/18 May 2012 “Optimal Drug Treatment Allocation with & without Stochastic Uncertainty,” UCLA Seminar

on Pharmaceutical Economics and Policy.” Los Angeles, CA. May 2012 “Optimal Personalized Treatment Allocation With & Without Stochastic Uncertainty,” Invited

seminar, SingHealth Academy Symposium on Health Care Decision-making and Personalized Medicines, Singapore.

May 2012 “Cancer Treatments, Expensive Medications and Cost Effectiveness: Perspectives of a Health

Economist,” Panel Discussion, SingHealth Academy Symposium on Health Care Decisionmaking and Personalized Medicines, Singapore.

May 2012 “Comparative Effectiveness & Outcomes Research: Where is the U.S. Headed?” National

University of Singapore invited seminar, Singapore. June 2012 “Introduction to Economic Assessment of Drugs, Devices and Medical Interventions,”

Conference Workshop, American Society for Health Economics 4’th Biennial Conference, Minneapolis, MN.

June 2012 “Cost Effectiveness Analysis With and Without Stochastic Uncertainty,” Organized Podium

Session, American Society for Health Economics 4’th Biennial Conference, Minneapolis, MN. October 2012 “U.S. Health Care Reform Issues,” Invited presentation, Arsalyn Foundation, Alhambra, CA. November 2012 “Preparing Drug Review Dossiers for the Academy of Managed Care Pharmacy,” Invited

presentation, USC Managed Care Pharmacy Student Association, Los Angeles, CA. February 2013 “Hemophilia Inhibitor Bypass Agents: A Clinical and Economic Review of the Literature,”

Invited Webinar on Hemophilia Treatment. February 2013 “Drug Patents, Intellectual Property and Pricing,” Invited seminar, Tulane University School of

Public Health, New Orleans, LA. February 2013 “Stated Preferences and Conjoint Analysis: Theory and Applications,” Invited seminar, Tulane

University School of Public Health, New Orleans, LA. March 2013 “Accountable Care Organizations and Health Care Reform,” Invited Seminar USC Medical and

Pharmacy Students Collaboration.” USC, Los Angeles, CA. April 2013 “Optimal Health Care Treatment Allocation with & without Stochastic Uncertainty,” Invited

Seminar, Veterans Affairs Health Care Program and University of New Mexico PEPPOR Graduate Program, Albuquerque, NM.

April 2013 “The Current State of Comparative Effectiveness & Outcomes Research,” Invited Seminar,

University of New Mexico PEPPOR Graduate Program, Albuquerque, NM. September 2013 “The U.S. Societal Costs of Cannabis,” Invited presentation. The Marijuana Conference,

Rancho Cucamonga, CA. October 2013 “Conjoint Analysis of Provider Preferences for Interventions for Reducing Inappropriate

Antibiotic Prescribing,” Invited presentation. BEARI Investigators Meeting. Los Angeles, CA. November 2013 “Pay-for-Delay Settlements for Pharmaceutical ANDA Cases: Right or Wrong?” Invited

seminar, UCLA School of Public Health, Los Angeles, CA. February 2014 “Why Drugs Should Not Be Legalized,” Invited presentation. Arsalyn Foundation Student

Conference, El Monte, CA.

Joel W. Hay, Ph.D. -- C.V. -72- 10/18/18 March 2014 “Cost-Effectiveness Analysis Under Stochastic Uncertainty,” Steven M. Teutsch Prevention

Effectiveness Fellowship invited presentation. U.S. Centers for Disease Control and Prevention, Atlanta, GA.

March 2014 “Assessment of Health-Related Quality of Life for Medical Interventions: A Discrete Choice

Experiment Application in Alzheimer Disease,” Steven M. Teutsch Prevention Effectiveness Fellowship invited presentation. U.S. Centers for Disease Control and Prevention, Atlanta, GA.

March 2014 “Hemophilia Treatments, Costs and Outcomes,” invited presentation. National Center on Birth

Defects and Developmental Disabilities; U.S. Centers for Disease Control and Prevention, Atlanta, GA.

September 2014 “Current U.S. Trends in Health Technology Pricing and Value,” invited presentation. Forum on

HTA and Reimbursement, Peking University, Beijing, China. September 2014 “US Healthcare Financing System & Reforms,” invited presentation. Health Care Financing

Forum, Party School of the Central Committee of the Communist Party of China, Beijing, China.

September 2014 “U.S. Health Care Reform,” invited Plenary Symposium presentation. ISPOR 6th Asia-Pacific

Conference, Beijing, China. February 2015 “Is there a Convergence of Health Economics with U.S. Health Policy?” Panel Discussion

Invited Presentation, DePaul University Conference on Health Economics. Chicago, IL.

March 2015 “Pharmaceutical Research & Development: An Economist's Perspective.” Invited Lecture, Harbor-UCLA Grand Rounds. Torrance, CA.

April 2015 “Cost Effectiveness Analysis with Stochastic Uncertainty,” Invited seminar, Pharmaceutical

Outcomes Research and Policy Program, University of Washington. Seattle, WA. April 2015 “Regulating Health Economics Modeling Claims,” Invited presentation to the Office of Medical

Policy and the Center for Drug Evaluation and Research, Food and Drug Administration. Silver Spring, MD.

September 2015 “Orphan, Specialty and Low Volume/High-Priced Drugs,” Workshop on Pharmaceutical

Economics and Policy, Center for Health Economics and Outcomes Sciences, University of British Columbia. Vancouver, BC, Canada.

November 2015 “Cost Effectiveness Analysis with Stochastic Uncertainty,” Invited seminar, Dept. of

Economics, University of Iowa, Iowa City, IA. March 2016 “What is Pharmacoeconomic Information Under FDAMA 114?” Invited Panel Discussion,

AMCP Partnership Forum, FDAMA 114: Improving the Exchange of Pharmacoeconomic Data, Washington, DC.

March 2016 “Marijuana Legalization: Costs and Medical Harms.” Invited discussion, USC Seminar,

Preventive Medicine PM547: Public Health Policy and Politics, Los Angeles, CA.

April 2016 “Health Economics: An Introduction for Biomedical Engineers,” Invited Keynote Lecture, 20th Annual Grodins Research Symposium, USC Dept. of Biomedical Engineering, Los Angeles, CA.

September 2016 “Enabling the Exchange of Clinical and Economic Data pre-FDA Approval,” Invited Panel

Discussion, AMCP Partnership Forum, Tysons Corner, VA.

Joel W. Hay, Ph.D. -- C.V. -73- 10/18/18 November 2016 “2016 National and California Election Implications for Pharmaceuticals,” Invited Seminar,

Pharmaceutical Economics and Policy, School of Public Health, University of California, Los Angeles, Los Angeles, CA.

April 2018 “The Value in Aging: Health Economics Applications in Gerontology,” Invited Seminar,

Université de Sherbrooke Centre de Recherche sur le Vieillissement, Sherbrooke, Quebec, Canada.

October 2018 “Cost-Effectiveness of Screening and Management Strategies for Familial

Hypercholesterolemia in the United States: A Markov Model Update,” Invited Podium Presentation, 2018 Familial Hypercholesterolemia GLOBAL SUMMIT, Marina Del Rey CA.

Joel W. Hay, Ph.D. -- C.V. -74- 10/18/18 RESEARCH CERTIFICATIONS:

Completion Date 05-Dec-2017Expiration Date 04-Dec-2020

Record ID 25188398

This is to certify that:

Joel Hay

Has completed the following CITI Program course:

CITI Good Clinical Practice (Curriculum Group)

GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus) (Course Learner Group)

2 - Refresher Course (Stage)

Under requirements set by:

University of Southern California

Verify at www.citiprogram.org/verify/?wc1e1ffe4-0274-4ac9-9dbf-3bc6325c99ec-25188398

7KLV�FHUWLILHV�WKDW

-RHO�+D\KDV�VXFFHVVIXOO\�FRPSOHWHG

6$16�6HFXULQJ�WKH�+XPDQ�$ZDUHQHVV�7UDLQLQJIRU

8QLYHUVLW\�RI�6RXWKHUQ�&DOLIRUQLD

0DUFK���WK������

���&3(�&UHGLW�

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)COURSEWORK REQUIREMENTS REPORT*

* NOTE: Scores on this Requirements Report reflect quiz completions at the time all requirements for the course were met. See list below for details.See separate Transcript Report for more recent quiz scores, including those on optional (supplemental) course elements.

•  Name: Joel Hay (ID: 618466)•  Institution Affiliation: University of Southern California (ID: 498)•  Institution Unit: 330•  Phone: 323-442-3296

•  Curriculum Group: CITI Good Clinical Practice•  Course Learner Group: Same as Curriculum Group•  Stage: Stage 1 - Basic Course

•  Report ID: 15187675•  Completion Date: 02/02/2015•  Expiration Date: N/A•  Minimum Passing: 80•  Reported Score*: 91

REQUIRED AND ELECTIVE MODULES ONLY DATE COMPLETED SCOREThe CITI Good Clinical Practice Course for Clinical Trials Involving Drugs and Devices 02/02/15 3/3 (100%) Overview of New Drug Development 02/02/15 4/5 (80%) Overview of ICH GCP 02/02/15 4/4 (100%) ICH - Comparison Between ICH GCP E6 and U.S. FDA Regulations 02/02/15 4/4 (100%) Conducting Investigator-Initiated Studies According to FDA Regulations and GCP 02/02/15 3/3 (100%) Investigator Obligations in FDA-Regulated Clinical Research 02/02/15 4/5 (80%) Managing Investigational Agents According to GCP Requirements 02/02/15 5/5 (100%) Overview of U.S. FDA Regulations for Medical Devices 02/02/15 2/3 (67%) Informed Consent in Clinical Trials of Drugs, Biologics, and Devices 02/02/15 2/4 (50%) Detecting and Evaluating Adverse Events 02/02/15 4/4 (100%) Reporting Serious Adverse Events 02/02/15 4/4 (100%) Audits and Inspections of Clinical Trials 02/02/15 5/5 (100%) Monitoring of Clinical Trials by Industry Sponsors 02/02/15 8/8 (100%) Completing the CITI GCP Course 02/02/15 No Quiz 

For this Report to be valid, the learner identified above must have had a valid affiliation with the CITI Program subscribing institutionidentified above or have been a paid Independent Learner. 

CITI ProgramEmail: citisupport@miami.eduPhone: 305-243-7970Web: https://www.citiprogram.org

Joel W. Hay, Ph.D. -- C.V. -75- 10/18/18

Completion Date 12-Jan-2018Expiration Date 11-Jan-2021

Record ID 19807572

This is to certify that:

Joel Hay

Has completed the following CITI Program course:

Human Research (Curriculum Group)

Biomedical Human Subjects (Course Learner Group)

2 - Refresher (Stage)

Under requirements set by:

University of Southern California

Verify at www.citiprogram.org/verify/?w674db35c-2e6b-4446-b79d-d5bf76d88b47-19807572

CERTIFICATE OF COMPLETIONJoel Hay

Has completed the following training:

Grants Management Training for Faculty Refresherby the Department of Contracts and Grants

Date: 10/6/2018